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ABSTRACT 
In order to maintain nutrient supply to fuel their rapid growth, cancer cells selectively upregulate 
expression of cell-surface nutrient transporters. One such transporter is alanine, serine, cysteine-
preferring transporter 2 (ASCT2), which catalyses the sodium-dependent uptake of small neutral 
amino acids, including glutamine, a “conditionally essential” amino acid in cancer cells. Glutamine 
promotes cell growth by supporting biosynthetic and bioenergetic metabolism, activating mTORC1 
signalling, and inhibiting apoptosis. Blocking ASCT2 to prevent glutamine uptake has been shown 
to inhibit cell growth in prostate cancer, non-small cell lung cancer, melanoma, and acute myeloid 
leukaemia. As ASCT2 expression and glutamine reliance are increased in aggressive breast cancer 
subtypes, such as triple-negative (TN) breast cancer, targeting ASCT2 may be a viable therapeutic 
approach. Analysis of ASCT2 function showed that TN, but not Luminal A, breast cancer cells 
require ASCT2-mediated uptake of glutamine to sustain cell growth in vitro and in vivo. Gene 
expression analysis of TN xenografts and patient samples suggested dynamic regulation of glutamine 
metabolism by MYC and ATF4, and suggested that TN breast cancers may have unique metabolic 
signatures that could be exploited therapeutically. Using targeted metabolomics, TN cells were shown 
to have higher levels of glutamine-dependent anaplerosis and less flexibility in their use of glutamine 
as a mitochondrial fuel than Luminal A cells. This phenotype was mirrored in gene expression 
analysis of the TCGA provisional dataset, which revealed a cluster of highly expressed glutamine-
metabolism genes in the TN samples. Despite this metabolic vulnerability, ASCT2 inhibition caused 
similar effects in Luminal A and TN cells, causing a global reduction in uptake and utilisation of 
glutamine. Finally, blocking ASCT2 in combination with the L-type amino acid transporter, LAT1, 
was able to inhibit cell growth in both Luminal A and TN breast cancer cells, extending the efficacy 
of targeting glutamine or leucine uptake alone. Taken together, these data provide preclinical 
evidence for targeting ASCT2 and downstream glutamine metabolism in breast cancer, particularly 
in the high-risk TN subgroup where there is increased glutamine dependence. 
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1.1 Introduction 
 
1.1 Amino acid transport in cancer 
1.1.1 Nutritional demands of cancer cells 
Rapid growth and proliferation are the defining features of tumour cells, creating a profoundly 
increased demand for nutrients to serve both as building blocks for the synthesis of macromolecules 
and a carbon source for the generation of metabolic energy. As a result, cancer cells employ a number 
of strategies to overcome nutrient deprivation and satisfy their increased metabolic demands. These 
altered metabolic processes are increasingly recognised as an important “hallmark of cancer” 
(Hanahan and Weinberg, 2011), critical for successful neoplastic transformation and continued 
tumour cell growth. Although formally recognised as a hallmark only recently, the foundations of 
cancer metabolism were first introduced almost one hundred years ago with the Warburg hypothesis: 
the phenomenon whereby tumour cells preferentially use aerobic glycolysis to produce lactate, rather 
than fully oxidising glucose to form carbon dioxide (Warburg, 1956). Tumour cells also inhibit 
oxidative phosphorylation to reinforce this diversion of glucose to glycolytic pathways, and can then 
use carbon skeleton intermediates of the aerobic glycolysis pathway as precursors for the synthesis 
of macromolecules to sustain growth and proliferation (Mazurek and Eigenbrodt, 2003). 
Identification and characterisation of these altered metabolic phenotypes – referred to as the tumour 
“metabolome” – is critical for the creation of targeted therapies that are able to exploit tumour-specific 
metabolic vulnerabilities. 
1.1.2 Importance of amino acids in sustaining tumour cell growth 
Amino acid availability is important for sustaining the tumour metabolome. The twenty standard 
proteinogenic amino acids contribute to a variety of pathways required for cell growth and 
proliferation, providing the primary source of cellular nitrogen used for the synthesis of nucleotides, 
amino sugars, and proteins; acting as a carbon source for energy production; producing glutathione, 
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a critical regulator of redox balance; supplying one-carbon metabolism; removing nitrogen through 
the urea cycle; and regulating mammalian target of rapamycin (mTOR) signalling (Figure 1.1).  
Firstly, the availability of amino acids is critical to sustain uninhibited proliferation by providing the 
building blocks for protein, nucleotide and glutathione synthesis (Christensen, 1990). This 
importance is accentuated by the fact that tumour cells synthesise less amino acids from carbohydrate-
carbon skeletons than normal tissues do (Busch et al., 1960) and consequently depend more than 
normal cells on an adequate amino acid supply from extracellular fluids. Amino acids contribute up 
to 30% of total cell biomass in rapidly proliferating cells, and amino acid-derived carbon is 
incorporated to some extent into all macromolecular classes (Hosios et al., 2016). Amino acids are 
also required for synthesis of the tripeptide antioxidant, glutathione, an important cellular antioxidant 
comprised of the three amino acids, glutamate, glycine and cysteine. Once formed, glutathione 
equilibrates intracellular thiol status, neutralises oxygen radical species, and acts as an intracellular 
store for unstable cysteine, an important amino acid in protein synthesis (Lu, 2009). 
 
The demand for amino acids in cancer cells is due not only to their utility as biosynthetic substrates 
but also to provide a substrate for adenosine triphosphate (ATP) production (Collins et al., 1998). 
This occurs in one of two ways: either being converted to TCA intermediates to supply anaplerosis 
and oxidative phosphorylation (“glucogenic”; glycine, alanine, serine, aspartate, asparagine, 
glutamate, glutamine, proline, valine, methionine, cysteine, histidine, arginine), or by being converted 
directly to acetyl-CoA and ketone bodies (“ketogenic”; lysine, leucine). The five remaining amino 
acids (tryptophan, phenylalanine, tyrosine, isoleucine, threonine) are both glucogenic and ketogenic, 
and can contribute to both metabolic pathways.  
 
Amino acids also contribute to one-carbon metabolism, an important series of reactions that involve 
the transfer of a single carbon unit. Some amino acids contribute to this cycle directly (serine, 
threonine, methionine, glycine, cysteine), while glucogenic amino acids are able to contribute  
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Figure 1.1. Amino acid availability is required to sustain the cancer cell metabolome. 
Amino acids support multiple interacting intracellular metabolic pathways, including one-
carbon metabolism, nucleotide and protein synthesis, redox control, nitrogen transfer 
through the urea cycle, activation of mTORC1 signalling, and anaplerotic and bioenergetic 
TCA cycle flux. Arrow colours: blue: anabolic and catabolic metabolism; grey: nitrogen 
transfer pathways; green: forward TCA; red: reductive carboxylation; black: activation of 
signalling. Abbreviations: aKG, alpha ketoglutarate; Glu, Glutamate; Gln, glutamine; OAA, 
oxaloacetate; Asp, aspartate; CoA, Coenzyme A; mTORC1, mammalian target of rapamycin 
complex 1; ROS, reactive oxygen species; TCA, tricarboxylic acid. 
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indirectly through production of pyruvate by anaplerotic TCA. One-carbon metabolism is important 
for facilitating folate metabolism, as well as generating glycine for nucleotide synthesis. 
 
Finally, amino acid availability is also critical in that it regulates growth signalling through the central 
growth controller, mTOR (Dodd and Tee, 2012, Nicklin et al., 2009, Taylor, 2009, Avruch, 2009). 
mTOR forms two distinct complexes: the nutrient-sensitive mTORC1 and nutrient-insensitive 
mTORC2 (Guertin and Sabatini, 2007), although there is evidence to suggest that both are involved 
in responding to nutrient levels in cancer (Kim et al., 2017, Moloughney et al., 2016). The mTORC1 
complex is composed of the TOR polypeptide and accessory proteins Raptor and GbL and is activated 
by amino acids and inhibited by nutrient starvation (Beugnet et al., 2003, Kim and Guan, 2011). It is 
strongly activated by cytosolic amino acids, such as leucine and arginine, which signal amino acid 
sufficiency through a variety of mechanisms including inhibition of GATOR1 (Avruch et al., 2009, 
Bar-Peled et al., 2013) and GATOR2 (Wolfson et al., 2016), and binding lysosomal transporters 
(Zoncu et al., 2011). The mTORC2 complex is composed of the TOR polypeptide and accessory 
proteins, Rictor, GbL and mSin1. Its mechanisms of activation are largely unknown, but despite being 
known canonically as “nutrient-insensitive”, it has been shown to be amino acid responsive 
(Moloughney et al., 2016, Tato et al., 2011). It plays an important role in anti-apoptotic survival 
signalling by phosphorylating and fully activating Akt, allowing it to inhibit its proapoptotic 
substrate, Bad (Sarbassov et al., 2005). The mTORC2 complex also plays a key role in regulating the 
cellular cytoskeleton (Jacinto et al., 2004) by activating a number of substrates, including Protein 
Kinase C (PKC; Populo et al., 2012).  
1.1.3 Transporters control amino acid availability in cancer cells 
The supply of amino acids that sustain mTORC1 activation and support these various metabolic 
pathways is transported across the plasma membrane by an active process, mediated by specific 
protein transporters (Ganapathy et al., 2009, Hediger et al., 2004, Palacin et al., 1998). These nutrient 
transporters are known collectively as solute carriers (SLC), and are divided into 52 functional SLC 
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families, each responsible for the transport of specific nutrients important for cell growth and survival 
(Hediger et al., 2004, He et al., 2009). Within these 52 families, there are over 390 individual 
transporters currently identified (http://slc.bioparadigms.org/). 
 
Studies to specifically define the transport mechanisms of amino acid uptake began in the early 1960s 
by Christensen et al. (Christensen, 1990) and have culminated in the definition of four main transport 
systems; that is, the Na+-dependent Systems A, ASC and N, and the Na+-independent System L 
(Palacin et al., 1998), as summarised in Table 1.1. In malignant transformation, or during times of 
cellular stress, cells induce or upregulate these transporters specifically to meet their metabolic 
demands, ensuring that substrate availability does not become rate-limiting in rapidly proliferating 
tumour cells (Bode et al., 1995, Medina et al., 1992, Wasa et al., 1996b, Broer, 2002). Elevated 
expression of a number of amino acid transporters have been described in human cancers, 
encompassing all four transporter systems, and the additional cationic transport System xc-, as 
summarised below. 
1.1.3.1 System A  
System A was named for being alanine-preferring, but it also transports a wide variety of other small 
aliphatic amino acids. It is present in nearly all cell types and catalyses the symport of most small 
neutral amino acids, cotransporting them into the cell along with a sodium ion (Mackenzie and 
Erickson, 2004). System A is made up of two transporter isoforms from the SLC38 gene family, 
termed SNAT1 (SLC38A1)  and SNAT2 (SLC38A2) (Nakanishi and Tamai, 2011). SNAT1 and 
SNAT2 have been shown to be essential for maintaining glutamine availability in cancer cells, 
particularly in the context of inhibition of System ASC transporters (Broer et al., 2016). SNAT2 
expression, although more ubiquitous than SNAT1, is better characterised in malignancy. SNAT2 
expression is regulated by cellular stresses such as amino acid starvation (Gaccioli et al., 2006) and 
endoplasmic reticulum (ER) stress (Jeon et al., 2015), both important in the hypoxic tumour micro- 
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Table 1.1. Amino acid transport systems in humans. 
Amino 
acid 
transport 
system 
SLC 
family Gene Protein Normal tissue distribution Primary substrates 
System A SLC38 
SLC38A1 SNAT1 Placenta, heart, brain, lung, skeletal muscle Alanine-preferring, but also transports most 
small neutral amino acids (Nakanishi and 
Tamai, 2011). 
SLC38A2 SNAT2 Ubiquitous 
SLC38A4 SNAT4 Liver and skeletal muscle 
System 
ASC SLC1 
SLC1A5 ASCT1 Most tissues – highly expressed in muscle, brain and pancreas 
Na+-dependent transport of alanine, serine 
and cysteine along with other small neutral 
amino acids (Christensen et al., 1967, Kanai 
and Hediger, 2004, Zerangue and 
Kavanaugh, 1996). 
SLC1A4 ASCT2 Placenta, kidney, pancreas, muscle and intestine 
System N SLC38 
SLC38A3 SN1 (SNAT3) Brain Amino acids with nitrogen in the side chain in Na+- coupled influx transport in exchange 
for H+ (Kilberg et al., 1980). SLC48A5 SN2 (SNAT5) Ubiquitous 
System L 
SLC7 
SLC7A5 LAT1 Foetal liver, bone marrow, brain, placenta and testis 
Na+-independent transport with high affinity 
for leucine and other large neutral amino 
acids (Bodoy et al., 2005, Kanai et al., 
1998, Yanagida et al., 2001). 
SLC7A8 LAT2 
Primarily kidney, less strongly expressed 
in placenta, brain, liver, spleen, skeletal 
muscle, heart, small intestine and lung 
SLC43 
SLC43A1 LAT3 Liver, skeletal muscle, pancreas 
SLC43A2 LAT4 Kidney and intestine 
System 
xc- SLC7 SLC7A11 xCT 
Central nervous system, eye, pancreas, 
macrophages  
Cystine imported 1:1 with glutamate 
countertransport (Bassi et al., 2001, Conrad 
and Sato, 2012, Lewerenz et al., 2013) 
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environment, and overexpression of this transporter has been reported in prostate cancer (Okudaira 
et al., 2011). 
1.1.3.2 System ASC  
 
System ASC transports alanine, serine and cysteine along with other small neutral amino acids 
(Christensen et al., 1967). System ASC activity is now attributed to two Na+-dependent antiporters 
termed ASCT1 and ASCT2 (alanine, serine, cysteine-preferring transporters 1 and 2; (Kanai and 
Hediger, 2004, Zerangue and Kavanaugh, 1996). As antiporters, ASCT1 and ASCT2 move their 
amino acid substrates against each other in a sodium-dependent manner, meaning they are unable to 
mediate net uptake of amino acids on their own. Glutamine uptake in many cancer cell lines and all 
solid tumours is mediated primarily through ASCT1 and ASCT2, (Collins et al., 1998, Wasa et al., 
1996a, Bode et al., 1995, Bode et al., 2002), and expression of ASCT2 is elevated in a variety of 
cancerous tissues (Fuchs and Bode, 2005) including colorectal (Witte et al., 2002), prostate (Li et al., 
2003, Wang et al., 2015), non-small cell lung (Hassanein et al., 2013, Shimizu et al., 2014), pancreatic 
(Kaira et al., 2014), melanoma (Wang et al., 2014a), and breast cancer (Kim et al., 2013b).  
1.1.3.3 System N  
System N preferentially transports amino acids with nitrogen in the side chain (Kilberg et al., 1980) 
– for example, glutamine, asparagine and histidine – in Na+- coupled influx transport in exchange for 
H+. Two System N transporters have been identified: SNAT3 (SN1) and SNAT5 (SN2). Like the 
System A SNATs, these transporters are part of the SLC38 gene family, but are more substrate-
specific, preferring glutamine, asparagine and histidine (Broer, 2014). System N transporters have 
not yet been comprehensively studied in cancer. Notably, however, SNAT5 has been shown to be a 
direct transcriptional target of the oncoprotein, MYC (Wise et al., 2008), in the activation of a 
glutaminolytic phenotype, suggesting dynamic regulation of SNAT5 expression throughout 
malignant transformation.  
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1.1.3.4 System L 
System L transporters are Na+-independent obligatory amino acid antiporters (LAT1, LAT2) and 
uniporters (LAT3, LAT4) with high affinity for leucine and other large neutral amino acids 
(Yanagida, 2001). System L activity is mediated by four Na+-independent transporters called LAT1, 
LAT2, LAT3 and LAT4 (L-type amino acid transporters 1-4; Bodoy et al., 2005, Kanai et al., 1998). 
LAT1 and LAT2 are in the SLC7 gene family and form functional heterodimers consisting of the 
LAT light chain, that constitutes the actual transporter, covalently attached by a disulphide bond to a 
membrane glycoprotein heavy chain (4F2hc, also known as CD98 or SLC3A2; Kanai et al., 1998). 
4F2hc serves as a chaperone for proper recruitment of the light chain to the plasma membrane 
(Nakamura et al., 1999). The remaining LAT transporters, LAT3 and LAT4, are from the SLC43 gene 
family and function as monomers without associating with 4F2hc (Wagner et al., 2001). As 
uniporters, they mediate facilitated diffusion of their amino acid substrates. Of the four System L 
leucine-preferring transporters, LAT1 and LAT3 appear to be most important in malignancy (Wang 
and Holst, 2015). Expression of LAT1 was shown to be essential for progression and metastasis of 
human neoplasms (Kaira et al., 2008a) and is associated with poor prognosis and poor overall disease-
free survival in a number of human cancers including glioma (Nawashiro et al., 2006), non-small cell 
lung cancer (Kaira et al., 2008b), pulmonary adenocarcinoma (Kaira et al., 2009b), squamous cell 
lung cancer (Kaira et al., 2009a), gastric carcinoma (Ichinoe et al., 2011), pancreatic carcinoma 
(Yanagisawa et al., 2012) and breast cancer (Furuya et al., 2012, Liang et al., 2011). LAT1 has also 
been linked to high pathological grade and malignancy in glioma (Haining et al., 2012) and prostate 
cancer (Sakata et al., 2009). LAT1 and LAT3 are both important in prostate cancer, where they show 
coordinated androgen-regulated expression throughout disease progression (Wang et al., 2011, Wang 
et al., 2013). 
1.1.3.5 Other important amino acid transport systems: System xc- 
One other important amino acid transport system in cancer is System xc-, or the cationic amino 
acid/glycoprotein transporters. This System contains one transporter, xCT (SLC7A11), which forms 
a heterodimer with 4F2hc to mediate influx of cystine in exchange for glutamate efflux (Sato et al., 
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1999). The xCT transporter performs a critical function in tumour cells by providing intracellular 
cystine for synthesis of glutathione. Increased expression and activity of xCT has been described in 
multiple human cancer tissues (Lo et al., 2008), including hepatocellular carcinoma (Guo et al., 2011), 
oral cancer (Toyoda et al., 2014), glioblastoma (Savaskan and Eyupoglu, 2010, Takeuchi et al., 2013), 
and breast cancer (Timmerman et al., 2013). xCT expression is regulated by nutrient stress, in 
particular the amino acid response (AAR) pathway protein, activating transcription factor 4 (ATF4) 
(Lewerenz et al., 2012), and MYC (Kim et al., 2008). 
1.2 Glutamine metabolism in cancer 
1.2.1 The primacy of glutamine in sustaining tumour cell growth 
The common feature of these transporters is that almost all are involved in some way in the transport 
of glutamine or its deamidation product, glutamate, emphasising the importance of this amino acid 
for sustaining tumour cell growth. The role of glutamine encompasses all aspects of amino acid 
metabolism discussed above; namely, as a carbon and nitrogen source for biosynthetic pathways, a 
fuel for energy production, a regulator of redox balance, and an activator of mTORC1 signalling, 
which are discussed in greater detail below.  
1.2.2 Glutamine supports anaplerotic and bioenergetic TCA 
One of the most important ways that glutamine contributes to cell growth is through its catabolic 
metabolism. This process, termed glutaminolysis (Daye and Wellen, 2012, Mazurek and Eigenbrodt, 
2003), refers to the series of biochemical reactions where glutamine is converted to glutamate, alpha-
ketoglutarate (aKG), and then fed into anaplerotic or reductive tricarboxylic acid (TCA) cycle, where 
it produces intermediates to supply biosynthetic pathways and is used to generate ATP (Figure 1.2). 
These reactions are also required for other non-metabolic pathways of glutamine utilisation; for 
example, glutaminolysis directly stimulates mTORC1 signalling through production of aKG (Duran 
et al., 2012). The importance of these pathways has been well-reviewed in recent years  (DeBerardinis 
and Cheng, 2010, Hensley et al., 2013, Still and Yuneva, 2017), highlighting a growing understanding 
of how glutamine dependence may be a therapeutic “Achilles’ heel” for many cancers.   
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Figure 1.2. Glutamine supports anaplerotic and bioenergetic TCA cycle. Cancer cells 
use the glutamine carbon skeleton (carbon number denoted by empty circles) to fuel 
biosynthetic pathways (blue) that provide precursors for fatty acid, protein and nucleotide 
synthesis; to maintain anaplerotic flux through TCA (green); and as a substrate for reductive 
carboxylation (red). Glutamine also participates in nitrogen transfer reactions (grey) that 
support these carbon-utlising pathways. The net results of this network are the ongoing 
replenishment of anaplerotic intermediates and production of acetyl-Coenzyme A (AcCoA) 
for ATP production. These processes occur in the mitochondria (illustrated in light and dark 
brown) and cytoplasm (illustrated in light blue), and involve movement of substrates to and 
from the extracellular milieu (illustrated as white space outside the dark blue plasma 
membrane). 
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The first and rate-limiting step of intracellular glutaminolysis is the deamidation of glutamine to 
glutamate by glutaminase (GLS). Overactivity of this enzyme is important for neoplastic 
transformation, particularly in cells where MYC is a driver (Wang et al., 2010, Xiang et al., 2015, 
Gao et al., 2009). Glutaminase activity is critical in acute myeloid leukaemia (AML) (Jacque et al., 
2015), TN breast cancer (Gross et al., 2014), and ovarian cancer (Yuan et al., 2016), where inhibition 
of glutaminase results in decreased cell growth and survival. Downstream of glutaminase, the 
glutamine carbon skeleton enters the TCA cycle as aKG, where it either fuels anaplerotic forward 
TCA to generate fumarate, malate, oxaloacetate and citrate; or is subjected to reductive carboxylation 
to form citrate through reverse TCA (Metallo et al., 2011, Mullen et al., 2011). These intermediates 
can then be used to generate ATP through either oxidative phosphorylation (OXPHOS) or aerobic 
lactate production (Fan et al., 2013).  
 
Cancer cells also use glutamine carbon flux through TCA to generate precursors for nucleotide, fatty 
acid, and protein biosynthesis (Vander Heiden et al., 2009, DeBerardinis et al., 2007). The key TCA 
branch points for these processes are oxaloacetate, which is readily transaminated to form aspartate; 
malate, which is converted by malic enzymes into pyruvate; and citrate, which is cleaved to generate 
acetyl-Coenzyme A (acetyl-CoA). As the first reaction of forward TCA, replenishment of 
oxaloacetate is essential for continued production of anaplerotic intermediates, achieved by increased 
activity of pyruvate carboxylase in some cancer cells, which catalyses the irreversible carboxylation 
of pyruvate to form oxaloacetate (Phannasil et al., 2017, Cheng et al., 2011). Oxaloacetate is also a 
critical biosynthetic intermediate in its own right, as its transamination product, aspartate, directly 
supports protein and nucleotide synthesis. Aspartate provides three of the four carbon atoms of the 
pyrimidine ring for nucleotide biosynthesis (Lane and Fan, 2015) and can be transamidated to 
generate asparagine for protein synthesis (Krall et al., 2016). Likewise, pyruvate is an important 
transamination substrate for the de novo synthesis of the non-essential amino acids, serine and 
glycine, which feed one-carbon metabolism and nucleotide synthesis, and alanine, which provides a 
		 26 
valuable nitrogen store and helps to regenerate aKG by its transamination of glutamate. Pyruvate can 
also be used as a bioenergetic substrate through fermentation to form lactate, or decarboxylation to 
acetyl-CoA to enter TCA. The third important TCA branch point intermediate is citrate, which can 
be formed either by reductive carboxylation of glutamine-derived aKG, or complete progression 
through forwards TCA ending with condensation of glutamine-derived oxaloacetate with an acetyl-
CoA molecule. Reductive carboxylation formation of citrate tends to be favoured in cells under 
hypoxic conditions (Wise et al., 2011, Metallo et al., 2011), where it supports fatty acid synthesis. 
Flux of glutamine carbon through TCA to replenish these intermediates therefore feeds into pathways 
of nucleotide, protein and fatty acid biosynthesis. 
1.2.3 Glutamine is an important source of cellular nitrogen 
Glutamine also contributes to whole cell nitrogen balance, contributing up to 30% of total cell 
nitrogen (Hosios et al., 2016). One way this occurs is through generation of glutamate, the product of 
glutaminase, which acts as an amino donor during its conversion to aKG by either aminotransferase 
(transaminase) or deaminase reactions. Interconversion between these two forms provides an 
important nitrogen balance mechanism. Aminotransferase enzymes (PSAT1, GPT1, GPT2, GOT1, 
GOT2, BCAT1, BCAT2) catalyse the transfer of amino groups from one amino acid to another, a 
required step in the de novo biosynthesis of non-essential amino acids. In contrast, deamination 
reactions, performed by the glutamate dehydrogenase enzymes (GLUD1, GLUD2), differ from 
transamination reactions in the source and fate of ammonia, which is released without transferring 
from one substrate to another. These provide important cellular mechanisms for storing and donating 
nitrogen, an important resource for biosynthetic pathways in rapidly proliferating cells. 
 
Another important nitrogen donor species for these reactions is aspartate, and its reciprocal nitrogen 
acceptor, oxaloacetate. Aspartate is a critical product of anaplerotic TCA (Sullivan et al., 2015), and 
is also regenerated by aminotransferase reactions (catalysed by GOT1, GOT2) that use glutamate and 
oxaloacetate as substrates. The reversible interconversion of glutamate and aspartate emphasises the 
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complexity of these interconnected pathways – glutamine provides both carbon and nitrogen for 
aspartate synthesis, while aspartate can partly compensate for glutamine deprivation in some cells 
(Patel et al., 2016). 
 
In addition to its carbon contributions via aspartate and glycine, glutamine also contributes directly 
to nucleotide synthesis as a nitrogen donor. Glutamine provides nitrogens to both purine and 
pyrimidine bases at multiple steps in the biosynthetic pathways. The first committed and rate-limiting 
step of purine biosynthesis requires glutamine (catalysed by PPAT enzyme), and an additional amide 
from glutamine is consumed (by PFAS enzyme) downstream to complete synthesis of the common 
purine precursor, inosine monophosphate (IMP). From the IMP branchpoint, synthesis of guanosine 
monophosphate (GMP) by GMP synthase (GMPS) also requires glutamine as a nitrogen donor. In 
pyrimidine synthesis, like purine synthesis, the first step requires an amide from glutamine (catalysed 
by the trifunctional CAD enzyme), and an additional glutamine is required for the final steps in 
conversion of uridine triphosphate (UTP) to cytidine triphosphate (CTP; catalysed by CTP synthase 
1 or 2, CTPS1 or 2). Glutamine availability is essential for these biosynthetic pathways, such that 
glutamine-dependent cancer cells that express glutamine synthetase will withdraw carbon from TCA 
to synthesise glutamine for purine synthesis (Tardito et al., 2015), and glutamine deprivation prevents 
DNA damage-induced de novo pyrimidine synthesis (Brown et al., 2017).  
 
Potential targets in these glutamine uptake and metabolism pathways were recently reviewed (Altman 
et al., 2016) and are summarised in Table 1.2.  
1.2.4 Glutamine promotes mTORC1 signalling 
The availability of glutamine is also critical to mTORC1 pro-growth signalling. Amino acids in 
general, and leucine in particular, are potent regulators of mTORC1 signalling (Dodd and Tee, 2012, 
Nicklin et al., 2009, Taylor, 2009). One way this occurs is through intracellular leucine charging of 
leucyl-tRNA synthetase, which functions as a leucine-dependent GTP-ase Activating Protein  (GAP) 
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for Rag GTPase (Bonfils et al., 2012, Han et al., 2012), priming it to activate mTORC1 (Sancak et 
al., 2010). However, intracellular glutamine – and subsequent glutaminolysis – is required for this 
leucine-mediated regulation of mTOR signalling. Glutaminolysis stimulates GTP loading of RagB 
and activates mTORC1 in a Rag-dependent manner by mediating the lysosomal translocation of 
mTORC1 (Duran et al., 2012). Clarifying this pathway has reinforced the connection between 
nutrient availability and cell growth, and particularly emphasises the primacy of glutamine 
availability to the proliferating cancer cell.  
1.2.5 Glutamine prevents apoptosis and inhibits autophagy 
Glutamine also promotes cell proliferation by inhibiting autophagy and apoptosis. This occurs firstly 
through stimulation of mTORC1 signalling by several overlapping mechanisms, including the 
production of aKG (Duran et al., 2012), increase in the ATP:AMP ratio through glutaminolytic 
production of ATP to cause inhibition of AMP kinase (Mihaylova and Shaw, 2011), and production 
of glutathione to counteract ROS (Meijer et al., 2015, Blommaart et al., 1995). These processes 
converge on mTORC1 to inhibit downstream activation of autophagic proteins such as microtubule 
associated protein 1 (MAP1) light chain 3 (LC3) (Kabeya et al., 2000). Accordingly, glutamine 
deprivation has been shown to induce autophagy in lung cancer and AML (Hassanein et al., 2015, 
Willems et al., 2013).  
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Table 1.2. Potential therapeutic targets in the glutamine uptake and metabolism pathways.  
Gene  Name Pathway Substrate 
GMPS GMP Synthetase Purine 
synthesis 
Glutamine 
GART Phosphoribosyl-Glycinamide Formyltransferase, 
Phosphoribosyl-Glycinamide Synthetase, 
Phosphoribosyl-Aminoimidazole Synthetase 
Purine 
synthesis 
None 
PSAT1 Phosphoserine Aminotransferase 1 One carbon 
metabolism 
(from 
pyruvate) 
aKG/ 
Glutamate 
ASNS Asparagine Synthetase Amino acid 
biosynthesis 
Glutamine 
CTPS1 CTP synthetase Pyrimidine 
synthesis 
Glutamine 
TYMS Thymidylate Synthetase Pyrimidine 
synthesis, 
folate 
metabolism 
None 
CAD Carbamoyl-Phosphate Synthetase 2, Aspartate 
Transcarbamylase, and Dihydroorotase 
Pyrimidine 
synthesis 
CPSII 
subunit uses 
glutamine 
GARS Glycyl-tRNA Synthetase Protein 
synthesis 
None 
GPT2 Glutamic-Pyruvic Transaminase 2 aKG 
synthesis 
Glutamate 
ADSL Adenylosuccinate Lyase Purine 
synthesis 
None 
ATF4 Activating Transcription Factor 4 Amino acid 
response 
pathway 
 
GLS Glutaminase Glutamate 
synthesis 
Glutamine 
UMPS UMP Synthetase Pyrimidine 
synthesis 
None but 
uses 
carbamoyl 
phosphate 
(CPSII 
activity) 
and PRPP 
PAICS Phosphoribosylaminoimidazole Carboxylase and 
Phosphoribosylaminoimidazolesuccinocarboxamide 
Synthase 
Purine 
synthesis 
 
PPAT Glutamine Phosphoribosylpyrophosphate 
Amidotransferase 
Purine 
synthesis 
Glutamine 
DHODH Dihydroorotate Dehydrogenase Pyrimidine 
synthesis 
None, 
downstream 
of 
carbamoyl 
phosphate 
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and 
upstream of 
PRPP usage 
GOT1 Glutamate-Oxalate Transaminase 1 Aspartate 
synthesis 
Glutamate/ 
aKG 
GCLM Glutamate-Cysteine Ligase Modifier Subunit Redox 
control 
(GSH 
synthesis) 
Glutamate 
DHFR Dihydrofolate reductase Pyrimidine 
synthesis, 
folate 
metabolism 
None  
CPS1 Carbamoyl Phosphate Synthetase I  Pyrimidine 
synthesis 
Glutamine 
SLC1A5/
ASCT2 
Alanine, Serine, Cysteine-preferring Transporter 2 Glutamine 
uptake 
Glutamine 
GPT Glutamic-Pyruvic Transaminase aKG 
synthesis 
Glutamate 
BCAT2 Branched Chain Amino Acid Transaminase 2 Glutamate 
synthesis 
aKG 
ATIC 5-Aminoimidazole-4-Carboxamide Ribonucleotide 
Formyltransferase/IMP Cyclohydrolase 
Purine 
synthesis 
None 
CTPS2 CTP Synthase 2 Pyrimidine 
synthesis 
Glutamine 
GCLC Glutamate-Cysteine Ligase Catalytic Subunit Redox 
control 
(GSH 
synthesis) 
Glutamate  
GOT2 Glutamate-oxalate transaminase 2 Aspartate 
synthesis 
Glutamate/ 
aKG 
GLUD2 Glutamate Dehydrogenase 2 aKG 
synthesis 
Glutamate 
GLUD1 Glutamate Dehydrogenase 1 aKG 
synthesis 
Glutamate 
GLS2 Glutaminase 2 aKG 
synthesis 
Glutamine 
GLUL Glutamate-Ammonia Ligase /  
Glutamine Synthetase 
Glutamine 
synthesis 
Glutamate 
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Glutamine also represses apoptosis directly by inhibiting caspases 2 and 9 (Fuchs et al., 2007, Fuchs 
et al., 2004), and indirectly by inhibiting the AAR pathway. This response pathway involves 
activation of eIF2a and GCN2, which causes translational upregulation of activating transcription 
factor 4 (ATF4), a key mediator of the cellular responses to nutrient and endoplasmic reticulum stress. 
The strength and duration of the activating signals dictate the pattern of response, with strong and 
persistent activation favouring apoptosis (Wei et al., 2015). In this context, ATF4 can induce 
expression of pro-apoptotic substrates such as CAAT/enhancer-binding protein-homologous protein 
(CHOP), PUMA, NOXA, GADD34, or TRB3 (Qing et al., 2012, Ren et al., 2015). Although 
responsive to all amino acids, glutamine deprivation alone appears to be sufficient to activate ATF4-
mediated apoptosis, causing cell death by a MYCN-dependent mechanism in neuroblastoma cells 
(Qing et al., 2012). In addition to these pro-apoptotic signalling cascades, the AAR pathway can also 
regulate global amino acid metabolism, as discussed below.  
1.2.6 Glutamine metabolism is regulated by ATF4, MYC and mTORC1 
It is becoming very clear that metabolic processes are not static; cancer cells are highly plastic, 
adaptively responding to stress by relying on alternative transporters (Broer et al., 2016, Broer, 2002) 
or reprogramming intracellular metabolic pathways (Ward and Thompson, 2012, Brown et al., 2017). 
In a subacute setting, the AAR pathway is also an important mechanism used by cancer cells to 
regulate amino acid metabolism. As described briefly above, the serine/threonine protein kinase, 
general control nonderepressible 2 (GCN2), mediates the initial response by sensing uncharged 
transfer RNA (tRNA) abundance, which is increased when intracellular amino acid availability is 
low. GCN2 then activates diverse signal transduction pathways through phosphorylation of 
eukaryotic initiation factor 2 alpha (eIF2a) (Zhang et al., 2002). One known outcome of these 
signalling pathways is increased expression of ATF4 (Kilberg et al., 2009), whose expression is 
upregulated translationally in times of cell stress (Harding et al., 2003). ATF4 is able to 
transcriptionally regulate gene expression by binding Amino Acid Response Elements (AARE) or 
Nutrient Sensing Response Elements (NSRE) in the promoter regions of many genes, including the 
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glutamine-dependent enzyme, asparagine synthetase (Siu et al., 2002). ATF4 activation is also 
associated with increased expression of amino acid transporters (Wang et al., 2015, Wang et al., 2013, 
Lewerenz et al., 2012), suggesting direct transcriptional control of amino acid uptake as a protective 
response. This is supported by other reports indicating that these AAR response mechanisms must be 
intact for adequate adaptive responses to cell stress (Ye et al., 2010, Zhang et al., 2002). 
 
Arguably the most important regulator of glutamine metabolism is the oncogenic transcription factor, 
c-MYC. Overexpressed c-MYC is able to induce a global reprogramming of cancer cell metabolism, 
inducing a profound shift to glutaminolysis for production of ATP and catabolic substrates (Wise et 
al., 2008). This transcriptional program involves direct activation of glutamine transporters, ASCT2 
and SNAT5 (Wise et al., 2008), upregulation of the glutamate antiporter, xCT (Kim et al., 2008) and 
the glutamine-dependent genes involved in nucleotide synthesis (Liu et al., 2008, Mannava et al., 
2008), as well as indirect control of glutaminase expression (Bott et al., 2015, Gao et al., 2009). This 
diverse network of transcriptional changes results in glutamine dependence in both cancer cell lines 
(Le et al., 2012, Qing et al., 2012, Yuneva et al., 2007) and mouse models (Xiang et al., 2015). 
Likewise, the related MYC family member, N-MYC, is also associated with increased expression of 
and reliance on glutamine metabolism-related genes, including ASCT2, LAT1, GLS2, and GOT2 
(Qing et al., 2012), indicating a different but complementary transcriptional program to that seen in 
c-MYC overexpression. 
 
Adding to the complexity of these regulatory mechanisms, the ATF4 and MYC-driven transcriptional 
pathways interact with each other and with mTORC1 signalling to drive glutamine metabolism. 
Glutamine-responsive mTORC1 stimulates entry of glutamine into anaplerotic TCA by upregulating 
GLUD enzymes in an ATF4-dependent manner (Csibi et al., 2013), and is also able to activate c-
MYC (Csibi et al., 2014). Activated c-MYC can bind the ATF4 promoter and induce ATF4 
expression, initiating expression of downstream pro-apoptotic mediators (Babcock et al., 2013). 
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Finally, ATF4 and N-MYC can coordinately stimulate expression of ASCT2 (Ren et al., 2015), and 
glutamine deprivation causes cell death in MYC-driven cells in an ATF4-dependent manner (Qing et 
al., 2012). 
1.2.7 Glutamine availability supports amino acid homeostasis 
Upstream of these intracellular pathways, a critical step in the metabolism of glutamine is its transport 
into the cell. Under normal conditions, cells use the overlapping substrate specificities of the four 
amino acid transport systems to selectively increase intracellular levels of essential amino acids. This 
process is dependent on the Na+/K+ pump, which maintains low intracellular Na+ by swapping K+ for 
Na+ ions in an ATP-dependent manner. This generates and maintains the electrochemical gradient 
that allows the Na+-dependent Systems A and N to mediate the concentrative uptake of neutral amino 
acids such as glutamine. This culminates in the elevated intracellular concentrations of non-essential 
amino acids, which can then be exchanged through System ASC and System L for essential amino 
acids such as leucine (Broer, 2002). This process is summarised in Figure 1.3. Transporters in 
Systems ASC and L function as obligatory acid exchangers, and therefore by definition do not modify 
the overall amino acid ratio between the two sides of the membrane but rather work together as 
“partners in crime” (Fuchs and Bode, 2005) to ensure that essential amino acid substrates are 
constantly imported into the cell at the expense of other non-essential amino acids.  
1.2.8 ASCT2 is a critical mediator of glutamine uptake in cancer 
In light of these observed changes in transporter expression, it has been proposed that during 
transformation, overexpressed ASCT2 takes over the functional role of System A and N uniporters 
in mediating the net uptake of glutamine. This agrees with previous work where the ASC transporter 
family (Collins et al., 1998, Wasa et al., 1996a, Bode et al., 1995) and ASCT2 specifically (Bode et 
al., 2002, Collins et al., 1998) are functionally increased in cancer cell lines. The excess intracellular 
glutamine imported by ASCT2 is then exchanged through LAT1 for extracellular leucine (Yanagida, 
2001, Meier et al., 2002, Nicklin et al., 2009), or deamidated and then effluxed through xCT as 
glutamate (Shin et al., 2017, Timmerman et al., 2013). This allows for continuous activation of the  
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Figure 1.3. Glutamine supports amino acid homeostasis through amino acid 
exchange. Cells use the overlapping substrate specificities of a combination of amino acid 
transporters to selectively increase intracellular levels of essential amino acids. The Na+/K+ 
pump maintains low intracellular Na+ by swapping K+ for Na+ ions in an ATP-dependent 
manner. This maintains the electrochemical gradient that allows the System A transporters, 
like SNAT2, to mediate the concentrative uptake of Na+ and neutral amino acids such as 
glutamine. This increase in intracellular glutamine drives the activity of the System L LAT1 
amino acid exchanger, which exchanges intracellular glutamine for extracellular leucine. 
Source: Dodd & Tee, 2012. 
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mTORC1 pathway through sustained availability of intracellular leucine and glutamine, inhibition of 
apoptosis, redox control through glutathione synthesis, continued TCA anaplerosis and ATP 
production through glutaminolysis, all of which promote and sustain tumour cell growth (Figure 1.4). 
Together this network suggests a potential therapeutic opportunity: targeting global cancer cell 
metabolism by preventing ASCT2-mediated uptake of the critical amino acid, glutamine. 
1.3 Amino acid metabolism as a therapeutic target in triple-negative breast 
cancer  
1.3.1 Targeting the glutamine transporter, ASCT2, as a therapeutic strategy 
As discussed in Section 1.1.3, ASCT2 is known to be overexpressed in a number of human cancers 
(Fuchs and Bode, 2005), and is a negative prognostic indicator in pancreatic, non-small cell lung and 
oral cancers (Kaira et al., 2014, Shimizu et al., 2014, Toyoda et al., 2014). Since the first publications 
describing the function of ASCT2 in hepatocellular carcinoma (Fuchs et al., 2004, Fuchs et al., 2007), 
numerous other groups have showed that inhibition of glutamine uptake by ASCT2 can suppress cell 
growth in prostate cancer (Wang et al., 2015), non-small cell lung cancer (Hassanein et al., 2013, 
Hassanein et al., 2015), melanoma (Wang et al., 2014a), and acute myeloid leukaemia (Willems et 
al., 2013). These studies show that glutamine uptake inhibition is a promising new therapeutic 
strategy in cancers that are reliant on glutamine, but highlight the need for further research to 
determine in which cancers this is a feasible approach, with breast cancer an ideal candidate.  
1.3.2 The national health burden of breast cancer 
Breast cancer remains the most common type of cancer in Australian females, accounting for 28% of 
all cancer diagnoses in 2008 (AIHW, 2009), with incidence rates  projected to increase to 18 087 new 
cases in 2018 (AIHW, 2017), meaning an estimated 1 in 8 Australian women will develop breast 
cancer during their lifetime (AIHW, 2017). The projected increase in the number of women diagnosed 
with breast cancer has important implications not only for women and the broader community, but 
also for the health system’s capacity to provide the health services required in the context of our 
ageing population. With the huge burden this places not only upon the health system but for  
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Figure 1.4. ASCT2 mediates glutamine uptake and drives cell growth in cancer. The 
MYC- and ATF4-regulated amino acid transporter, ASCT2, mediates uptake of small neutral 
amino acids, including glutamine, a “conditionally essential” amino acid in cancer cells. Once 
inside cells, glutamine fuels multiple MYC-regulated intracellular pathways, including the 
biosynthesis of macromolecules and glutaminolytic ATP production. Glutamine also 
facilitates influx of essential amino acids, such as leucine, by being exchanged through 
LAT1. Intracellular leucine availability combined with increased aKG from glutaminolysis 
permits maximal mTORC1 stimulation. ASCT2-mediated uptake of glutamine sustains all of 
these processes, which together promote cancer cell growth and proliferation.  
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individuals and families, there is clearly a need for efficient and effective treatment strategies for 
breast cancer (AIHW, 2008). 
1.3.3 Breast cancer classification and subtypes 
Breast cancer is a highly heterogeneous disease with different molecular alterations driving growth, 
survival and response to therapy, with no single therapy being effective in all tumours. In clinical 
practice, the pattern of expression of three receptors – estrogen receptor (ER), progesterone receptor 
(PR), and human epidermal growth factor receptor (HER2) – is used to broadly categorise breast 
cancer into subtypes; and, more importantly, based on the critical functions of these receptors to drive 
cell growth pathways, is used to stratify patients for appropriate therapies. For example, expression 
of the hormone receptors, ER and PR, renders breast cancer cells responsive to estradiol-mediated 
mitogenic signalling and thus sensitive to estradiol deprivation therapies, whereas HER2 expression 
indicates reliance on receptor tyrosine kinase signalling pathways and thus a unique susceptibility to 
HER2-directed antagonists. When combined with staining for the proliferation marker, Ki67 (Gnant 
et al., 2015, Bustreo et al., 2016), and, increasingly, in situ hybridisation for copy number 
amplification at the HER2 locus, immunohistochemistry (IHC) analysis of these four markers is 
sufficient to group patients into the four molecular subtypes: Luminal A, Luminal B, HER2-
amplified, and triple-negative (TN) breast cancers (Figure 1.5).  
 
With the increasing availability of gene expression analysis for clinical diagnostic and prognostic 
procedures, there has been much effort devoted over the last fifteen years to further refining these 
molecular subtypes into more specific subgroups based on gene expression profiles. The best- 
characterised gene expression classification system is the Prediction Analysis of Microarray 50 
(PAM50), which is a 50-gene classifier that groups breast tumours into five intrinsic subtypes (Perou 
et al., 2000, Sorlie et al., 2001). These PAM50 intrinsic subtypes correspond to different extents to 
the molecular subtypes classified using IHC (Figure 1.5; refer to concordance and relative 
frequencies), and also differentiate an additional “normal-like” subtype. This normal-like subtype is 
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poorly characterised, and there remains some controversy over whether it represents contamination 
of normal tissue or whether this is a true subgroup in its own right (Weigelt et al., 2010). An additional 
TN subtype enriched for mesenchymal markers and stem-cell-like features has since been added to 
this taxonomy (Figure 1.5) to give the “PAM50 + claudin-low” classification (Prat et al., 2010, 
Sabatier et al., 2014). Considerable efforts have been invested into developing the PAM50 and other 
multigene classifiers into clinically useful prognostic and/or predictive tools (Gyorffy et al., 2015, 
Wallden et al., 2015), some of which are now employed discretionally to guide clinical decision-
making in early-stage or low-risk breast cancers (Cardoso et al., 2016, Paik et al., 2004). However at 
present intrinsic subtype testing is performed for clinical trials only and is not yet recommended for 
use in clinical practice (Gnant et al., 2015, Guiu et al., 2012). Likewise, proposed gene expression-
based subclassifications of the TN subtype (Chen et al., 2012, Lehmann et al., 2011) are not yet used 
clinically. 
1.3.4 Clinicopathological features of breast cancer subtypes 
The molecular and intrinsic subtypes of breast cancer have distinct clinicopathological features, 
treatment response profiles, and prognoses (Carey et al., 2005, Yoo et al., 2012, Zhen et al., 2017, 
Perou et al., 2000, Sorlie et al., 2001, Sorlie et al., 2003). The key features of each subtype are 
summarised below. 
1.3.4.1 Luminal A 
Luminal A subtype is the most common subtype and represents 30-70% of all breast cancers (Sorlie 
et al., 2001, Dai et al., 2015, Carey et al., 2005). Luminal A cancers express hormone receptors, lack 
expression of HER2 and generally have good prognosis (Sorlie et al., 2001, Sotiriou et al., 2003). 
However, there is marked heterogeneity among Luminal A tumours (Ciriello et al., 2013, Cancer 
Genome Atlas, 2012, Aure et al., 2017), with some refractory to current treatment options while 
others are indolent and subject to over-treatment. Luminal A tumours respond well to hormone 
therapy but are less responsive to chemotherapy (Gnant et al., 2015). 
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Figure 1.5. Hierarchical classification of breast cancer subgroups. In clinical settings, 
a descriptive classification of breast cancer subtypes is used to stratify patients for therapy. 
This classification is based on the immunohistochemical detection of estrogen receptor, 
progesterone receptor, Ki67, and human epidermal growth factor receptor expression to 
define four molecular subtypes, each with distinct clinical outcomes and approaches to 
therapy: Luminal A, Luminal B, HER2-amplified, and triple-negative. The relative frequency 
(% of total invasive breast cancers) is indicated above each molecular subtype. There are 
differing levels of discordance between these molecular subtypes and the intrinsic subtypes 
used in research (% concordance with cognate molecular subtype, with colour-coding 
indicating relative distribution of each molecular subtype within that intrinsic subtype). 
Intrinsic subtype determined by PAM50 analysis revealed an additional controversial 
subtype, normal-like, and later studies delineated the claudin-low TN subtype. ER: estrogen 
receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; 
PAM50: Prediction Analysis of Microarray 50.  
 
Sources: Gnant et al., 2015; Prat et al., 2015; Higgins et al., 2011; Perou, 2011; Valentin et 
al., 2011; Blows et al. 2010; Carey et al., 2010; Charafe-Jauffret et al., 2006; Perou al., 2000.  
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1.3.4.2 Luminal B 
Luminal B tumours tend to be higher grade, or more anaplastic, than Luminal A, as assessed 
histologically by increased numbers of mitoses, increased nuclear:cytoplasmic ratio, and reduced 
evidence of glandular structure. Luminal B tumours are associated with lower expression and/or 
activity of ER, increased rates of DNA mutation (Cancer Genome Atlas, 2012), more frequent lymph 
node involvement (Inwald et al., 2015), and enrichment of pro-proliferative gene signatures such as 
those associated with human epidermal growth factor receptor-1 (HER1) and HER2 (Loi et al., 2009, 
Carey et al., 2005). Pathologically they are differentiated from Luminal A tumours based on Ki67 
expression (>20% positivity cutoff recommended by St Gallen Consensus 2014-5, although this is 
not yet a standardised measure; Focke et al., 2016, Bustreo et al., 2016), and have a significantly 
worse outcome than Luminal A tumours (Sorlie et al., 2001). They are much less common than 
Luminal A tumours, representing 15-40% of all breast cancers (Prat et al., 2015, Yersal and Barutca, 
2014). Like Luminal A tumours, these cancers respond well to hormonal therapy, however there is 
emerging evidence suggesting that more proliferative Luminal B tumours may benefit from adjuvant 
chemotherapy (Dai et al., 2015, Gnant et al., 2015). 
1.3.4.3 HER2-amplified 
HER2-amplified subtype is clinically classified as ER/PR negative and HER2-positive by IHC, with 
increasing usage of in situ hybridisation (ISH) to confirm copy number amplification at the HER2 
gene locus. Gene expression analysis of this group has the highest rates of discordance with molecular 
subtyping (Prat et al., 2015, Guiu et al., 2012), as enrichment of the HER2-associated gene expression 
signature is observed in some tumours of all subtypes, and around 30% of HER2 expressing tumours 
are Luminal B by gene expression analysis (Loi et al., 2009). HER2 subtype is significantly associated 
with shorter overall survival (Carey et al., 2005, Sorlie et al., 2001), high frequency of TP53 mutation 
(Sorlie et al., 2001), high rates of DNA mutation (Prat et al., 2015), and high grade (Dai et al., 2015). 
However, despite these unfavourable clinicopathological features, HER2-amplified tumours respond 
well to chemotherapy and the novel HER2-targeted therapeutic agents, trastuzumab and lapatinib. 
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Use of these agents in the aggressive HER2-positive subtype has drastically improved the survival of 
patients with both advanced and early-stage disease (Di Cosimo, 2010).  
1.3.4.4 Triple-negative (TN) 
The TN subgroups (basal-like and claudin-low) display high-risk, aggressive phenotypes: basal-like 
tumours are associated with increased recurrence and mortality (Chen et al., 2010), tend to have a 
higher recurrence rate after diagnosis, a shorter disease-free interval, rapid progression from distant 
recurrence to death, and shorter overall survival when compared to other subgroups (Abd El-Rehim 
et al., 2004, Sorlie et al., 2003, Sotiriou et al., 2003, Sorlie et al., 2001, van de Rijn et al., 2002), while 
claudin-low tumours have poor survival rates overall and invasive biological features (Prat et al., 
2010). Large-scale population studies have shown that basal-like tumours (those that express the basal 
markers, EGFR and cytokeratin 5/6; Cheang et al., 2008) have the highest prevalence of unfavourable 
histologies; after adjusting for age, race and stage, the basal-like subtype was 11 times more likely to 
have a high mitotic index, 9.7 times more likely to have high nuclear grade, and 2.5 times more likely 
to have high histologic grade than the lower-risk Luminal A subgroup (Carey et al., 2005). Similarly, 
TN breast cancers in general are associated with more aggressive clinical features and poorer 
prognosis overall (Dent et al., 2007, Haffty et al., 2006, Rakha et al., 2007), tend to be larger in size, 
higher grade, and have lymph node involvement at diagnosis (Haffty et al., 2006). TN tumours are 
associated with increased recurrence and death (Chen et al., 2010) and show high mortality rates in 
the first five years post-diagnosis (Blows et al., 2010), with high incidence of visceral metastasis 
(Anders and Carey, 2008). In addition, an association between BRCA1 germline mutations and both 
basal-like and TN breast cancers has been well described (Santarosa and Maestro, 2011). As a result, 
while TN breast cancers are only responsible for 15-20% (Dent et al., 2007, Rakha et al., 2007, Bauer 
et al., 2007) of all breast cancers, they result in a disproportionate number of breast cancer mortalities. 
However, these negative prognostic features tend to predominate in the first five years after diagnosis; 
beyond this, survival rates for TN breast cancers converge with or even overtake other subtypes (Dent 
et al., 2007, Chen et al., 2010).  
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The TN subtype is highly heterogeneous, with at least six genetic TN subgroups identified (Lehmann 
et al., 2011) that display different biological behaviours, responses to chemotherapy, and clinical 
outcomes (Masuda et al., 2013, Lehmann et al., 2016). Even the basal-like subgroup, which is the 
largest TN subgroup, can be subdivided into at least two different groups using integrative clustering, 
with these two clusters showing significant differences in outcome (Curtis et al., 2012). Despite this 
knowledge, to date there are no approved targeted therapies for TN breast cancer, and chemotherapy, 
radiotherapy and surgery remain the only therapeutic options in the majority of these cancers (Gluz 
et al., 2009), as ER, PR and HER2-directed therapies are ineffective.  
1.3.5 Current evidence for targeting glutamine metabolism in TN breast cancer 
In light of this pressing clinical need, numerous studies have examined glutamine metabolism in 
breast cancer for the purposes of determining the therapeutic feasibility of targeting these pathways. 
Like many other tumour cells, breast cancers rely on glutamine to fuel cell growth and proliferation, 
but show subtype-specific differences in glutamine metabolism. Luminal breast cancers have higher 
expression of glutamine synthetase, and as a consequence are less dependent on glutamine availability 
to sustain their growth (Kung et al., 2011). In contrast, TN breast cancer patient samples and cell lines 
show increased expression of glutamine-utilising genes, as well as increased consumption of 
glutamine and increased reliance on exogenous glutamine than other subtypes (Terunuma et al., 2014, 
Jeon et al., 2015, Kim et al., 2013b, Kung et al., 2011, Timmerman et al., 2013). Together these 
changes suggest a unique metabolic vulnerability in TN breast cancer cells that could be exploited 
therapeutically, “starving” cells of this essential nutrient to prevent cell growth.  
 
Alterations in the global transcriptional landscape of TN cells also suggests that glutamine 
metabolism may be a viable target in this subset. MYC is an important initiator and regulator of 
glutamine metabolism (Wise et al., 2008), and is a common oncogenic driver in breast cancer, 
occurring in around 15% of all tumours (Deming et al., 2000). A recent gene ontology analysis of 
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two independent breast cancer cohorts showed that all processes significantly associated with high 
MYC expression in ER-negative tumours were involved in glucose metabolism, amino acid 
metabolism or transmembrane transport (Green et al., 2016), suggesting profound alterations in 
metabolic phenotype in ER-negative tumour cells. Overexpression of MYC is also significantly 
associated with poor prognosis, hormone-receptor negativity (Alles et al., 2009), and basal-like 
subtype (Sorlie et al., 2001, Sotiriou et al., 2003, Xu et al., 2010), emphasising that these MYC-driven 
metabolic changes promote aggressive biological behaviour.  
 
A number of the enzymes involved in the metabolism of glutamine have been shown to be important 
for TN cell growth and proliferation. For example, many of the glutamate-utilising aminotransferase 
enzymes are overexpressed in breast cancer (Jin et al., 2015, Zhang and Han, 2017), with some 
showing an association with TN subtype (Thornburg et al., 2008), ER negativity (Kim et al., 2013b), 
and glutamine dependence (Korangath et al., 2015). Inhibition of these enzymes using the pan-
transaminase inhibitor, amino oxyacetate, is able to suppress proliferation of TN breast cancer cells 
in vitro and in vivo (Thornburg et al., 2008, Korangath et al., 2015), suggesting that these glutamine-
dependent nitrogen transfer pathways are essential for maintaining metabolism in these cells.  
 
Similarly, the TCA replenishing enzyme, pyruvate carboxylase, which catalyses the irreversible 
conversion of pyruvate to oxaloacetate, is overexpressed in breast cancer and is associated with the 
TN subtype and metastasis (Phannasil et al., 2015). Knockdown of pyruvate carboxylase in TN breast 
cancer cells decreases glutamine-dependent anaplerotic flux through TCA, presumably by inhibiting 
the malate to oxaloacetate shuttle through pyruvate, causing decreased cell proliferation and viability 
(Phannasil et al., 2017). This emphasises the importance of glutamine-derived carbon to TCA cycle 
for TN breast cancer cell growth.  
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Of the glutaminolytic enzymes, the best described is glutaminase, whose expression and activity in 
TN breast cancer is well-documented (Budczies et al., 2013, Cassago et al., 2012, Kung et al., 2011, 
Timmerman et al., 2013). Accordingly, recent studies have demonstrated the efficacy of targeting 
glutaminase (GLS), the first and rate-limiting step of intracellular glutamine metabolism (Gross et 
al., 2014), with the glutaminase inhibitor CB-839 currently in clinical trials for TN breast cancers, as 
well as other solid tumours (NCT02071862). Alternatively, targeting glutamine metabolism may also 
be effective as an adjunct therapy, as glutamine deprivation and/or glutaminase inhibition sensitises 
TN breast cancer cells to existing chemotherapeutics (Chen et al., 2016, Dilshara et al., 2017, Brown 
et al., 2017), thus reinforcing the feasibility of therapies targeting the pathways of glutamine 
metabolism.  
1.3.6 Current knowledge of ASCT2 expression and function in breast cancer 
To support these intracellular pathways of glutamine metabolism, the transport mechanisms required 
for sustained glutamine uptake are also altered in breast cancer. ASCT2 is known to be upregulated 
in breast cancer (Fuchs and Bode, 2005, Kim et al., 2014, Kim et al., 2013b, Kim et al., 2013a) and 
shows differential expression across subtypes, with highest expression of ASCT2 in poor prognosis, 
highly-proliferative subtypes (HER2 and basal-like) and lower expression in less aggressive, Luminal 
A tumours (Kim et al., 2013b, Jeon et al., 2015). These studies suggest that ASCT2 has functional 
importance in TN breast cancer, however, little is known about the role of ASCT2 in these settings. 
High ASCT2 expression is also correlated with reduced disease-free survival in breast cancer (Jeon 
et al., 2015), supporting the suggestion that it plays a role in breast cancer cell growth and 
proliferation. Based on these data, our hypothesis is that ASCT2 is upregulated in high-risk, 
proliferative breast cancers that require glutamine for their growth, and in this context, may present 
a novel target for therapeutic intervention. Importantly, two recent reports of an ASCT2-/- mouse 
model revealed either no phenotype, or only a mild immune phenotype (Masle-Farquhar et al., 2017, 
Nakaya et al., 2014); suggesting that drugs selectively targeting ASCT2 would have a tolerable safety 
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profile with potentially less on-target toxicity in normal cells compared to current untargeted 
mainstays of TN breast cancer treatment. 
1.4 Summary and Aims 
Elevated expression of glutamine metabolism-related genes, MYC-driven transcriptional events, and 
increased consumption and reliance on glutamine are all associated with aggressive breast cancers, 
including the high-risk TN subtype, where there is a need for novel targeted therapies. ASCT2 is a 
key mediator of glutamine uptake in cancer, and blocking its function can effectively inhibit cell 
growth and proliferation in numerous human cancers. As ASCT2 is expressed in highly proliferative 
subtypes of breast cancer (Kim et al., 2013b), this transporter and its downstream intracellular 
pathways may be a viable therapeutic target in TN breast cancers.  
Aim 1: Assess the glutamine transporter, ASCT2, as a therapeutic target in breast cancer 
This chapter aims to delineate breast cancer cell dependency on ASCT2 function and glutamine 
metabolism using a suite of basic science techniques integrated with clinical analyses. Firstly, the 
effect of ASCT2 inhibition in a variety of human breast cancer cell lines will be assessed. This will 
involve characterising the protein expression and subcellular distribution of ASCT2 in cell lines, 
followed by functional assessment using both pharmacologic inhibition and shRNA protein 
knockdown. Pharmacologic inhibition of the ASCT2 transporter will be undertaken using the 
competitive inhibitor, L-g-glutamyl-p-nitroanilide (GPNA), while shRNA knockdown will be 
achieved using both stable and inducible lentiviral delivery systems for use both in vitro and in vivo. 
Measurements of viability, proliferation, cell cycle progression, autophagy, and apoptosis will be 
performed for in vitro experiments, and assessment of tumour engraftment and growth will be 
performed for in vivo experiments. These data will be complemented by Taqman Low Density Array 
(TLDA) gene expression analysis of xenograft tissue to assess transcriptional changes when ASCT2 
is knocked down in vivo. Nanostring assessment of ASCT2 gene expression will also be performed 
in ~90 TN breast cancer patient samples to confirm the clinical utility of any findings, and to 
investigate any correlations with genes associated with amino acid uptake and metabolism, 
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proliferation, or nutrient stress response, as well as genes that have significant associations with 
overall patient survival in breast cancer. 
Aim 2: Characterise the intracellular metabolism of glutamine in breast cancer cells 
This chapter aims to determine whether highly proliferative TN breast cancers that are sensitive to 
ASCT2 inhibition have a unique metabolic signature that could be additionally exploited for 
therapeutic purposes. This will be investigated using a targeted metabolomics approach, combining 
heavy isotope-labelled glutamine tracing, liquid chromatography coupled tandem-mass spectrometry 
(LC-MS/MS) and gas chromatography mass spectrometry (GC-MS) to analyse intracellular levels of 
key TCA cycle intermediates, glycolytic metabolites, fatty acid precursors, and amino acids in human 
breast cancer cell lines. Incorporation of glutamine into biosynthetic pathways will be assessed using 
a cell fractionation approach that allows tracing of total radioisotope-labelled glutamine into CO2 
production, RNA, DNA, protein, acid-soluble polar metabolites, organic soluble metabolites, and 
effluxed extracellular metabolites, in a single sample. The contribution of glutamine to ATP 
production will be assessed using Seahorse live cell analysis, comparing oxidative metabolism and 
lactate production pathways, to characterise the glutaminolytic phenotype of breast cancer cells and 
assess their flexibility in utilisation of glutamine as a fuel. These analyses will be performed across 
multiple cell lines representative of both Luminal A and TN breast cancer to compare glutamine fate 
and utilisation, and then compared to cells treated with the ASCT2 inhibitor, GPNA, to determine the 
critical metabolic nodes that dictate glutamine reliance in the TN subtype. Our in vitro data will be 
complemented by in silico analysis of samples included in The Cancer Genome Atlas (TCGA) 
provisional dataset for invasive breast cancer, to assess whether any subtype-specific metabolic 
differences are reflected in changes at a gene expression level. 
Aim 3: Determine the efficacy of dual glutamine and leucine uptake inhibition in breast 
cancer cells 
This chapter aims to investigate whether dual targeting of glutamine and leucine uptake is effective 
in inhibiting breast cancer cell growth, as it is in melanoma (Wang et al, 2014). This will build on the 
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findings from Aim 1 which showed that blocking glutamine uptake prevents cell growth in TN basal-
like breast cancer cells, and results from other recent studies showing that breast cancer cells are 
sensitive to leucine deprivation (Xiao et al, 2016). This combinatorial approach will be assessed using 
the ASCT2 inhibitor, Benzylserine (BenSer), which we have previously shown can also inhibit 
leucine uptake by LAT1 (Wang et al., 2014a), thus making it an ideal putative inhibitor for this dual 
leucine-glutamine deprivation therapy. Using a suite of basic science techniques combined with 
targeted metabolomics analyses, the effects of BenSer treatment on cell viability, proliferation, cell 
cycle progression, apoptosis, intracellular amino acid levels, activation of mTORC1 pro-growth 
signalling, and amino acid response stress signalling, will be assessed across multiple breast cancer 
cell lines.  
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CHAPTER 2  
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2.1 Materials and Methods 
 
2.1 Mammalian tissue culture 
2.1.1 Materials for tissue culture: 
Phosphate Buffered Saline (PBS) 
PBS (10´; LifeTechnologies), diluted to 1´ in MilliQ water, pH 7.4. Autoclaved before use. 
2-Amino-2-norbornanecarboxylic acid (BCH) solution 
BCH stock solution (200 mM; diluted in PBS). Stored at room temperature. 
Benzylserine solution 
Benzylserine stock solution (100 mM; diluted in water). Stored at room temperature and 
heated for 10 min at 56°C to ensure complete dissolution before use. 
GPNA solution 
GPNA stock solution (10 mM; diluted in water). Stored at room temperature and heated for 
10 min at 56°C to ensure complete dissolution before use. 
Sulfasalazine solution 
Sulfasalazine (SASP) stock solution (5 mM; diluted in water). Stored at room temperature. 
2.1.2 Cell lines  
Human breast cancer cell lines T47D, HCC1806, HCC1937, MDA-MB-231 and MDA-MB-468 were 
purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). MCF-7 and 
MCF10a cells were a kind gift from the Vascular Biology Group, Centenary Institute, Camperdown, 
Sydney, NSW, Australia. BT20, HCC1500 and HCC1569 cells were a kind gift from the Tumour 
Progression Laboratory, Garvan Institute, Darlinghurst, Sydney, NSW, Australia. Cell lines were 
authenticated by STR fingerprinting every 2 years (CellBank Australia, Westmead, Sydney, NSW, 
Australia) and were cultured in specific growth media as follows:  
MCF10a cells were cultured in high-glucose DMEM (Life Technologies, Australia) containing 5% 
(v/v) fetal bovine serum (FBS), 20 ng/mL epidermal growth factor (EGF; Abcam, United Kingdom), 
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0.5 µg/mL hydrocortisone (Sigma-Aldrich, Australia), 100 ng/mL cholera toxin (Sigma-Aldrich), and 
10 µg/mL insulin (Sigma-Aldrich), as described by Debnath et al. (Debnath et al., 2003). MCF-7 
cells were grown in MEM medium (Life Technologies) containing 10% (v/v) FBS, 2 mM L-
glutamine (Life Technologies), 1mM sodium pyruvate (Life Technologies) and penicillin-
streptomycin solution (Sigma-Aldrich). BT20, T47D, HCC1500, HCC1569, HCC1806, HCC1937, 
MDA-MB-231 cells were grown in RPMI-1640 medium (Life Technologies) containing 10% (v/v) 
FBS, 1 mM sodium pyruvate (Life Technologies) and penicillin-streptomycin solution (Sigma-
Aldrich, Australia). MDA-MB-468 cells were grown in DMEM (Life Technologies) containing 10% 
(v/v) FBS, 2 mM L-glutamine (Life Technologies), 1 mM sodium pyruvate (Life Technologies) and 
penicillin-streptomycin solution (Sigma-Aldrich). 
2.1.3 Maintenance of cells in culture 
 
All cells were maintained at 37°C/5% CO2 and cultured in Corning® 25, 75 or 175 cm2 canted neck 
tissue culture flasks with filter caps (Sigma-Aldrich; St Lois, MO, USA). Experiments were carried 
out using Corning® 10 cm plates or Corning® Costar® 6, 12, 24 or 96-well plates (Sigma-Aldrich). 
Adherent cells were passaged every 3-5 days upon reaching an approximately 70% confluent 
monolayer to prevent overgrowth and cell death. Following removal of the media, TrypLEÔ Express 
(Invitrogen) was added to detach the cells. Complete media was added to inactivate the TrypLEÔ, 
cells were resuspended and centrifuged at 1500 rpm for 5 min to pellet the cells. The supernatant was 
removed and cells were resuspended in complete media before being transferred into a new flask 
containing fresh media. Cells were passaged at a ratio of 1:2 to 1:20 depending on the cell type. Cells 
were periodically frozen down for long-term storage in liquid nitrogen to ensure sufficient stocks. 
For freezing, cells were washed, detached and centrifuged as normal, however after removal of 
supernatant, cells were resuspended in FCS supplemented with 10% (v/v) dimethyl sulfoxide 
(DMSO; Sigma-Adrich) as a cryoprotectant. Cell suspensions were aliquoted into 1 mL cryovials 
(Nunc International, Rochester, NY, USA), placed into a cryofreezing container (Nunc International) 
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and frozen at -80°C for at least 12 h prior to transfer to a liquid nitrogen tank for long term storage. 
Cyropreserved cells were thawed in a 37°C water bath, and then diluted in 9 mL of complete media 
in a 15 mL tube. Following centrifugation, the supernatant was removed and the cell pellet 
resuspended in fresh complete media. The cell suspension was then transferred to a 6-well plate or 
T25 flask and incubated at 37°C/5% CO2. 
All cell lines were routinely tested for mycoplasma using a PCR detection system (see Appendix for 
primers and assay details). Mycoplasma-positive cells were discarded immediately and only cells that 
were confirmed to be mycoplasma-negative were used for further culture. Any data obtained using 
mycoplasma-positive cells was excluded. 
2.1.4 Drug Administration in Cell Culture 
Cells were seeded into appropriate culture dishes in complete media and allowed to adhere overnight. 
Media was then aspirated and replaced with complete media containing 2-Amino-2-norbornane-
carboxylic acid (BCH; 10 mM; Sigma-Aldrich), H-Ser(Ezl)-OH (Benzylserine, Ben; 10 mM; Sigma-
Aldrich), L-g-glutamyl-p-nitroanilide (GPNA; 1 mM; Sigma-Aldrich), or sulfasalazine (SASP; 0.5 
mM; Sigma-Aldrich). Inhibitors were resuspended in PBS (BCH) or H2O (Ben; GPNA; and  SASP). 
Drug dilutions in complete media were prepared fresh immediately before use from 20´ (BCH) or 
10´ (BCH, Ben, GPNA and SASP) stock solutions, after heating at 56°C for 20 min to ensure 
complete dissolution of any crystals. 
2.2 Molecular cloning 
2.2.1 Materials for molecular cloning 
Luria-Bertani (LB) broth 
2% (w/v) LB powder (Life Technologies) in water 
LB-Agar 
LB broth containing 1.5% (w/v) bacteriological grade agar (Bacto) 
Chemically-competent E.coli bacteria cells 
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One Shot TOP10 E.coli (Invitrogen) expanded in-house by Cynthia Metierre and Yue Feng 
(Research Assistants, Gene Therapy Lab, Centenary Institute) to generate chemically-
competent stocks using the calcium chloride method 
Superoptimal broth with catabolite repression (SOC) 
2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 20 mM glucose, 10 
mM MgCl2 
Bromophenol blue buffer 
30% (v/v) glycerol, 0.25% (w/v) bromophenol blue 
2.2.2 Nucleic acid quantitation using UV spectrophotometry 
Nucleic acid (RNA or DNA) concentration and purity was measured by placing 1-2 µL of nucleic 
acid solution on a Nanodrop 1000 spectrophotometer (Biosciences; Victoria, Australia). The nucleic 
acid purity was assessed by determining the absorbance of the sample at 230 nm, 260 nm and 280 
nm and calculating the ratios appropriately. For RNA, an A260:A280 ratio of >2.0 was considered 
pure. For DNA, an A260:A280 ratio of >1.8 was considered pure. An A260:A230 ratio of ~2 was 
used as a secondary measure of purity for RNA and DNA preparations that had been isolated from 
TRIzol. 
2.2.3 Bacterial transformation 
At least 100 ng of plasmid DNA was used to transform chemically-competent TOP10 E.coli bacterial 
cells (produced in-house) using the heat shock method. This consisted of a 30 min incubation of 
plasmid DNA and TOP10 cells on ice, followed by a 90 sec incubation at 42°C, 120 sec incubation 
on ice, and subsequent aseptic addition of 1 mL SOC medium for recovery at 37°C with shaking for 
at least 1 h. Bacterial cells were aseptically streaked onto LB agar plates containing the appropriate 
antibiotic selection agent, as detailed in Table 2.1, and left to grow for 16-18 h at 37°C. 
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Table 2.1.  Bacterial antibiotic selection agents. 
 
2.2.4 Plasmid DNA production and purification 
Single bacterial colonies from cultured LB agar plates were aseptically picked using a sterile pipette 
tip and used to inoculate 3 mL of sterile LB medium containing the appropriate antibiotic selection 
agent, as detailed in Table 2.1. Cultures were grown in vented tubes for 16-18 h at 37°C with orbital 
shaking. Bacterial cells were then sedimented by centrifugation at 3 000 g for 10 min and plasmid 
DNA was purified from the resulting pellets using the PureLink® Quick Plasmid Miniprep Kit 
(ThermoFisher) according to manufacturer’s instructions. Alternatively, if larger amounts of plasmid 
DNA were required, bacterial starter cultures were used to inoculate 60 mL of sterile LB medium 
containing the appropriate antibiotic selection agent, as detailed in Table 2.1. These larger cultures 
were grown in vented bottles for an additional 16-18 h at 37°C with orbital shaking and then harvested 
by centrifugation at 3000 g for 10 min. Plasmid DNA was purified from the resulting bacterial pellets 
using the HiSpeed Plasmid Midiprep Kit (Qiagen) according to manufacturer’s instructions.  
2.2.5 Production of stable knockdown constructs (pLKO.1 vector) 
shControl: Control plasmid consisted of a plant microRNA sequence (ath-miR159a; shControl), in 
the pLKO.1 vector backbone (plasmid was cloned in-house and provided by Dr Chuck Bailey, Gene 
& Stem Cell Therapy Program, Centenary Institute). The shControl hairpin has no specific targets in 
mammalian cells as detailed previously (Wang et al., 2011). Plasmid DNA was transformed and 
prepared as described above.  
shASCT2: Two pLKO.1-puro lentiviral vectors containing ASCT2-specific short hairpin RNAs were 
purchased as bacterial glycerol stocks (Sigma-Aldrich; hairpin sequences detailed in Appendix). 
Plasmid DNA was prepared from bacterial cultures grown and harvested as described above. 
Antibiotic Abbreviation/s Concentration 
Ampicillin Amp/A 100 µg/mL 
Chloramphenicol Chlor/C 20 µg/mL 
Kanamycin Kan/K 30 µg/mL 
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2.2.6 Production of inducible knockdown constructs (pH1tet-flex/FH1t(INSR)UTG 
vector system) 
shControl: Control plasmid was cloned in-house and provided by Dr Chuck Bailey, Gene & Stem 
Cell Therapy Program, Centenary Institute. It contained the plant microRNA sequence (ath-miR159a; 
shControl), as detailed above. 
shASCT2: Inducible ASCT2 knockdown was achieved using the pFH1t(INSR)UTG vector (Herold 
et al., 2008) obtained from Chuck Bailey, Gene & Stem Cell Therapy Program, Centenary Institute, 
containing an ASCT2-specific short hairpin RNA under the control of an H1-TetO promoter. This 
plasmid was cloned using the pH1tet-flex/FH1t(INSR)UTG two-step cloning strategy 
(TaconicArtemis), with some modifications as detailed below. 
2.2.6.1 shASCT2 insert preparation 
Firstly, an ASCT2-specific shRNA (Integrated DNA Technologies, Australia) was purchased as 
sense/antisense oligonucleotides with BbsI/XhoI overhangs (see Appendix for full sequences). These 
oligonucleotides were first treated with T4 Polynucleotide Kinase (PNK) by combining 0.3 nmol of 
each primer with 1 U of T4 PNK (NEB) in 1´ T4 DNA ligase buffer (NEB) in a reaction volume of 
50 µL, and incubating at 37°C for 30 min. Primers were then annealed by combining 0.12 nmol of 
each primer and incubating at 94°C for 1 min followed by a gradient cooling step (1°C per 10 sec) to 
a final incubation for 1 min at 15°C. Annealed primers were then diluted 1:100 for future use and 
stored at -30°C. 
2.2.6.2 pFH1tet-flex vector digestion and purification 
Vector (pFH1tet-flex; 2 µg) was mixed with 1 U BbsI (NEB), 1 U XhoI (NEB) and 1 U calf intestinal 
phosphatase (CIP; NEB) in 1´ NEB-approved reaction buffer in a total reaction volume of 20 µL. 
This mixture was incubated at 37°C for 2 h, then mixed with bromophenol blue loading buffer and 
loaded into a 1% (w/v) agarose gel containing GelRed (Biotium). Uncut pFH1tet-flex (200 ng) was 
loaded into an adjacent well as a control. These samples were subjected to electrophoresis at 90 V for 
45 min to ensure good resolution of bands. Correctly digested bands were then excised from the gel 
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using a scalpel, under brief UV illumination, prior to purification using Wizard® SV Gel and PCR 
Clean-up Kit (Promega), as per manufacturer’s protocol. 
2.2.6.3 Ligation of shASCT2 into pFH1tet-flex 
The annealed oligonucleotides (0.012 nmol) were mixed with 0.05 µg of BbsI/XhoI-digested 
pFH1tet-flex vector, 0.5 U of T4 Rapid Ligase (Promega), and 1´ Rapid Ligase Buffer (Promega) in 
a reaction volume of 20 µL, and then annealed at 25°C for 30 min. Ligation mixture (5 µL) was then 
used to transform chemically competent TOP10 E.coli cells as described above. Digested and CIP-
treated parent vector was ligated with UltraPureTM distilled water and separately transformed as a 
negative control. DNA from successful clones was prepared and purified as described above.  
2.2.6.4 Excision and purification of the H1-TetO-shASCT2 cassette from 
pFH1tet-flex 
Plasmid DNA from each clone was then digested using PacI to excise a fragment containing the 
shRNA insert and the upstream H1-TetO promoter region. This fragment was then isolated using 
agarose gel extraction and purified using the Wizard® SV Gel and PCR Clean-up Kit (Promega), as 
detailed above. Purity and yield after clean-up was confirmed using agarose gel electrophoresis.  
2.2.6.5 pFH1t(INSR)UTG vector digestion and purification 
Plasmid DNA (2 µg) of the pFH1t(INSR)UTG vector was digested using PacI to excise the INSR 
fragment by mixing with 1 U PacI (NEB), 1 U XhoI (NEB) and 1 U calf intestinal phosphatase (CIP; 
NEB) in 1´ NEB-approved reaction buffer in a total reaction volume of 20 µL. This mixture was 
incubated at 37°C for 2 h, then mixed with bromophenol blue loading buffer and loaded into a 1% 
(w/v) agarose gel containing GelRed (Biotium). Uncut pFH1tet-flex (200 ng) was loaded into an 
adjacent well as a control. These samples were subjected to electrophoresis at 90 V for 45 min to 
ensure good resolution of bands. Correctly digested bands were then excised from the gel using a 
scalpel, under brief UV illumination, prior to purification using Wizard® SV Gel and PCR Clean-up 
Kit (Promega), as per manufacturer’s protocol. 
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2.2.6.6 Ligation of the H1-TetO-shASCT2 cassette into pFH1t(INSR)UTG 
Successfully purified PacI-digested H1-TetO-shASCT2 fragments were then mixed with PacI-
digested pFH1t(shRNA)UTG vector in a 3:1 molar ratio (as determined by agarose gel 
electrophoresis) with 0.5 U of T4 Rapid Ligase (Promega), and 1´ Rapid Ligase Buffer (Promega) 
in a reaction volume of 20 µL. This mixture was then annealed at 25°C for 30 min. Ligation mixture 
(5 µL) was then used to transform chemically-competent TOP10 E.coli cells and plasmid DNA was 
prepared and purified as described above. Resulting clones were sequence-verified using BigDye3.1 
Sanger sequencing (Ramaciotti Centre for Genomics, University of NSW, Randwick, Australia).  
2.2.7 Production of mCherry-luciferase reporter construct 
Stoichiometric expression of mCherry and firefly luciferase was achieved by stable transduction with 
lentivirus, using the third-generation lentiviral expression vector pHIV1SDm (Koldej et al., 2005) 
containing a mCherry-P2A-luciferase cassette. This plasmid was cloned in-house and provided by Dr 
Chuck Bailey, Gene & Stem Cell Therapy Program, Centenary Institute.  
2.2.8 Ethanol precipitation of plasmid DNA 
Purified plasmid DNA was precipitated for the purposes of concentration and/or sterilisation using 
the ethanol precipitation method. After determining the total volume of plasmid DNA, 1/10th volume 
of 3 M sodium acetate was added followed by two volumes of 100% ethanol. This mixture was then 
placed on ice for 10 min to allow plasmid DNA to precipitate. Precipitated DNA was then sedimented 
by centrifugation at 12 000 g for 10 min. The DNA pellet was washed once with 70% ethanol and 
then air dried before resuspension in sterile 1/10th TE buffer to final concentration of 1 µg/µL. 
Concentrated sterile plasmid DNA was stored at -30°C. 
2.3 Lentivirus production 
2.3.1 Materials for lentivirus production 
300 mM phosphate buffer 
195 mM Na2HPO4, 105 mM NaH2PO4, pH 7.05 
2X HEPES buffer 
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140 mM NaCl, 50 mM HEPES, pH 7.05 
1/10th TE buffer 
1 mM Tris-Cl, 0.1 mM EDTA, pH 7.6 
75% Ethanol 
75% (v/v) reagent-grade ethanol (Sigma), 25% (v/v) UltraPureTM DNase/RNase-Free distilled 
water (Invitrogen) 
2.3.2 Plasmid DNA preparation and packaging systems 
Replication-incompetent shRNA-knockdown lentiviral particles were produced using the 4-plasmid 
retroviral packaging system (Vigna et al., 2005). HEK293T cells were seeded at 4 ´ 106 cells per 15 
cm plate in complete DMEM and incubated overnight at 37°C. The following day when cells had 
reached ~50% confluence, the cell medium was supplemented with 25 µM chloroquine (Sigma; St 
Lois, MO, USA) 1 h prior to transfection. Sterile concentrated plasmid DNA was heated at 65°C for 
10 mins to dissociate plasmid aggregates and was combined as shown in Tables 2.2 and 2.3 for 
transfection. 
 
Table 2.2. Composition of plasmid DNA solution used for calcium phosphate transfection 
for the production of lentiviral particles with four-plasmid packaging system. 
Plasmid DNA Concentration (µg/µl) 
Amount 
required for 15 
cm plate (µg) 
Supplier 
pLKO.1-athmir159a 1 
29.5 
Charles G. Bailey, 
Centenary Institute 
pLKO.1-shA28 1 Sigma 
pLKO.1-shA63 1 Sigma 
pLKO.1-shLAT1  Charles G. Bailey, Centenary Institute 
pFH1t-UTG-
athmiR159a 1 
Charles G. Bailey, 
Centenary Institute 
pFH1t-UTG-shASCT2 1 Cloned as described in Section 2.2.6 
pMDLg/prre 1.033 12.7 Elim Biopharmaceuticals 
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pRSVRev 1.092 3.9 Elim Biopharmaceuticals 
pMDZ-VSV-G 0.770 4.9 Elim Biopharmaceuticals 
 
The mCherry-luciferase lentiviral particles were produced in a similar manner, using a HIV-1, Tat-
dependent, five-plasmid retroviral packaging system (Koldej et al., 2005) as outlined in Table 2.3 
below: 
 
Table 2.3. Composition of plasmid DNA solution used for calcium phosphate transfection 
for the production of lentiviral particles with five-plasmid packaging system. 
pHIV1SDmCMVmCherry2
Aluciferase 1 47 
Charles G. Bailey, 
Centenary Institute 
pcDNA3Tat101ml 0.856 0.940 Elim Biopharmaceuticals 
pHCMVRevmlwhvpre 0.579 0.940 Elim Biopharmaceuticals 
pHCMVgagpolmllstwhv 0.942 4.7 Elim Biopharmaceuticals 
pHCMV-G (VSV-G) 0.573 2.4 Elim Biopharmaceuticals 
 
2.3.3 Calcium phosphate transfection 
Solution A was prepared by combining 16.7 µl of 300 mM phosphate buffer and 3.33 ml 2´ HEPES 
buffer. Solution B was prepared by combining 333 µl of 2.5 M CaCl2, 3 mL of 1/10th TE buffer and 
plasmid DNA. Solution B was added dropwise to solution A whilst vortexing and incubated for 1 
min at room temperature to allow precipitation. The precipitate was added dropwise to the cells, and 
the plates incubated overnight at 37°C. At ~16 hrs post-transfection, the medium was removed and 
replaced with 30 mL of DMEM media supplemented with 10% FCS and 2.5 mM sodium butyrate, 
to enhance viral production. After an additional 24 h, the virus-containing supernatant was collected 
Plasmid DNA Concentration (µg/µl) 
Amount 
required 
for 15 cm 
plate (µg) 
Supplier 
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and filtered with a 0.45 µm syringe filter (MillexHV Millipore; Billerica, MA, USA) to remove any 
cell debris. Where possible, the transfection efficiency was confirmed qualitatively prior to collection 
by viewing eGFP or mCherry positive cells using an inverted fluorescence microscope, M205 FA 
(Leica Microsystems, Wetzlar, Germany).  
2.3.4 Concentration of lentiviral supernatant 
Viral supernatants were transferred to ultracentrifuge tubes (Beckman Coulter; Fullerton, CA, USA) 
on ice and spun at 26 000 g for 2 h at 4°C, in a Beckman L8-70M Ultracentrifuge using an SW28 
rotor (Beckman). The resulting pellet was resuspended in DMEM at 1/100th of the original volume, 
snap-frozen in 25 µL aliquots and stored at -80°C.		
2.4 Real-time quantitative polymerase chain reaction (RT-qPCR)  
2.4.1 Materials for RT-qPCR 
Primers 
All primers were designed by the author unless otherwise specified. All were purchased from 
Integrated DNA Technologies. For full sequences see Appendix. 
2.4.2 RNA extraction 
Cultured cells (1-5 × 106) or macerated tissue (10 mg) was lysed in 1 mL TRI ReagentÒ (Ambion; 
Austin, TX) and stored at -80°C until frozen. Samples were then thawed on ice followed by a 5 min 
incubation at room temperature to ensure complete cell lysis. Chloroform (200 µL; Sigma) was added 
to each 1 mL sample and then mixed to homogeneity by inversion and incubated for 15 min at room 
temperature. Samples were then centrifuged at 12 000 g at 4°C for at least 20 min. The top aqueous 
fraction (~450-500 µL) was then carefully removed to fresh tubes and 800 µL isopropanol was added 
(Sigma). RNA was precipitated overnight at -20°C and then sedimented by centrifugation at 20 000 
g for 15 min at 4°C. Pellets were washed once with 1 mL 75% ethanol, then air-dried and resuspended 
in at least 18 µL UltraPureTM distilled water (Gibco).  
		 60 
2.4.3 cDNA synthesis 
Total RNA (1 µg per sample) was DNase treated using 1 U of amplification-grade DNAseI 
(Invitrogen) in 1´ DNase Reaction Buffer in a total reaction volume of 20 µL and then incubating at 
room temperature for 15 min. DNase I activity was terminated by adding 2.5 mM EDTA (Invitrogen) 
and heating at 67°C for 15 min. RNA was then reversed transcribed into first strand cDNA using 
Superscript III reverse transcriptase (Invitrogen). Reaction mixes consisted of 1 µg of total DNase I-
treated RNA and 50 ng random hexamers (Bioline, United Kingdom), made up to a final volume of 
33 µl with UltraPureTM DNase/RNase-free distilled water (ThermoFisher Scientific; Massachusetts, 
USA). Samples were heated to 70°C for 5 mins to denature the RNA before being cooled on ice for 
1 min. The final reaction volume was then made up to 50 µl by addition of 1´ FS buffer, 5 mM DTT, 
0.5 mM dNTPs (Bioline), 40 U of RNase inhibitor (RNase OUT; Invitrogen) and 200 U of 
SuperScript III reverse transcriptase. Identical negative control samples were set up in parallel 
without the addition of reverse transcriptase (RT-). Samples were incubated at 25°C for 10 min, then 
50°C for 1 h followed by 75°C for 15 mins to inactivate the enzymes. cDNA was stored at -80°C.  
2.4.4 Real-time quantitative PCR 
Real-time quantitative PCR (RT-qPCR) was carried out using the SYBR green detection method on 
a BioRad CFX96 Real-Time System with a C1000 Thermal Cycler (BioRad; California, USA) to 
analyse gene expression. Reactions were set up in a 20 µl final volume containing 2 µl of cDNA, 0.3 
µM each of forward and reverse primers, and 0.5´ iQ SYBR Green Supermix (Qiagen). No template 
control (NTC) samples were set up in conjunction using UltraPureTM distilled water instead of cDNA, 
as well as parallel samples using RNA that had not been reverse transcribed (as outlined above; RT-
). Following each run, the cycle threshold (Ct) was automatically selected by the instrument software 
at the level that most reflected the optimal kinetic PCR parameters, and melt curves were analysed to 
ensure single PCR product formation. Analysis of the fold change in gene expression was carried out 
using the absolute quantitation method (2DCt) and normalised to a reference gene, human beta-2 
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microglobulin (HB2M). The thermal cycle conditions are outlined in Table 2.4 and primers are listed 
in the Appendix.       
 
Table 2.4. Thermo-cycling conditions used for PCR. 
R
T
-q
PC
R
 Temperature (°C) Time (sec) Number of cycles 
95 180 1 
95 10 
40 60 30 
72 20 
M
el
t 
cu
rv
e 
60-95, increment 0.5 5 1 
 
2.5 Lentiviral transduction 
2.5.1 Materials for lentiviral transduction: 
Concentrated lentivirus aliquots 
Produced as described in Section 2.4. Stored at -80°C until use. 
PolybreneÒ 
Hexadimethrine bromide (Millipore) dissolved in TDW, 8 mg/mL stock solution.  
Stored at -30°C until use. 
2.5.2 Transduction 
Cells were seeded into a 6-well plate (5 × 105 cells/well) in complete medium and incubated at 37°C 
overnight. The next day, 4 mL of complete media containing 4-8 µg/mL PolybreneÒ and ~5 × 105 
transducing units of concentrated lentivirus was added to each well. The cells were incubated with 
the virus for 16-24 h, after which the media was replaced with fresh media. 
2.5.3 Selection of lentivirally transduced cells  
After 24-48 h recovery, transduced cells were selected either by antibiotic selection or by 
fluorescence-activated cell sorting (FACS).  
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2.5.3.1 Antibiotic selection 
Stably transduced cells were selected by 7 days culture in 10 µg/mL puromycin, and were 
subsequently maintained in media containing 2 µg/mL puromycin. Gene expression knockdown was 
confirmed by RT-qPCR and/or protein knockdown was confirmed by western blotting.  
2.5.3.2 Fluorescence-activated cell sorting (FACS)  
Expression of GFP and/or mCherry was examined using a Leica M205 A stereo fluorescent 
microscope (Leica; GmbH, Wetzlar, Germany) or with flow cytometry to confirm transduction. 
Successfully transduced cells were expanded in culture to ~5 × 106 cells, then trypsinised, pelleted, 
and resuspended in FACS-wash (PBS/2%FCS) containing 1 µg/mL DAPI. Live cells (DAPI-
negative) were aseptically sorted for GFP- or mCherry-positivity by flow cytometry using a BD 
FACS Influx. In the case of mCherry-positivity, only a bright, narrow band (mCherryhi) was included 
for collection to ensure uniform expression of the mCherry-luciferase cassette in the cells used for in 
vivo imaging experiments. Purity after FACS was confirmed to be >95% for each experiment. Cells 
were maintained in 100 µg/mL normocin for 7 days following FACS to minimise the risk of bacterial 
infection. Hairpin expression was induced for experiments by treatment with 1 µg/mL doxycycline. 
Protein knockdown after doxycycline administration was confirmed by Western blotting.  
2.6 Immunofluorescence staining 
2.6.1 Materials for immunofluorescence staining: 
4% Paraformaldehyde 
4% (w/v) PFA (Sigma-Aldrich), 10% (v/v) 10´ PBS, 90% (v/v) TDW 
PBT Permeabilisation Buffer 
0.1% Triton-XÒ (Sigma) in PBS.  
Blocking Buffer 
20% (v/v) Blocking Reagent (Aves Laboratories; Tigard, OR, USA) in PBS.         
		 63 
2.6.2 Cell Culture 
All staining of cells took place in 8-well chamber culture slides (BD Falcon; MA, USA), containing 
3 × 104 cells/well that had been allowed to adhere overnight before incubation with fresh media for 
5 h.  
2.6.3 Fixation and Staining 
Media was removed and cells were washed briefly by addition and aspiration of PBS. Cells were then 
fixed by addition of 4% paraformaldehyde (PFA) solution (200 µl/well). After allowing fixation for 
15 min at room temperature, the fixative was removed and cells were washed three times in PBS for 
5 min each. Cells were then permeabilised using PBT for 10 min and were then blocked for 60 min 
at room temperature in a solution of blocking buffer. Following removal of blocking buffer, cells 
were then incubated in 150-300 µl/well of blocking buffer containing primary antibodies at the 
appropriate dilution (see Appendix), overnight at 4°C. Cells were then rinsed three times in PBS for 
5 min each, prior to the addition of fluorochrome-conjugated secondary antibodies diluted in blocking 
buffer for 2 h at room temperature in the dark. Following five rinses in PBS for 5 min each, 1 µg/mL 
DAPI was added to the final PBS wash to stain the nuclei. The 8-well chamber was then removed 
from the base of the slide and coverslips containing ProlongÒ Gold anti-fade reagent were used to 
mount the slide. The edges of the coverslip were sealed with clear nail polish to prevent drying out. 
Specimens were then examined using a Deltavision Personal DV microscope (Applied Precision; 
Issaquah, WA, USA) at the appropriate excitation wavelength. The resulting images were analysed 
using softWoRX (Applied Precision) by subjecting image data to 10 cycles of deconvolution to 
produce a final z-stack, from which the best slice was selected for analysis. Long-term storage of 
slides took place at room temperature, protected from light.  
2.7 Amino acid uptake assays 
2.7.1 Materials for amino acid uptake assays 
HBSS buffer 
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HBSS (Invitrogen) supplemented with 10% (v/v) dialysed FCS (LifeTechnologies). Stored at 
4°C. 
Glutamine-free MEM media 
MEM supplemented with Pen/Strep and 10% (v/v) dialysed FCS. Stored at 4°C. 
Leucine-free RPMI media 
RPMI 1640 with L-glutamine and sodium bicarbonate (Sigma) supplemented with 10% 
dialysed FCS, 0.2 mg/L L-arginine (Sigma), and 0.05 g/L L-lysine hydrochloride (Sigma). 
2.7.2 Leucine uptake assay 
Cells (3 × 105 per sample) were prepared by detaching and centrifuging as previously described 
before being washed in HBSS buffer and resuspended in leucine-free RPMI media containing 0.3 
mCi [3H]-L-leucine (200 nM, Perkin Elmer). Cells (1 × 105) were seeded in triplicate into wells of a 
flat-bottomed 96-well plate and incubated for 15 min at 37°C, with or without the additional 
administration of the inhibitory drugs immediately after resuspension. Cells were collected, 
transferred to filter paper using a FilterMate 96-well plate harvester (PerkinElmer; Waltham, MA, 
USA), dried, exposed to scintillation fluid (Betaplate scintillation fluid, PerkinElmer) and counts 
measured using a MicroBeta® liquid scintillation counter (PerkinElmer).  
2.7.3 Glutamine uptake assay 
Cells (3 × 105 per sample) were prepared by detaching and centrifuging as previously described 
before being washed in HBSS buffer and resuspended in glutamine-free MEM media containing 0.3 
mCi [3H]-L-glutamine (200 nM, Perkin Elmer). Cells (1 × 105) were seeded in triplicate into wells of 
a flat-bottomed 96-well plate and incubated for 15 min at 37°C, with or without the additional 
administration of the inhibitory drugs immediately after resuspension. Cells were collected, 
transferred to filter paper using a FilterMate 96-well plate harvester (Wallac PerkinElmer), dried, 
exposed to scintillation fluid (Betaplate scintillation fluid, PerkinElmer) and counts measured using 
a MicroBeta® liquid scintillation counter (Perkin Elmer).  
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2.8 Western blot  
2.8.1 Materials for western blot 
Cell lysis buffer 
20 mM Tris-Cl, 150 mM NaCl, 1 % (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, 
0.1% (w/v) SDS. Stored at 4°C. 
Cathode buffer 
25 mM Tris-Cl, 40 mM glycine, 10% (v/v) methanol in TDW, pH 9.4. Stored at 4°C. 
Anode buffer I 
0.3 M Tris, 10% (v/v) methanol in TDW, pH 10.4. Stored at 4°C. 
Anode buffer II 
25 mM Tris, 10% (v/v) methanol in TDW, pH 10.4. Stored at 4°C. 
BSA Blocking buffer 
2.5% (w/v) bovine serum albumin (Amresco, USA) in PBST. Stored at 4°C. 
Skim milk Blocking buffer 
5% (wv) skim milk powder in PBST. Stored at 4°C. 
PBST 
1´ PBS containing 0.1% TweenÒ 20. Stored at room temperature. 
2.8.2 Cell culture 
Cells were seeded at a density of 8 × 105 cells/well into 6-well plates and allowed to adhere overnight. 
The next day, media was removed and replaced with 1 mL fresh media for 6 h. Where appropriate, 
drugs were included in the fresh medium for these 6 h. 
2.8.3 Cell lysis and protein quantification 
Media was removed and cells were washed three times in cold PBS to remove all traces of FCS. 
Protein was isolated from ~1 × 106 cells by addition of 200 µl of cell lysis buffer, containing 1´ 
protease inhibitor cocktail III (A.G. Scientific, San Diego, CA) and 1´ phosphatase inhibitor cocktail 
(Cell Signalling).  Cells were incubated on ice with gentle agitation for 5-10 min before transfer to 
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labelled eppendorf tubes and immediate storage at -80°C. The next day, protein samples were 
sonicated for 10 cycles of 30 sec on:30 sec off using a BioRuptorÒ Plus (Diagenode; NJ, USA) to 
ensure complete membrane and DNA fragmentation. Protein concentration of the resulting sonicate 
was determined by bicinchoninic (BCA) assay using a micro-BCA kit (Pierce; Rockford, IL, USA). 
This was performed by diluting duplicate aliquots of protein lysate 1:50 in TDW, and then combining 
each aliquot with an equal volume of pre-mixed Reagents A+B in a 96-well plate. Samples were 
incubated at 37°C for 30 min and then absorbance was read at 570 nm using a POLARstar plate 
reader. 
2.8.4 SDS- polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples (20-50 µg) were separated using a 4-12% NuPAGEÒ NovexÒ Bis-Tris 10- or 12- 
well mini gel, 1.0 or 1.5 mm thickness (Invitrogen). The mini gel was assembled into the XCell 
SureLockÔ Mini Cell and the outer chamber was filled with 400 mL of 1´ NuPAGEÒ MOPS SDS 
Running buffer. The inner chamber was filled with 200 mL of fresh running buffer.  Prior to loading, 
samples were incubated for 10 min at 85°C with 1´ NuPAGEÒ LDS sample buffer and 10 mM 
Dithiothreitol (DTT) reducing agent. Electrophoresis was run at 120 V for 120 min or until the loading 
dye had reached the bottom of the gel. Protein sizes were determined by comparison with Precision 
Plus ProteinÔ Standard (BioRad; Hercules, CA, USA) run in a lane adjacent to protein samples.       
2.8.5 Western blot 
Following resolution of the proteins, the gel was removed and calibrated in cathode buffer for 2 min. 
The Immobilon Polyvinylidene fluoride (PVDF) membrane (Millipore; Merck, USA) was prepared 
by cutting it to the dimensions of the gel and notching the corner to orientate it. The PVDF membrane 
was immersed in 100% methanol for 15 sec, rinsed briefly in TDW, and then equilibrated in anode 
buffer II for 2 min. Two sheets of filter paper (Whatman; Dassel, Germany) cut to the dimensions of 
the gel were immersed in anode buffer I and placed in the centre of a semi-dry blotter (BioRad). One 
sheet of filter paper immersed in anode buffer II was placed on the transfer stack, followed by the 
pre-prepared PVDF membrane and the gel. Three sheets of filter paper soaked in cathode buffer were 
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then placed on top and the transfer stack was run at 1.5 – 2 mA/cm2 for 1 h. Following transfer, the 
filter paper and gel were discarded and the PVDF membrane was incubated in blocking buffer for 
either 15 min (skim milk blocking solution) or 1 h (BSA blocking solution) at room temperature. The 
membrane was then incubated overnight at 4°C in blocking buffer containing primary antibody at an 
appropriate dilution (see Appendix). The membrane was then washed 3 times for 5 min each in PBST, 
before incubation with the secondary antibody conjugated to horseradish peroxidase (HRP) for 2 h at 
room temperature. The membrane was washed again as previously described, prior to development 
using a chemiluminescent HRP substrate. The SuperSignal West Pico chemiluminescent substrate 
(Pierce) was prepared by mixing 1 mL each of the stable peroxide buffer and the luminal/enhancer 
solution, and added to the membrane for 30 sec at room temperature. The membrane was then imaged 
using the Kodak Image Station 4000R Pro (Carestream Health; Rochester, NY, USA) or BioRad 
ChemiDoc Touch Imaging System (BioRad).  
2.9 Cell proliferation assays 
2.9.1 Materials for cell proliferation assays 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent 
5 mg/mL stock solution stored at 4°C after thawing. Further aliquots stored at -30°C	until	use.  
Isopropanol/HCl solution 
Isopropanol with 0.04 N HCl. Stored at 4°C. 
2.9.2 Cell culture 
Cells were seeded (MCF10A, MCF-7, T47D, HCC1806, MDA-MB-231, BT20: 3 × 103/well; 
HCC1500, HCC1569, MDA-MB-468: 1 × 104/well) into a flat-bottomed 96-well plate. The cells 
were incubated overnight at 37°C in complete media, prior to drug administration and subsequent 
incubation for a further 24, 48 or 72 h. Media was removed and administration of drugs was repeated 
every 24 h.  
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2.9.3 MTT Assay 
Mitochondrial activity as an indirect measure of cell proliferation was assessed at days 0, 1, 2 and 3 
by the addition of MTT solution (10 µL) to each well and returning plates to incubation for at least 4 
h. Following this, 100 µL of isopropanol/HCl solution was added to each well and then mixed 
thoroughly using a multichannel pipette. Absorbance in each well was then immediately read at 570 
nm and 630 nm in a POLARstar Omega microplate reader or a FLUOstar Omega microplate reader 
(BMG Labtech; VIC, Australia). Background absorbance was eliminated by subtracting absorbance 
at 630 nm from absorbance at 570 nm. Results were then plotted as percentages of the absorbance 
observed in control wells at day 0. All experiments were performed in triplicate. 
2.9.4 CyQUANT Direct Cell Proliferation Assay 
Proliferation was measured at days 0, 1, 2 and 3 by the addition of 2´ CyQUANT Detection reagent 
(100 µL; LifeTechnologies; comprising Kit Components A and B diluted in media according to 
manufacturer’s instructions) to each well and returning plates to incubation for at 1 h. Following this, 
fluorescence intensity was measured with an excitation wavelength of 484 nm and an emission 
bandpass filter of 520/20 nm on a FLUOstar microplate reader (BMG Labtech). Results were then 
plotted as percentages of the absorbance observed in control wells at day 0. All experiments were 
performed in triplicate. 
2.10 Propidium Iodide cell cycle analysis 
2.10.1 Materials for cell cycle analysis 
 
Propidium Iodide (PI) staining solution 
20 µg/mL PI, 0.1% (v/v) Triton X-100, 200 µg/mL RNase-A (Amresco) in PBS  
2.10.2 Cell Culture 
Cells were seeded (MCF-7: 2 × 105/well; T47D: 5 × 105/well; HCC1806: 2 × 105/well) into 6-well 
plates and allowed to adhere overnight. After 24 h, media was removed and drugs were administered 
in complete media (1 mL total volume per well). Cells were returned to incubation and cultured for 
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a further 24-48 h. Media was removed and replaced with fresh media containing the drugs every 24 
h.  
2.10.3 Fixation and Staining 
Cells were washed, detached and pelleted prior to fixation in an excess of ice-cold 70% ethanol and 
stored overnight at 4°C. Cells were then washed once with PBS to remove all traces of ethanol and 
resuspended in PI staining solution solution. Cells were incubated for 45 min on ice and then analysed 
on a Becton Dickinson (BD) Canto II flow cytometer. Cell cycle analysis was done using FlowJo 
6.4.3 (TreeStar Inc.; Ashland, OR, USA). 
2.11 Bromodeoxyuridine (BrdU) incorporation assay 
2.11.1 Cell culture 
Cells were seeded (3 × 105/well) in duplicate into 6-well plates and allowed to adhere overnight. The 
next day, media was removed and drugs were administered in complete media (1 mL total volume 
per well). Cells were returned to incubation and cultured for 24 h.  
2.11.2 BrdU pulse 
Cells were pulsed by adding BrdU (Becton Dickinson) directly to each well (150 µg/mL) for the final 
2 h of the 24 h incubation. 
2.11.3 Fixation and analysis 
Media was removed and cells were detached using TrypLETM Express, then sedimented by 
centrifugation for 5 min at 300 g at 4°C. The resulting pellet was washed once with PBS and then 
fixed by adding 100 µL of BD Cytofix/Cytoperm Buffer (Becton Dickinson) dropwise while 
vortexing gently. Cells were incubated for 30 min on ice and then centrifuged at 300 g for 5 min at 
4°C. After removing the supernatant, fixed cells were resuspended in 70% ethanol and stored at 4°C 
until analysis. Fixation and staining was done using the APC BrdU Flow Kit (BD Pharmingen) 
according to manufacturer’s instructions. Analysis was performed on a Becton Dickinson (BD) Canto 
II flow cytometer.  
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2.12 IncuCyteTM ZOOM live cell imaging 
2.12.1  Cell culture 
Cells were seeded into 12-well (1 × 105/well), 24-well (2 × 104/well), or 96-well (5 × 103/well) plates 
and allowed to adhere overnight. The next day, media was removed and replaced with fresh media 
containing drug/vehicle where appropriate. 
2.12.2  Staining 
Live cells were stained with 0.1´ CyQUANT Detection reagent mix in 100 µL media for 1 h in the 
dark at 37°C. Dead cells were then counter stained with 1 µg/mL PI (Sigma) by diluting 1000´ stock 
directly in the wells. Plates were then incubated for 10 min in the dark at 37°C.  
2.12.3  Imaging and analysis  
Plates were imaged using the 10´ objective on an IncuCyteTM ZOOM microscope with an IncuCyteTM 
ZOOM HD/Dual Color Filter Cube placed inside a humidified 37°C/5% CO2 incubator. Using the 
inbuilt fluorescence and phase contrast filters, images were captured for green fluorescence (live 
cells; 0.4 sec exposure time), red fluorescence (dead cells; 0.8 sec exposure time) and phase contrast. 
At least three images were acquired for each well. Using the IncuCyteTM ZOOM software, a 
processing definition was created for each experiment that correctly identified individual green cells, 
red cells, and phase-contrast cells with sufficient detection sensitivity and object edge discrimination. 
These analyses were used to determine the average number of green objects/image, red objects/image, 
and phase objects/image for each well. These values were used for subsequent analysis. A 
representative image from each well was selected manually for use in figures. 
2.13 Annexin-V apoptosis assay 
2.13.1 Materials for Annexin-V apoptosis assay 
10´ Annexin-V Binding Buffer 
0.1 M HEPES, 1.4 M NaCl, 25 mM CaCl2. Stored at room temperature and diluted in TDW 
to 1´ working stock. 
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2.13.2 Cell culture 
Cells were seeded (3 × 105/well) in duplicate into 6-well plates and allowed to adhere overnight. The 
next day, media was removed and drugs were administered in complete media (1 mL total volume 
per well). Cells were returned to incubation and cultured for 24 h. At approximately 16 h before 
analysis, apoptosis was induced in additional untreated wells by exposing the plate to 300 mJ of 
ultraviolet radiation using a UV Stratalinker 2400 and then returning to incubation. 
2.13.3 Staining and analysis 
Cells and media (containing any detached cells) were collected and sedimented by centrifugation, 
then washed once with PBS before being resuspended in 100 µL of 1´ Annexin-V Binding Buffer 
containing 1:100 anti-Annexin-V-APC. Samples were incubated for 1 h on ice in the dark and then 
100 µL of 20 µg/mL PI solution (Sigma) was added to each sample for 15 min prior to analysis. UV-
irradiated cells were stained in the same way and used as a positive control for apoptosis. Samples 
were then immediately analysed on a Fortessa flow cytometer (BD). Using quadrant gating, cells that 
were Annexin-V-negative/PI-negative were classified as “viable”, Annexin-V-positive/PI-negative 
cells were classified as “early stage apoptotic”, Annexin-V-positive/PI-positive cells were classified 
as “late stage apoptotic”, and Annexin-V-negative/PI-positive cells were classified as “necrotic”. 
2.14  Detection of cleaved caspase 
2.14.1 Materials for detection of cleaved caspase 
4% Paraformaldehyde 
4% (w/v) PFA (Sigma-Aldrich), 10% (v/v) 10´ PBS, 90% (v/v) TDW 
PBT Permeabilisation Buffer 
0.1% Triton-XÒ (Sigma) in PBS 
Blocking Buffer 
20% (v/v) Blocking Reagent (Aves Laboratories; Tigard, OR, USA) in PBS  
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2.14.2 Cell culture 
Cells were seeded (1 × 105/well) in duplicate into 8-well chamber slides (BD Falcon; MA, USA) and 
allowed to adhere overnight. The next day, media was removed and cells were transduced with 
lentivirus as described in Section 2.5.2. Cells were returned to incubation and cultured for 24 h, then 
media was removed and replaced with fresh media. Cells were then returned to incubation for an 
additional 48 h. 
2.14.3 Fixation and staining 
Media was removed and cells were washed briefly by addition and aspiration of PBS. Cells were then 
fixed by addition of 4% PFA solution (200 µl/well). After allowing fixation for 15 min at room 
temperature, the fixative was removed and cells were washed three times in PBS for 5 min each. Cells 
were then permeabilised using PBT for 10 min and were then blocked for 60 min at room temperature 
in a solution of blocking buffer. Following removal of blocking buffer, cells were then incubated in 
150 µl/well of blocking buffer containing anti-cleaved caspase 3 (Cell Signalling) at the appropriate 
dilution (see Appendix), overnight at 4°C. Cells were then rinsed three times in PBS for 5 min each, 
prior to the addition of goat anti-rabbit AlexaFluor488 (Life Technologies, Carlsbad, CA, USA) diluted 
in blocking buffer (see Appendix) for 2 h at room temperature in the dark. Following five rinses in 
PBS for 5 min each, 1 µg/mL DAPI was added to the final PBS wash to stain the nuclei. The 8-well 
chamber was then removed from the base of the slide and coverslips containing ProlongÒ Gold anti-
fade reagent were used to mount the slide. The edges of the coverslip were sealed with clear nail 
polish to prevent drying out. Specimens were then examined using the 20´ objective on a DM6000B 
microscope (Leica) at the appropriate excitation wavelength. At least three images were captured per 
well. Long-term storage of slides took place at room temperature, protected from light.  
2.14.4 Analysis 
The resulting images were analysed using Volocity 6.3 (PerkinElmer) by training a macro (developed 
with assistance from Centenary Imaging Support, Centenary Institute, Camperdown) to detect green 
objects (cleaved caspase-positive cells) and blue objects (DAPI-positive nuclei) and then calculating 
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the average number of objects in duplicate samples. The number of cleaved caspase 3-positive objects 
was expressed as percentage of DAPI-positive nuclei. 
2.15  Orthotopic xenograft experiments 
2.15.1 Materials for orthotopic xenograft experiments 
D-luciferin solution 
D-luciferin potassium salt (Gold Biotech) dissolved in sterile 0.9% saline at 15 mg/mL. 
Aliquots (1 mL) were stored at -30°C until use and any unused luciferin was discarded after 
thawing. 
2.15.2 Ethics approvals 
All animal experiments were performed according to protocols approved by the Sydney Local Health 
District Animal Welfare Committee (Ethics Approval 2013/030A). 
2.15.3 Cell preparation 
HCC1806 cells were transduced with pHIV1SDmCMVmCherry2Aluciferase and sorted for 
mCherryhi cells as described in Section 2.5.3.2. Pure mCherryhi-HCC1806 cells were then transduced 
with either pFH1t-shASCT2 or pFH1t-shControl and sorted for GFP-positivity as described in 
Section 2.5.3.2.  
2.15.4 Experiment 1 – Doxycycline from time of injection 
Once expanded, double positive GFP+/mCherryhi HCC1806 cells were then suspended in a solution 
of ice-cold 50:50 Matrigel® (Corning):RPMI (final concentration 4 × 106 cells per 100 µL) and 100 
µL was implanted orthotopically into the left and right abdominal mammary glands of anaesthetised 
8-12 week old female athymic nu/nu mice (Animal Resource Centre, Perth, Australia), 5 mice per 
group from two separate experiments (n=10). Doxycycline (200 µg/mL; Scientifix) was administered 
ad libitum in drinking water from Day 0 and tumour growth was measured twice weekly as described 
below until shControl tumours reached ~1000 mm3, when all mice were humanely euthanised. At 
experimental endpoint, lungs and liver were imaged for bioluminescence, and tumours were weighed, 
photographed, and collected for protein, RNA and formalin-fixed tissue sections. One shControl 
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mouse was excluded from analysis as it was culled early due to development of an ulcer at the tumour 
injection site. 
2.15.5 Experiment 2 – Doxycycline after initial latency period 
Double positive GFP+/mCherryhi HCC1806 cells were suspended in a solution of ice-cold 50:50 
Matrigel®:RPMI (final concentration 1 × 106 cells per 100 µL) and 100 µL was implanted 
orthotopically into the left and right abdominal mammary glands of anaesthetised 8-12 week old 
female athymic nu/nu mice (Animal Resource Centre, Perth, Australia), 5 mice per group from two 
separate experiments (n=10). Tumours were measured twice weekly as described below until all 
tumours were ~100 mm3 in volume (10-12 days after injection). Doxycycline (200 µg/mL) was then 
administered ad libitum in drinking water from this time. Tumour growth was measured twice weekly 
and mice were humanely euthanised individually when one of their tumours reached ~1000 mm3. At 
the time of euthanasia, lungs and liver were excised and imaged for bioluminescence, and tumours 
were weighed, photographed, and collected for protein, RNA and formalin-fixed tissue sections. 
2.15.6 Methods of tumour measurement 
Tumours were measured using digital calipers and tumour volume was calculated using the equation: 
d1 x d22 x p/3, where d1 was the longest tumour diameter measurement and d2 was the tumour diameter 
measurement perpendicular to d1. At the time of caliper measurements, mCherry fluorescence and 
luciferase activity of xenografted cells was also detected using a Xenogen IVIS Lumina II (Caliper 
Life Sciences; Hopkinton, MA, USA). Mice were anaesthetised and positioned in the IVIS Lumina 
II chamber with continuous light sedation (2-4 % isoflurane at a flow rate of 3 L/min oxygen) 
delivered throughout the imaging procedure. mCherry fluorescence was measured first, and then 150 
mg/kg D-luciferin was injected intraperitoneally into each mouse, allowed to diffuse for 15 min, and 
then bioluminescence was measured. All images were captured from a ventral view. For all image 
captures the field of view was set to 15 cm and the CCD camera aperture was set to f-stop 8, with 
acquisition binning set to “small”. Exposure times ranged from 1-5 secs and high-resolution images 
were quantified in photons/sec (p/s) using Living Image software (Caliper Life Sciences). All work 
		 75 
was approved under Sydney Local Health District Animal Ethics Approval Protocol Number 2013-
030. 
2.15.7 Taqman Low Density Array gene expression analysis 
Tumour RNA was extracted from approximately 10 mg of dissected xenograft tissue, using TRIzol® 
(Ambion) as described in Section 2.4.2. RNA (1 µg) was then reverse transcribed into cDNA as 
described in Section 2.4.3. Relative gene expression was measured by RT-qPCR using a custom 
Taqman Low-Density Array (Taqman, Life Technologies, Carlsbad, CA, USA) loaded with 1 µg of 
cDNA according to manufacturer’s instructions. Amplification and detection was performed using a 
QuantStudio 12K Flex Real-Time PCR System. Analysis of the fold change in gene expression was 
carried out using the absolute quantitation method (2DCt) and normalised to two reference genes, 
GAPDH and beta actin (ACTB). Heat map of relative expression (fold-change compared to the first 
shCont tumour) was generated in Gene-E (Broad Institute). The thermal cycle conditions are outlined 
in Table 2.4 and primers are listed in the Appendix.    
2.15.8 Quantitative RT-PCR gene expression analysis 
Tumour RNA was extracted from approximately 10 mg of dissected xenograft tissue, using TRIzol® 
(Ambion) as described in Section 2.4.2. RNA (1 µg) was then reverse transcribed into cDNA as 
described in Section 2.4.3.  
2.15.9 Western blot protein expression analysis 
Approximately 10 mg of dissected xenograft tissue was transferred to eppendorfs containing 0.5 mL 
cell lysis buffer with 1´ protease inhibitor cocktail III (A.G. Scientific, San Diego, CA) and 1´ 
phosphatase inhibitor cocktail (Cell Signalling). Tissue was macerated in this solution using an 
Eppendorf micropestle, then frozen at -80°C for at least 12 h, followed by sonication for 10 min using 
a BioRuptorÒ Plus (Diagenode; NJ, USA) to ensure complete membrane and DNA fragmentation. 
Samples were then centrifuged at 12 000 g for 5 min to remove debris and the supernatant was 
transferred to new tubes. Protein concentration in the supernatant was determined using a micro-BCA 
kit (Pierce; Rockford, IL, USA), according to manufacturer’s instructions. Equal amounts of tumour 
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tissue (20-50 µg) was then separated using SDS-PAGE and then transferred to PVDF membrane to 
be analysed by Western blot as outlined in Sections 2.8.4 and 2.8.5.  
2.16 Nanostring analysis of human tissue samples 
2.16.1 Cohort details 
Primary triple-negative breast cancer samples were obtained from Royal Prince Alfred Hospital and 
Concord Repatriation General Hospital, Australia, in accordance with ethics approval from the 
Sydney Local Health District Ethics Board (ethics approval number: X13-0241).  
2.16.2 Nanostring gene expression analysis 
RNA was extracted from 90 formalin-fixed paraffin-embedded triple-negative (TN) patient sample 
cores using an AllPrep DNA/RNA FFPE Kit (Qiagen, Melbourne, Australia). RNA concentration 
was quantified using Nanodrop as described previously (Section 2.2.2). Unamplified mRNA levels 
in 600 ng total RNA were measured directly using a custom probeset (see Appendix; Section 9.4) on 
the NanoString nCounter DX platform according to manufacturer’s instructions. Expression data was 
analysed using Nanostring nCounter software. Individual gene expression was normalised to mean 
expression of six housekeeper genes (CLTC, GAPDH, GUSB, HPRT1, PGK1, TUBB). Six patient 
samples failed RNA inbuilt quality-control checks and were excluded from subsequent analysis. 
 
2.17 Heavy isotope (13C)-labelled glutamine tracing 
2.17.1 Materials for 13C-glutamine tracing 
Glutamine-free MCF-7 media 
MEM (Life Technologies) supplemented with 10% dialysed FCS (HyClone), 1 mM sodium 
pyruvate (Life Technologies), and Pen/Strep  
Glutamine-free HCC1806 and MDA-MB-231 media 
Glutamine-free RPMI 1640 supplemented with 10% dialysed FCS (HyClone), 1 mM sodium 
pyruvate (Life Technologies), and Pen/Strep  
Saline solution 
0.9% NaCl (w/v; Sigma) in HPLC grade water (Sigma) 
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Chlorophenylalanine/norvaline standard mix 
100 µM Chlorophenylalanine (Sigma) and 100 µM of norvaline in HPLC grade water (Sigma) 
2.17.2 In vitro labelling 
Cells were plated in triplicate at a density of 7 × 105 cells/well in 6-well plates in normal growth 
media and allowed to adhere for 12-18 h. Growth media was then removed and the cell monolayer 
was washed once with PBS. Media was then replaced with 1mL of the appropriate glutamine-free 
media containing 2 mM L-[13C(U)]-Glutamine and 100 µL Benzylserine (final concentration 10 mM) 
or GPNA (final concentration 1 mM), or 100 µL sterile endotoxin-free tissue culture grade water 
(Sigma) as a vehicle control. As normalisation controls for protein content, triplicate wells for each 
treatment condition were set up and subjected to the same PBS wash and media change, but using 
unlabelled normal growth media containing drug or vehicle control instead of heavy isotope labelled 
media as detailed above. All cells were then returned to 37°C incubator for 12 h. 
2.17.3 Metabolite extraction 
After 12 h incubation, metabolites were extracted using methanol:chloroform phase extraction 
method. Firstly, 100 µL of extracellular medium was removed and set aside for LC-MS/MS analysis. 
Remaining medium was then promptly removed and the cell monolayer was washed once with 5 mL 
of ice-cold 0.9% (w/v) NaCl solution. This was removed as quickly as possible and cells were rapidly 
quenched in 2.5 mL of 50% (v/v) methanol:water mixture that had been prechilled to -30°C. A 
chlorophenylalanine/norvaline standard mix (1 or 2 nmoles/well) was added to each well at this step 
to control for extraction efficiency. Cells were scraped into this mixture and then the entire volume 
was transferred to prechilled Falcon tubes and kept on ice. Each well was then rinsed once with 2.5 
mL of ice-cold UltraPureTM water (ThermoFisher) and this was then transferred to the Falcon tubes 
to combine with the first extract. One volume (5 mL) of chloroform that had been prechilled to -30°C 
was then added to each tube. The extraction mixes were then vortexed vigorously for 10 sec and 
centrifuged at 3200 g for 5 min. The aqueous top phase of each sample was then transferred to a 
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prechilled glass tube. All aqueous extracts were gradually cooled to -30°C and then evaporated to 
dryness without heat using a SpeedVac.  
2.17.4 Protein normalisation controls 
After 12 h incubation, cell lysates from protein normalisation controls were collected using normal 
cell lysis procedures as previously described (Section 2.8.3). These samples were stored at -30°C 
until sonication, where they were subjected to 10 rounds of 30 sec on:off sonication at 4°C in a 
BioRupter2000 (Diagenode) to ensure complete cell lysis. After sonication, samples were centrifuged 
at 12 000 g for 5 min to pellet any cell debris and then supernatant was used for protein quantification 
using the BCA method (Pierce) as outlined in Section 2.8.3. 
2.17.5 Mass spectrometry analysis 
Gas chromatography mass spectrometry (GCMS) or liquid chromatography tandem mass 
spectrometry (LC-MS/MS) analysis of extracted metabolites was performed by Lake-Ee Quek. 
Processed peaks were normalised to internal standard (chlorophenylalanine/norvaline mix) and these 
normalised intensities were used for data analysis. 
2.17.6 Data analysis  
2.17.6.1 Intracellular amino acid concentration 
Normalised intensities of all mass species for each metabolite were summed and normalised to 
average protein content in protein normalisation control samples (Section 2.17.4). These data were 
expressed as fold-change compared to Control (untreated) samples. 
2.17.6.2 13C fractional contribution calculations 
Normalised intensities for each of the mass species (m+0 to m+6) were substituted into the equation 
below to calculate fractional contribution: 
 
Fractional Contribution (FC) = (0 ´ m+0) + (1 ´ m+1) + (2 ´ m+2) + (3 ´ m+3) + (4 ´ m+4) + (5 
´ m+5) + (6 ´ m+6) / (m+0 + m+1 + m+2 + m+3 + m+4 + m+5 + m+6) 
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The relative abundance of each mass species was calculated by substituting the normalised intensities 
into the equation below, with m+2 glutamine shown as an example: 
 
Relative abundance of m+2 glutamine = (m+2) / (m+0 + m+1 + m+2 + m+3 + m+4 + m+5) 
 
2.18 Radioisotope (14C)-labelled glutamine tracing 
2.18.1 Materials for 14C-glutamine tracing 
Protein wash buffer 
0.3 M guanidine hydrochloride (Sigma) in 95% (v/v) molecular grade ethanol (Sigma), 2.5% 
(v/v) glycerol (Astral Scientific) 
Final protein wash buffer 
95% (v/v) molecular grade ethanol (Sigma), 2.5% (v/v) glycerol (Astral Scientific) 
Cell lysis buffer 
20 mM Tris-Cl (Astral Scientific), 150 mM NaCl (Sigma), 1% (v/v) Triton X-100 (Sigma), 
0.5% (w/v) sodium deoxycholate (Sigma), 0.1% sodium dodecyl sulphate (SDS; Sigma) in 
milli-Q water 
2.18.2 In vitro labelling 
Cells were plated in triplicate at a density of 7 × 105  cells/well in 6-well plates in normal growth 
media and allowed to adhere at 37°C for 12-18 h. Once cells were ~70% confluent, growth media 
was removed and the cell monolayer was washed once with PBS. Media was then replaced with 600 
µL of glutamine-free DMEM (LifeTech) containing 2% (w/v) bovine serum albumin (BSA; 
Amresco), and 2 mM L-glutamine (Gibco). In vitro labelling proceeded in one of three ways: (a) a 
15 min labelling experiment, (b) a 4 h labelling experiment, or (c) a 15 min labelled pulse with 4 h 
unlabelled chase. In all experiments, 0.5 µCi L-[14C(U)]-Glutamine (PerkinElmer) was included in 
the labelled media. Where inhibitors were used, they were diluted 1:10 in the media described above, 
and sterile endotoxin-free tissue culture grade water (Sigma) was used as a vehicle control.  
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2.18.3 Phase extractions 
At the end of each experiment, the carbon pool was resolved into six fractions using a TRIzol® 
extraction protocol modified from Hosios et al (2016). These fractions were: extracellular dissolved 
CO2, intracellular RNA, DNA and protein, and the intracellular polar and organic pools. For pulse-
chase experiments, an additional seventh fraction was also collected which measured extracellular 
effluxed carbon. Details of each extraction are as follows: 
2.18.3.1 Extracellular CO2 
Extracellular dissolved CO2 was used as a measure of complete beta oxidation and was captured using 
the sodium hydroxide absorption method. This was achieved by the addition of an equal volume of 1 
M perchloric acid to the extracellular media to liberate 14CO2 in gaseous form. This was performed 
in a glass jar which also contained 500 µL 1 N sodium hydroxide in an open Eppendorf tube. 
Immediately after the addition of the media to the perchloric acid, the lid was sealed so that liberated 
14CO2 was trapped in the glass jar and could be absorbed by the sodium hydroxide in the eppendorf. 
To ensure complete capture, the sealed glass jars were incubated at room temperature for at least 1 h 
with gentle agitation. The total volume of sodium hydroxide was then transferred to scintillation tubes 
and 3 mL Ultima GoldTM scintillation fluid (PerkinElmer) added. 14C activity was then measured by 
liquid scintillation counting in a Tri-Carb® Liquid Scintillation Analyser (PerkinElmer). 
2.18.3.2 Intracellular fractions 
After removal of the extracellular medium, the cell monolayer was washed once with PBS and then 
homogenised in 1 mL TRIzol®. Homogenates were stored at -80°C overnight and then thawed to 
room temperature and incubated for 5 min to ensure complete cell lysis. A guanidium thiocyanate-
phenol-chloroform extraction was then performed by adding 200 µL chloroform (Sigma) and 
incubating at room temperature for 15 min, then centrifuging at 12 000 g for 20 min at 4°C. After 
centrifugation, the top aqueous phase was transferred to a new tube and RNA was precipitated by 
adding 800 µL isopropanol (Sigma). DNA was precipitated from the interphase and lower organic 
phase material by the addition of 300 µL 100% ethanol (Sigma) and 2 µL molecular biology-grade 
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glycogen (Astral Scientific). All tubes were then incubated at -30 °C overnight. The following day, 
all samples were centrifuged at 20 000 g for at least 20 min at 4°C to pellet the precipitated nucleic 
acids. RNA pellets were briefly washed once with 70% ethanol, air dried and then resuspended in 
100 µL sterile nuclease-free water and stored at -30°C until analysis. DNA pellets were washed twice 
with 70% ethanol for 10 min at room temperature with gentle inversion, air dried and then 
resuspended in 100 µL dilute sodium hydroxide solution (8mM in sterile nuclease-free water) and 
stored at -30°C until analysis. The aqueous supernatant from the RNA extraction tubes was removed 
and transferred to new tubes as the “polar” fraction, and stored at -30°C until analysis. The organic 
supernatant from the DNA extraction tubes was removed and transferred to new tubes, where protein 
was then precipitated by the addition of 3 volumes (2.4 mL) of acetone. The protein precipitation 
reaction was incubated at room temperature for 20 min and then centrifuged at 3200 g for 20 min. 
The supernatant was removed and transferred to new tubes as the “organic” intracellular fraction, and 
stored at -30°C until analysis. Precipitated protein pellets were washed three times by vigorously 
dispersing in 4 mL of 95% ethanol/2.5% glycerol/0.3 M guanidine hydrochloride wash buffer using 
a pipette tip and then incubating at room temperature for at least 30 min, followed by 20 min 
centrifugation at 3200 g at 4°C and removal of the resulting supernatant. Protein pellets were then 
stored overnight in 95% ethanol/2.5% glycerol/0.3 M guanidine hydrochloride wash buffer at 4°C. 
The next day, a fourth and final wash was performed using wash buffer without guanidine 
hydrochloride (97.5% ethanol/2.5% glycerol final wash buffer) and centrifugation as before. The 
protein pellets were air dried briefly and then solubilised in 100 µL of cell lysis buffer for 20 min at 
room temperature with intermittent gentle mixing. The tubes were then heated at 98°C for 3 min to 
enhance protein solubility and centrifuged as before. The resulting supernatants were then transferred 
to new tubes as the “protein” fraction and stored at -30°C until analysis. For analysis, the total 
volumes of the “RNA”, “polar”, “DNA” and “protein” fractions were then transferred to scintillation 
vials and 3 mL Ultima GoldTM scintillation fluid (PerkinElmer) was added. 14C activity was measured 
by liquid scintillation counting in a Tri-Carb® Liquid Scintillation Analyser (PerkinElmer). The 
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“organic” fraction was divided into two 1.4 mL aliquots and each was transferred into separate 
scintillation vials to ensure that the scintillation reaction was not quenched by the residual phenol 
present in this fraction.  
2.18.3.3 Extracellular effluxed carbon 
In pulse-chase experiments only, the chase medium was collected after 4 h and divided into two 300 
µL aliquots. The first aliquot was used for extracellular CO2 capture as described above. The second 
aliquot was transferred undiluted to a scintillation vial and 3 mL Ultima GoldTM scintillation fluid 
(PerkinElmer) was added. 14C activity was then measured by liquid scintillation counting in a Tri-
Carb® Liquid Scintillation Analyser (PerkinElmer). 
2.18.4 Analysis 
Each tube was then counted for 5 min and the average counts per minute (CPM) from each tube was 
used for subsequent analysis. To calculate the specific activity of the 14C-glutamine, 100 µL of unused 
labelled medium from each experiment was transferred into duplicate scintillation vials and 
scintillation was measured as described above. The CPM values for these duplicate vials were 
averaged and used to extrapolate the specific activity of the 14C glutamine in decays per minute per 
picomole (dpm/pmol). This specific activity value was then used to calculate the 14C activity of each 
sample in equivalent pmol of 14C-glutamine. All samples from an experiment were counted and 
analysed together to minimise any variability in counting efficiency.  
 
2.19  Seahorse XFp metabolic analysis 
2.19.1 Seahorse Mito Fuel Flex: Data Analysis 
Oxygen consumption rate (OCR) and proton production rate (PPR) in each well was measured at 6.5 
minute intervals for 100 min. These measurements captured four baseline measurements, six 
measurements post-injection from Port A, and six measurements post-injection from Port B. Data 
were analysed manually by taking the 4th baseline OCR measurement (“baseline OCR”), 6th OCR 
measurement post-injection from port A, and 6th OCR measurement post-injection from Port B. These 
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measurements were substituted into the equations below to calculate dependency, capacity and 
flexibility: 
 
Dependency % = [ (Baseline OCR – post-Port A OCR)/(Baseline OCR – post-Port B OCR) ] ´ 100 
 
Capacity % = [1 – [(Baseline OCR – post-Port A OCR)/(Baseline OCR – post-Port B OCR)] ] ´ 100 
 
Flexibility % = Capacity - Dependency 
 
2.20 In silico gene expression analysis 
2.20.1 Data retrieval 
All gene expression data was retrieved using cBioPortal (http://www.cbioportal.org/; Cerami et al., 
2012, Gao et al., 2013). Expression of glutamine metabolism genes (Table 1.2) and amino acid 
transporters (Table 1.1; also SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7, SLC6A5, and 
SLC6A9) was queried for the Molecular Taxonomy of Breast Cancer International Consortium 
(METABRIC; Curtis et al., 2012, Pereira et al., 2016, data accessed 18-25 April, 2017), The Cancer 
Genome Atlas (TCGA; provisional dataset, data accessed February, 2017), and The Cancer Cell Line 
Encyclopaedia (TCCLE; Barretina et al., 2012, data accessed 18-25 April and 26 June, 2017) cohorts. 
mRNA expression data was exported from the “Plots” tab.  
2.20.2 Subtype grouping 
Samples were grouped into Basal and Luminal A subtypes manually (Figure 4.6; C. Perou, personal 
communication, February, 2017) or using the “Clinical Attributes” > “PAM50 subtype + Claudin 
low” data recorded in cBioPortal (Figure 5.5). 
2.21 Statistical analysis 
Heatmap analyses were performed using GENE-E (Broad Institute; 
https://software.broadinstitute.org/GENE-E/) or MORPHEUS (Broad Institute; 
https://software.broadinstitute.org/morpheus/). All other statistical analyses were performed using 
GraphPad Prism 7.0. Statistical significance was assessed using non-parametric (Mann-Whitney) 
analysis, t-tests or ANOVA as indicated in figure legends. All error bars represent the standard error 
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of the mean from independent experiments (n>=3 unless otherwise indicated). P<0.05 was considered 
statistically significant. 
  
		 85 
 
 
 
 
CHAPTER 3 
		 86 
3.1 Assessment of the glutamine transporter, ASCT2, as a therapeutic 
target in breast cancer 
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3.2.1 Abstract 
Alanine, serine, cysteine-preferring transporter 2 (ASCT2; SLC1A5) mediates uptake of glutamine, 
a conditionally essential amino acid in rapidly proliferating tumour cells. Uptake of glutamine and 
subsequent glutaminolysis is critical for activation of the mTORC1 nutrient-sensing pathway, which 
regulates cell growth and protein translation in cancer cells. This is of particular interest in breast 
cancer, as glutamine dependence is increased in high-risk breast cancer subtypes. Pharmacological 
inhibitors of ASCT2-mediated transport significantly reduced glutamine uptake in human breast 
cancer cell lines, leading to suppression of mTORC1 signalling, cell growth and cell cycle 
progression. Notably, these effects were subtype-dependent, with ASCT2 transport critical only for 
triple-negative (TN) basal-like breast cancer cell growth compared to minimal effects in luminal 
breast cancer cells. Both stable and inducible shRNA-mediated ASCT2 knockdown confirmed that 
inhibiting ASCT2 function was sufficient to prevent cellular proliferation and induce rapid cell death 
in TN basal-like breast cancer cells, but not in luminal cells. Using a bioluminescent orthotopic 
xenograft mouse model, ASCT2 expression was then shown to be necessary for both successful 
engraftment and growth of HCC1806 TN breast cancer cells in vivo. Lower tumoral expression of 
ASCT2 conferred a significant survival advantage in xenografted mice. These responses remained 
intact in primary breast cancers, where gene expression analysis showed high expression of ASCT2 
and glutamine metabolism-related genes, including GLUL and GLS, in a cohort of 90 TN breast 
cancer patients, as well as correlations with the transcriptional regulators, MYC and ATF4. This study 
provides preclinical evidence for the feasibility of novel therapies exploiting ASCT2 transporter 
activity in breast cancer, particularly in the high-risk basal-like subgroup of TN breast cancer where 
there is not only high expression of ASCT2, but also a marked reliance on its activity for sustained 
cellular proliferation.  
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3.2.2 Introduction 
Despite being a highly heterogenous disease, the breast cancer therapeutic strategy is dictated largely 
by tumoural expression of only three cell-surface markers: estrogen receptor (ER), progesterone 
receptor (PR) and human epidermal growth factor receptor 2 (HER2). Tumours that lack clinically 
detectable expression of all three receptors are classified as triple-negative (TN) and, in the absence 
of any targeted therapies, rely largely on surgery, radiotherapy and cytotoxic chemotherapy for their 
management (Gluz et al., 2009). TN breast cancers generally display distinct features on gene 
expression analysis, as the PAM50 classification (Sorlie et al., 2001, Perou et al., 2000) and 
subsequent molecular profiling (Prat et al., 2010) showed enrichment of genes associated with 
proliferation, hypoxia, and stem-like features. As a result, TN breast cancers have poorer prognosis 
overall (Dent et al., 2007, Haffty et al., 2006, Rakha et al., 2007), and are usually associated with 
increased recurrence and death compared to other subtypes (Chen et al., 2010). Attempts to stratify 
this generally poor-prognosis subtype into clinically useful subgroups have revealed at least seven 
different molecular subtypes of TN breast cancer (Lehmann et al., 2011), highlighting the need for 
novel and effective targeted therapies for these patients. Because glutamine dependence is increased 
in proliferative subtypes of breast cancer (Kim et al., 2013b, Timmerman et al., 2013), we 
hypothesised that highly proliferative TN tumours may be uniquely sensitive to inhibitors of 
glutamine uptake. 
 
Alanine, serine, cysteine-preferring transporter 2 (ASCT2; SLC1A5) is a cell-surface solute-carrying 
transporter that mediates uptake of neutral amino acids including glutamine (Kanai and Hediger, 
2004, Kekuda et al., 1996). Although a non-essential amino acid in normal cells, the demand for 
glutamine is dramatically increased throughout malignant transformation to support increased 
metabolic demands; namely, provision of catabolic substrates for ATP production and anabolic 
substrates for macromolecule biosynthesis (DeBerardinis et al., 2007). The intracellular glutamine 
pool is also critical for sustained activation of mTORC1 signalling (Duran et al., 2012), a master 
regulator of cell growth and protein translation (Wullschleger et al., 2006), as well as prevention of 
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apoptosis (reviewed in Green et al., 2014). Blocking ASCT2 to prevent glutamine uptake has been 
shown to successfully prevent tumour cell proliferation in melanoma (Wang et al., 2014a), non-small 
cell lung cancer (Hassanein et al., 2013, Hassanein et al., 2015), prostate cancer (Wang et al., 2015) 
and acute myeloid leukaemia (Willems et al., 2013), however its role in breast cancer cell growth 
remains unknown. 
 
In this study we aimed to investigate the role of ASCT2 in breast cancer using a combination of in 
vitro and in vivo approaches combined with gene expression analysis of clinical TN patient samples. 
We show that although ASCT2 is highly expressed in most breast cancer subtypes, only basal-like 
TN breast cancer cells require ASCT2-mediated uptake of glutamine to sustain mTORC1 signalling, 
cell growth and cell cycle progression. Targeted knockdown of ASCT2 showed that loss of ASCT2 
alone was sufficient to cause rapid cell death in vitro and reduce engraftment and subsequent growth 
of xenografted cells in vivo. These effects were accompanied by significantly altered gene expression, 
which suggested dynamic regulation of ASCT2 and other glutamine metabolism-related genes (GLS, 
GLUL) by a coordinated MYC- and ATF4-driven transcriptional program in TN breast cancer. 
Absolute mRNA measurements of these genes in TN breast cancer samples showed that these genes 
were highly expressed across all samples and were significantly correlated in a subgroup of patients. 
Our data provide the first conclusive evidence that ASCT2 represents a novel therapeutic axis in a 
challenging subset of breast cancers.  
 
3.2.3 Results & Discussion 
Basal-like TN breast cancer cell growth is dependent on ASCT2 activity 
We examined ASCT2 protein expression and cell-surface localisation in a normal basal mammary 
cell line (MCF10A) and a variety of breast cancer cell lines representing the luminal (ER+, HER2-; 
MCF-7 and T47D), basal-like (triple-negative, TN; HCC1806, HCC1937, HCC1500, HCC1569,  
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Figure 3.1. Inhibiting glutamine uptake represses cell growth in HCC1806 basal-like 
breast cancer cells but not luminal MCF-7 cells. A, ASCT2 protein (60-75 kDa; Cell 
Signaling, Beverly, MA, USA; Cat. No. 8057S) expression was measured by Western 
blotting in two luminal (MCF-7, T47D) and six triple-negative breast cancer cell lines 
including basal-like (HCC1806, HCC1937, MDA-MB-468/MDA468) and claudin-low (CL) 
(MDA-MB-231/MDA231) subsets, with GAPDH (37 kDa; Abcam, Cambridge, UK; Cat. No. 
ab8245) used as loading control. MCF-7 cells were a kind gift from the Vascular Biology 
Laboratory, Centenary Institute, Sydney, Australia, and identity-confirmed using STR 
testing. T47D, HCC1806, HCC1937, MDA231 and MDA468 cells were obtained from ATCC, 
Manassas, VA, USA. HCC1500 and HCC1569 cells were a kind gift from the Tumour 
Progression Laboratory, Garvan Institute of Medical Research, Sydney, Australia. All cell 
lines were routinely confirmed to be mycoplasma-free using PCR testing. B, ASCT2 
localisation was determined in breast cancer cell lines by immunofluorescence staining with 
primary antibody as in (A), goat anti-rabbit AlexaFluor488 (Life Technologies, Carlsbad, CA, 
USA; Cat. No. A11034; green) as secondary antibody, and nuclei visualised using 4',6-
diamidino-2-phenylindole (DAPI; blue). Scale bar, 30 µm. C, Normal mammary cells 
(MCF10A; grey), luminal breast cancer cell lines (MCF-7, T47D; black), and triple-negative 
breast cancer cell lines (HCC1806, HCC1937, HCC1500, HCC1569, MDA231; red) were 
treated with L-γ-glutamyl-p-nitroanilide (GPNA; 1 mM; Sigma-Aldrich, St Louis, MO, USA) 
along with 0.3 mCi [3H]-L-glutamine (PerkinElmer, Waltham, MA, USA) for 15 min to assess 
uptake as previously described (Wang et al., 2011). Uptake data are presented as reduction 
in raw scintillation counts by GPNA compared to control, while MTT data are expressed as 
% inhibition compared to control. MCF-7 (D) and HCC1806 (E) cells were cultured in 96-
well plates (MCF-7: 3 ´  103 cells/well; HCC1806: 1 ´ 103 cells/well) for 3 days with or without 
1 mM GPNA. MTT assays were conducted every 24 h to assess cell growth according to 
manufacturer’s instructions (MTT Cell Growth Assay Kit; Merck-Millipore, Billerica, MA, 
USA). Cell cycle progression for MCF-7 (F) and HCC1806 (G) cells was analysed using 
APC-BrdU Flow Kit according to manufacturer’s instructions (BD Pharmingen, San Jose, 
CA, USA) after 24 h culture with or without 1 mM GPNA. H, MCF-7 and HCC1806 cells were 
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incubated in GPNA or control media for 6 h. Total and phosphorylated (p-) p70S6K signalling 
protein (70, 85 kDa; both from Cell Signaling, Beverly, MA, USA; Cat. No. 9205S/9202S) 
was then detected by Western blotting, with GAPDH (37 kDa) as loading control. I, MCF-7 
and HCC1806 cells were cultured in in 96-well plates (MCF-7: 3 ´ 103 cells/well; HCC1806: 
1 ´ 103 cells/well) glutamine-free media (containing 10% dialysed FBS) for 3 days with MTT 
assays conducted every 24 h to assess cell growth according to manufacturer’s instructions 
(MTT Cell Growth Assay Kit; Merck-Millipore, Billerica, MA, USA). Asterisks denote P-values 
as follows: *P≤0.05; **P≤0.01; ***P≤0.001; ****P≤0.0001, n.s.=not significant; 2-way 
ANOVA. Data in C-G, I represent mean ± SEM, n≥3 experiments. Data in A, B, H are 
representative of 3 independent experiments, with blots in H cropped to exclude extraneous 
lanes. Full blots are in Supplementary Figure 3.1. 
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MDA-MB-468/MDA468) and claudin-low (CL; MDA-MB-231/MDA231) molecular subtypes of 
breast cancer (Figure 3.1A and 3.1B; higher resolution images can be found in Appendix). ASCT2 
protein was expressed and present on the plasma membrane for all cell lines (shown in green, Figure 
3.1B), although cytoplasmic staining was mainly seen in the claudin-low (Prat et al., 2010) glutamine-
sensitive (Timmerman et al., 2013) cell line, MDA-MB-231 (Figure 3.1B). To determine which cells 
require ASCT2 function, we examined radiolabelled glutamine uptake in the presence of the ASCT2 
inhibitor L-γ-glutamyl-p-nitroanilide (GPNA; Esslinger et al., 2005). GPNA significantly decreased 
ASCT2 function in normal (grey), luminal (black) and basal-like (red) breast cell lines, but showed 
variable efficacy in inhibiting cell growth (Figure 3.1C and Supplementary Figure 3.1A-E). As 
previously reported, basal-like cells, but not luminal cells, were uniquely sensitive to glutamine 
availability (Gross et al., 2014, Kung et al., 2011), and had significantly lower growth rates when 
treated with GPNA (Supplementary Figure 3.1B-E) despite maintaining relatively high levels of 
glutamine transport (Supplementary Figure 3.1A). Both MCF-7 and T47D are believed to be 
glutamine independent due to increased levels of glutamine synthetase expression, which allows them 
to synthesise glutamine from glutamate (26). Interestingly, while we confirmed that luminal MCF-7 
cells were insensitive to ASCT2 inhibition and subsequent glutamine deprivation, T47D cells were 
not. This suggests that other amino acids transported by ASCT2 may be important for T47D 
proliferation. We therefore chose two cell lines with distinct clinical backgrounds and biological 
behaviours for further analysis: MCF-7 (luminal) and HCC1806 (basal-like TN). These two cell lines 
exhibited high cell surface ASCT2 expression (Figure 3.1A, B) but differential responses to GPNA.  
 
We first confirmed that despite significant inhibition of glutamine uptake in both cell lines, GPNA 
treatment repressed cell growth (Figure 3.1D, E) and cell cycle progression (Figure 3.1F, G) in 
HCC1806 cells only. We next showed that inhibition of ASCT2-mediated glutamine uptake reduced 
the mTORC1 signalling axis in HCC1806 cells (Figure 3.1H; Supplementary Figure 3.1F). Since 
mTORC1 inhibition mediates G1 blockade (Fingar and Blenis, 2004, Saqcena et al., 2013), this is a 
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likely mechanism of action, as previously published (Duran et al., 2012, Nicklin et al., 2009). As 
ASCT2 inhibition has also been shown to activate mTORC2 activity upstream of apoptotic signalling 
(Fuchs et al., 2007), downstream phosphorylation levels of mTORC2 substrate, Akt (p-Ser473) were 
measured after 6 h GPNA treatment and showed a modest increase in HCC1806 cells (Supplementary 
Figure 3.1G). This change was reflected in a significant increase in the number of apoptotic cells in 
HCC1806 cells, but no change in viability in MCF-7 cells (Supplementary Figure 3.1H, I). Thus in 
contrast to the basal-like cell line, the luminal cell line was largely insensitive to glutamine 
deprivation alone. We confirmed that MCF-7 cells were able to sustain proliferation in the absence 
of exogenous glutamine, compared to the dramatic loss of cell viability in the basal-like HCC1806 
cells (Figure 3.1I). Together these data indicated a differential reliance on ASCT2 activity across 
breast cancer cell lines, whereby only basal-like cells required ASCT2-mediated glutamine uptake 
for cell growth.  
 
ASCT2 expression is required for basal-like breast cancer cell growth in vitro 
We next performed targeted knockdown of ASCT2 to determine whether ASCT2 was directly 
responsible for the observed glutamine-dependent effects on basal-like breast cancer cell growth. This 
was achieved by lentiviral transduction of a control shRNA (shCont; plant miRNA ath-mir159a, 
sequence and specificity detailed previously, Wang et al., 2011), or one of two different shRNAs 
against ASCT2 (shA28, sequence in Figure 3.2 legend; or shA63 (Wang et al., 2015). Protein 
knockdown was confirmed in MCF-7 and HCC1806 cells (Figure 3.2A, B) by Western blotting. 
Glutamine uptake was reduced in both MCF-7 and HCC1806 cells transduced with shA28 and shA63, 
as compared to cells transduced with shCont (Figure 3.2C). ASCT2 knockdown had no effect on 
MCF-7 cell growth (Figure 3.2D), while expression of either shRNA against ASCT2 significantly 
reduced HCC1806 cell growth in the 72 h following transduction (Figure 3.2E), and caused an 
increase in cleaved PARP protein levels and LC3B-II accumulation (Figure 3.2F), as well as 
significantly increased levels of cleaved-caspase 3 as detected by immunofluorescence microscopy  
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Figure 3.2. ASCT2 expression is required for HCC1806 cell growth. MCF-7 (A) and 
HCC1806 (B) cells were transduced with a lentiviral vector (pLKO.1) containing control 
shRNA (shCont; shRNA sequence and specificity detailed previously (Wang et al., 2011)) 
or one of two shRNAs against ASCT2 (shA28: 
CCGGGCTGCTTATCCGCTTCTTCAACTCGAGTTGAAGAAGCGGATAAGCAGCTTTTT
G; or shA63: 
CCGGCTGGATTATGAGGAATGGATACTCGAGTATCCATTCCTCATAATCCAGTTTTTG; 
both from Sigma-Aldrich, St Louis, MO, USA). ASCT2 expression (60-75 kDa) was 
measured by Western blotting at 24, 48 and 72 h post-transduction and after long-term 
puromycin (Puro) selection (A only). C, MCF-7 cells (Puro) and HCC1806 cells (72 h) were 
incubated with [3H]-L-glutamine for 15 min as previously described (Wang et al., 2011) to 
assess uptake after ASCT2 knockdown. Transduced MCF-7 (D) and HCC1806 (E) cells 
were cultured for 3 days post-selection or post-transduction, respectively. MTT assays were 
conducted every 24 h to assess cell growth according to manufacturer’s instructions (MTT 
Cell Growth Assay Kit; Merck-Millipore, Billerica, MA, USA). F, Levels of full-length and 
cleaved poly ADP ribose polymerase (PARP) protein (116 and 89 kDa; Cell Signaling, 
Beverly, MA, USA; Cat. No. 9541S) and LC3B-I/II protein forms (14, 16 kDa; Cell Signaling, 
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Beverly, MA, USA; Cat. No. 2775S) with GAPDH as loading control (37 kDa) were measured 
in HCC1806 cells by Western blotting at 24, 48 and 72 h post-transduction. MCF-7 (G) and 
HCC1806 (H) cells were transduced with lentiviral vector (pFH1tUTG) that encoded 
doxycycline (dox)-inducible expression of the control shRNA (shCont; sequence and 
specificity detailed previously (Wang et al., 2011)) or the shA63 shRNA (shASCT2; shRNA 
sequence as above) also encoding an eGFP reporter tag (Herold et al., 2008). Transduced 
cells were sorted for GFP-positive cells using fluorescence activated cell sorting and then 
shRNA expression was induced by treatment with 1 µg/mL dox. ASCT2 expression (60-75 
kDa) was measured by Western blotting at 24, 48 and 72 h ± dox with GAPDH as loading 
control (37 kDa), I, Transduced MCF-7 and HCC1806 cells were incubated with 0.3 mCi 
[3H]-L-glutamine to assess uptake after 72 h dox treatment, as previously described (Wang 
et al., 2011). Transduced MCF-7 (J) and HCC1806 (K) cells were cultured with dox for 3 
days and MTT assays were conducted every 24 h to assess cell growth according to 
manufacturer’s instructions (MTT Cell Growth Assay Kit; Merck-Millipore, Billerica, MA, 
USA). Asterisks denote P-values as follows: *P≤0.05; **P≤0.01; ***P≤0.001; ****P≤0.0001, 
n.s.=not significant; 2-way ANOVA. Data in C-E, I-K represent mean ± SEM, n≥3 
experiments. Data in A, B, F-H are representative of 3 independent experiments. For MTT 
assays (E), stars under growth curves refer to shCont vs shA28 (top) and shCont vs shA63 
(bottom). 
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(Supplementary Figure 3.2A, B). Furthermore, analysis of CyQUANT/PI staining showed a 
significant decrease in live cell numbers coupled with a significant increase in dead cells (PI+) after 
72 h (Supplementary Figure 3.2C-E). Stable antibiotic selection of shASCT2-expressing cells was 
only successful in MCF-7 cells as HCC1806 cells died rapidly after transduction, further suggesting 
induction of apoptosis, and confounding the results for uptake and cell growth assays. We therefore 
generated an inducible ASCT2 shRNA (shA63) using a doxycycline-inducible lentiviral vector 
(Herold et al., 2008). ASCT2 knockdown was confirmed in MCF-7 (Figure 3.2G) and HCC1806 cells 
(Figure 3.2H) in the presence of doxycycline at 24, 48, and 72 h. A significant reduction in glutamine 
uptake was observed in both MCF-7 and HCC1806 shASCT2 cells as compared to shCont after 72 h 
doxycycline treatment (Figure 3.2I), however MCF-7 cell growth was again unaffected by ASCT2 
knockdown (Figure 3.2J) while HCC1806 cells showed a significant reduction in proliferation when 
cultured in doxycycline (Figure 3.2K). Since MTT assay results may be confounded by changes in 
cellular metabolism, we confirmed the significant inhibitory effect on cell growth by analysing uptake 
of CyQUANT live cell stain (Supplementary Figure 3.3A). These are the first data to conclusively 
show that ASCT2 loss is sufficient to significantly reduce basal-like breast cancer cell growth in vitro. 
 
ASCT2 knockdown in vivo represses basal-like tumour growth and improves xenografted 
mouse survival 
To enable analysis of ASCT2 knockdown on in vivo cell growth, HCC1806 cells were transduced 
with an additional lentivirus engineered to enable stoichiometric expression of both mCherry and 
firefly luciferase reporters. Sorted HCC1806-mCherryhi GFP+ cells (shCont and shASCT2) were 
then orthotopically injected into the mammary fat pad of athymic nu/nu mice, after confirming 
doxycycline-inducible ASCT2 protein knockdown (Supplementary Figure 3.3B) and repression of 
cell growth in vitro (Supplementary Figure 3.3A). Mice were then imaged twice weekly while 
doxycycline was delivered in the drinking water from Day 0 (as per Figure 3.3A). Knockdown of 
ASCT2 caused a reduction in tumour take-rate, with only 80% of shASCT2 tumours engrafting  
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Figure 3.3. ASCT2 knockdown in vivo represses tumour growth and improves 
survival. A, HCC1806 cells expressing an additional mCherry-luciferase reporter construct 
(pHIV1SDm-CMV-mCherry-P2A-luc; Tiffen et al., 2010) and doxycycline-inducible shRNAs 
(see Figure 3.2H legend), shControl or shASCT2 (pFH1tUTG; Herold et al., 2008) were 
sorted for mCherryhi/GFP+ cells using fluorescence activated cell sorting and then 4 × 106 
cells suspended in a solution of 50% Matrigel in RPMI (100 µL) were implanted orthotopically 
into the left and right abdominal mammary glands of 8-12 week old female athymic nu/nu 
mice (Animal Resource Centre, Perth, Australia), 5 mice per group from two separate 
experiments (n=10). Sample size was estimated based on previous publications (Wang et 
al., 2015) with no randomisation or blinding. Doxycycline (200 µg/mL) was administered ad 
libitum in drinking water from Day 0 and tumour growth was measured twice weekly until 
individual shControl tumours reached ~1000 mm3, when all mice were humanely euthanised 
in accordance with ethics approval protocol 2013/030A from Sydney Local Health District 
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Animal Welfare Committee. B, Bioluminescence was detected twice weekly using a 
Xenogen IVIS Lumina II following intraperitoneal injection of 150 mg/kg D-luciferin. At 
endpoint, all mice were euthanised and tumours collected for measurement of size (C) and 
weight (D; error bars represent mean ± SD). E, Tumour RNA was extracted from shCont 
and shASCT2 (n=4 each) tumours using TRI Reagent, then reverse transcribed using 
SuperScript III (Life Technologies, Carlsbad, CA, USA) and random hexamers. Relative 
gene expression (GAPDH/ACTB) was measured by RT-qPCR using a custom Taqman 
Low-Density Array (Taqman, Life Technologies, Carlsbad, CA, USA) run on a QuantStudio 
12K Flex Real-Time PCR System. Heat map of relative expression (compared to the first 
shControl lane) for each gene was generated in Gene-E (Broad Institute). Average fold-
change between the shControl and shASCT2 groups are indicated to the right of the heat-
map, asterisks indicate significant difference (p<0.05, n=4; Mann-Whitney U test). F, 
HCC1806-mCherryhi/GFP+ cells (2 × 106) were injected orthotopically as in (A) and allowed 
to establish (tumour size ~100 mm3) before administration of doxycycline (200 µg/mL). 
Tumour size was measured twice weekly using digital calipers to calculate mean tumour 
volume per mouse (G) and individual mice were euthanised when they reached ethical 
endpoint (individual tumour size >1000 mm3; H). Data in B represents mean ± SEM, n=9 
(shCont; one mouse was euthanased due to ulceration at tumour site and is not included in 
the analyses) or n=10 (shASCT2) mice (with 2 tumours per mouse), 5 mice per group in 2 
independent experiments. Data in G represents mean, n=10 (shCont) or n=10 (shASCT2) 
mice (with 2 tumours per mouse), 5 mice per group in 2 independent experiments. Asterisks 
denote P-values as follows: *P≤0.05; **P≤0.01; ***P≤0.001; ****P≤0.0001, n.s.=not 
significant; 2-way ANOVA (B), Mann-Whitney U test (D, E), or logrank Mantel-Cox test (H). 
Data in C are representative of 2 independent experiments.  
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successfully compared to 100% of shCont tumours, as well as statistically significant decreases in 
tumour growth (Figure 3.3B, Supplementary Figure 3.3C), size (Figure 3.3C) and weight (Figure 
3.3D) at endpoint. Relative quantification of mRNA in tumours collected at endpoint also showed 
significantly altered gene expression as a result of ASCT2 knockdown throughout tumour 
establishment and growth (Figure 3.3E). As expected, ASCT2 (SLC1A5) expression was 
significantly decreased (2.34-fold, P<0.0286). Expression of several master regulators of tumour 
metabolism was altered, including a significant reduction (2.26-fold, P=0.0286) in oncogenic MYC 
(amplified in HCC1806 cells; Barretina et al., 2012) and upregulation of transcription factors, HIF1a 
(2.93-fold, P=0.0286), and ATF4 (1.77-fold, P=0.0286). Together, these changes indicate a shift to 
glycolytic metabolism as a cellular survival mechanism when ASCT2 expression is lost. They were 
accompanied by increased expression of glutaminogenic genes (glutamine-ammonia ligase, GLUL, 
2.57-fold, P=0.0286; glutamyl-tRNA synthetase, QARS, 2.23-fold, n.s.). Also significantly increased 
were several genes with known pro-apoptotic roles in cellular stress (HIPK2, BAX; Puca et al., 2010, 
Yee et al., 2009), suggesting initiation of a dynamic transcriptional program in response to loss of 
ASCT2 transport.  
 
To ensure that a reduced tumour take-rate was not masking the effects of ASCT2 knockdown, we 
next allowed tumours to establish before introduction of doxycycline (as per Figure 3.3F). In this 
setting, ASCT2 knockdown continued to significantly reduce tumour volume (Figure 3.3G) and also 
more than tripled the median survival time from 24 to 73.5 days post-doxycycline treatment. This 
indicated that lower tumoural ASCT2 expression conferred a significant survival advantage even in 
established tumours (Figure 3.3H; logrank HR=3.405 (1.951-15.69), P=0.003, Mantel-Cox test). 
These data indicate that ASCT2 expression is required for successful basal-like tumour engraftment 
and tumour growth in vivo, and suggest that the presence of ASCT2 expression decreases time to 
ethical endpoint in mice with basal-like breast cancer xenografts. This is consistent with recent 
findings showing that low ASCT2 expression correlated with increased disease-free survival in a 
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large cohort of human breast cancer patient samples, and showed a strong association with other 
clinicopathological predictors of poor prognosis, such as positive node status and absence of ER 
expression (Jeon et al., 2015). Together these data indicated that ASCT2 expression promotes basal-
like breast tumour growth in vivo, and is similarly associated with aggressive biological behaviour in 
clinical disease.  
 
Triple-negative breast cancers globally increase ASCT2 expression and glutamine metabolism 
Given that basal-like tumours make up at least half of the broader clinical TN subtype (Perou, 2010), 
we hypothesised that ASCT2 may be a critical driver of cell growth in these breast cancers and thus 
present a possible axis for targeted therapeutic intervention. We therefore designed a custom 
NanoString nCounter DX codeset to quantify absolute RNA expression of a subset of glutamine 
metabolism genes in a cohort of 90 TN breast cancer patients. Using a previously defined TN breast 
cancer gene expression signature (Lehmann et al., 2011), samples were manually clustered into six 
TN subgroups based on 26 genes (Figure 3.4A). Global gene expression for this subset (as opposed 
to relative gene expression), revealed high expression of a number of genes associated with TN breast 
cancer, including MYC, RAD21, and CTNNB1, with widespread downregulation of hormone-
receptor signalling genes (AR) outside the LAR subtype. Strikingly, however, expression of ASCT2 
and glutamine metabolism-related genes (GLS, GLUL) was uniformly high across all TN subgroups 
(Figure 3.4A, B), suggesting a broad reliance on glutamine availability in both basal-like and non-
basal-like TN breast cancers and reinforcing a link between increased glutamine metabolism and 
clinically aggressive breast cancers (Terunuma et al., 2014). Furthermore, the stress-responsive 
transcription factor, ATF4, was also highly expressed in all TN subsets (Figure 3.4A, B). ATF4 
expression was also significantly increased after ASCT2 knockdown in vivo (Figure 3.3E), supporting 
previous data in PC-3 prostate cancer cells in vitro (Wang et al., 2015). In that study, GPNA was 
shown to increase not only ATF4 expression, but also led to concomitant increases in a range of 
amino acid transporters including ASCT2, SLC1A4, SLC3A2, SLC7A11, SLC7A1 and  
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Figure 3.4. ASCT2 is highly expressed in human triple-negative breast cancer patient 
samples. RNA was extracted from 90 formalin-fixed paraffin-embedded triple-negative (TN) 
patient sample cores (AllPrep DNA/RNA FFPE Kit, Qiagen, Melbourne, Australia) obtained 
from Royal Prince Alfred Hospital and Concord Repatriation General Hospital, Australia, in 
accordance with ethics approval from Sydney Local Health District Ethics Board with 
informed patient consent. Unamplified mRNA levels were measured directly using a custom 
probeset on the NanoString nCounter DX platform according to manufacturer’s instructions 
and normalised to mean expression of six housekeeper genes (CLTC, GAPDH, GUSB, 
HPRT1, PGK1, TUBB). Six patient samples failed quality-control checks and were excluded 
from subsequent analysis. Heat map (A) was generated in Gene-E (Broad Institute) and 
shows the global absolute gene expression (log2, global min and max values shown) after 
manual clustering into TN breast cancer subtypes according to gene expression patterns 
previously described (Lehmann et al., 2011); UNS/BL1, unstable/basal-like 1; BL2, basal-
like 2; IM, immunomodulatory; M, mesenchymal; MSL, mesenchymal stem-like; LAR, 
luminal androgen receptor). Log2 gene expression of ASCT2/SLC1A5, glutamine 
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metabolism-related genes (GLUL, GLS), and transcription factors, MYC and ATF4 (B) 
across TN subtypes in our patient cohort as defined in (A). Correlation between 
ASCT2/SLC1A5 and transcriptional regulators, MYC and ATF4, was analysed for TN patient 
subgroups in our cohort (Supplementary Table 3.1), and subgroups that showed significant 
correlations (r>0.4, P <0.05; Pearson’s correlation statistic; exact P-values shown inset) 
were grouped and the correlation shown in (C). Black line shows the best-fit linear 
regression (SLC1A5 vs. ATF4: r2=0.314; SLC1A5 vs. MYC: r2=0.345). 
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SLC38A1 (Wang et al., 2015). While it has been shown that ATF4 directly regulates many of these 
transporters (Wang et al., 2011, Wang et al., 2013), in our study increased ATF4 expression after 
ASCT2 knockdown in vivo was not able to increase either ASCT2 or SLC3A2 expression (Figure 
3.3E). Despite this, in patient samples, our data show that ASCT2 expression correlates with ATF4 
expression in UNS/BL1, M and MSL subtypes (P<0.001, r=5607; Figure 3.4C and Supplementary 
Table 3.1), suggesting direct transcriptional regulation. Other recent data has shown that ASCT2 is 
not only regulated by ATF4, but also by N-Myc (Ren et al., 2015, Qing et al., 2012), adding to the 
well described role of c-Myc in transcriptionally regulating glutamine metabolism (Gao et al., 2009, 
Wise et al., 2008). Similar to ATF4, ASCT2 expression correlated with MYC in BL2, IM, M and 
MSL subsets (P<0.0001, r=0.5877; Figure 3.4C and Supplementary Table 3.1). It is therefore possible 
that while amino acid transporters are increased in a variety of cancers, this may merely reflect Myc- 
and ATF4-mediated transcriptional programs, rather than the reliance of a particular cancer on the 
relevant substrate amino acid(s). It is therefore crucial to determine which cancer, and subsets, not 
only express the relevant transporters and enzymes, but importantly rely on them for critical 
metabolic functions. It is clear that the ER+ breast cancer cell line MCF-7, despite high ASCT2 
expression, is not sensitive to glutamine deprivation (Figure 3.1). However, our data for 5 different 
basal-like TN breast cancer cell lines, together with a recent report showing the importance of ASCT2 
and SNAT2 in regulating glutamine uptake and growth in the claudin-low TN cell line, MDA-MB-
231 (Jeon et al., 2015), suggests that the majority of TN molecular subsets may be susceptible to 
therapies targeting glutamine uptake or glutamine metabolic pathways. Therefore, further preclinical 
development and testing of therapeutics targeting ASCT2, SNAT2 or downstream metabolic 
pathways such as glutaminase (Gross et al., 2014, Jacque et al., 2015) should therefore be undertaken 
across a range of TN breast cancer subtypes. 
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Adjunct unpublished results and discussion 
As our Nanostring gene expression analysis showed global upregulation of ASCT2 and other 
glutamine-metabolism related genes in TN breast cancer (Figure 3.4), we then assessed ASCT2 
protein expression in a larger cohort of 155 TN breast cancer cores (0-3 scale). This tissue microarray 
(TMA) analysis has shown 154/155 express ASCT2 (with 37 score 3 and 75 score 2; data not shown). 
In parallel, we assessed nine patient derived xeonograft (PDX) models from an independent cohort 
of TN samples, confirming that these have a similar pattern of ASCT2 expression, with protein 
expression in 4/9 at score 3, 4/9 at score 2 and only 1/9 at score 1 (data not shown). These data provide 
strong support for the functional significance of ASCT2 protein in disease, and confirm the suitability 
of these PDX models for in vivo screening of our novel ASCT2 inhibitors. 
 
Although not discussed in detail here, the immunological phenotype of TN tumours is rapidly 
emerging as a clinically significant feature of disease. For example, expression of the immune 
checkpoint molecule, programmed death ligand 1 (PD-L1), is becoming increasingly relevant as a 
prognostic and predictive biomarker in TN disease (Mittendorf et al., 2014, Sabatier et al., 2015), and 
the presence of tumour-infiltrating lymphocytes is associated with increased disease-free survival 
(Denkert et al., 2018). Given this potential role of the immune system in the progression and 
recurrence of TN breast cancer, PD-L1-inhibitors are now the subject of ongoing clinical trials in TN 
breast cancer (NCT01375842) and have shown efficacy in metastatic disease (Gibson, 2015). We 
therefore analysed the expression of PD-L1 in our TMA cohort, and showed that ASCT2 was 
significantly associated with expression of PD-L1 (data not shown). Future studies with our 
collaborators at the Garvan Institute will investigate this association further to assess whether ASCT2 
inhibition may synergise with immunotherapy in this patient population. 
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3.2.4 Supplementary Data 
 
 
Supplementary Figure 3.1. A, 3 × 105 cells from each cell line were incubated with 0.3 µCi 
[3H]-L-glutamine (PerkinElmer, Waltham, MA, USA) for 15 min in the presence or absence 
of L-γ-glutamyl-p-nitroanilide (GPNA; 1 mM; Sigma-Aldrich, St Louis, MO, USA) to assess 
glutamine uptake as previously described21. MDA-MB-231 (B; 3 × 103 cells/well), HCC1937 
(C; 1 × 104 cells/well), HCC1500 (D; 1 × 104 cells/well) and HCC1569 (E; 1 × 104 cells/well) 
cells were cultured for 3 days in the presence or absence of 1 mM GPNA. MTT assays were 
conducted every 24 h to assess cell growth according to manufacturer’s instructions (MTT 
Cell Growth Assay Kit; Merck-Millipore, Billerica, MA, USA). F, as in Figure 3.1H, MCF-7 
and HCC1806 cells were incubated in control media or media containing 1 mM GPNA for 6 
h. Total and phosphorylated (p-) p70S6K signalling protein (70, 85 kDa; both from Cell 
Signalling, Beverly, MA, USA) was then detected by Western blotting, with GAPDH (37 kDa) 
as loading control. G, MCF-7 and HCC1806 cells were incubated in control media, media 
containing 1 mM GPNA, or glutamine-free (Gln-) media for 6 h. Total and phosphorylated 
(p-Ser473) Akt signalling protein (60 kDa; both from Cell Signalling, Beverly, MA, USA) was 
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then detected by Western blotting, with GAPDH (37 kDa) as loading control. Annexin-V 
staining and PI positivity (Annexin-V:APC Apoptosis Detection Kit; BD Pharmingen, San 
Jose, CA, USA) was measured in live cells using flow cytometry to measure apoptosis and 
necrosis according to manufacturer’s instructions in MCF-7 (H) and HCC1806 (I) cells 
cultured with or without 1 mM GPNA for 24 h. Asterisks denote p-values as follows: *≤ 0.05; 
**≤ 0.01; ***≤ 0.001; ****≤ 0.0001, n.s.=not significant; 2-way ANOVA. Data in represent 
mean ± SEM, n≥3 experiments. Data in A, B are representative blots from 3 independent 
experiments. 
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Supplementary Figure 3.2. HCC1806 cells were transduced with a lentiviral vector 
(pLKO.1) containing control shRNA (shCont; shRNA sequence and specificity detailed 
previously (29)) or one of two shRNAs against ASCT2 (shA28: 
CCGGGCTGCTTATCCGCTTCTTCAACTCGAGTTGAAGAAGCGGATAAGCAGCTTTTT
G; or shA63: 
CCGGCTGGATTATGAGGAATGGATACTCGAGTATCCATTCCTCATAATCCAGTTTTTG; 
both from Sigma-Aldrich, St Louis, MO, USA). A, Cleaved caspase 3 levels (Cell Signaling, 
Beverly, MA, USA) after 72 h were detected in fixed HCC1806 cells by immunofluorescence 
staining with anti-cleaved caspase 3 (Cell Signalling, Beverly, MA, USA) as primary 
antibody, goat anti-rabbit AlexaFluor488 (Life Technologies, Carlsbad, CA, USA; green) as 
secondary antibody, and nuclei visualised using 4',6-diamidino-2-phenylindole (DAPI; blue). 
Scale bar, 100 μm. B, Number of cleaved caspase 3-positive objects (green) as percentage 
of DAPI-positive nuclei (blue) was quantified using Volocity 6.3. C, Cell viability was 
measured in transduced HCC1806 cells after 72 h using IncuCyteZOOM fluorescent live 
cell imaging, immediately following 1 h incubation with CyQUANT Direct Cell Proliferation 
reagent (green; Life Technologies, Carlsbad, CA, USA) and 15 min incubation with 5 μg/mL 
propidium iodide (red) in normal cell culture media. D-E, Total number of CyQUANT positive 
live cells in 9 images (D) and % PI positive dead cells (E) were quantified using IncuCyte 
software. Asterisks denote P-values as follows: *≤ 0.05; **≤ 0.01; ***≤ 0.001; ****≤0.0001, 
n.s.=not significant; Kruskal-Wallis test (B), unpaired t-test with Welch’s correction (D, E). 
Data in represent mean ± SEM, n=3 experiments. Data in A, C are representative images 
from 3 independent experiments performed in duplicate (A) or triplicate (C). 
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Supplementary Figure 3.3, HCC1806 cells were transduced with a lentivirus expressing 
both a mCherry-luciferase reporter construct (pHIV1SDm-CMV-mCherry-P2A-luc47) and 
the doxycycline-inducible shRNAs, shControl or shASCT2 (pFH1tUTG34) after 
fluorescence activated cell sorting (mCherryhiGFP+), with GAPDH (37 kDa) as loading 
control. Cell proliferation was measured using CyQUANT Direct Cell Proliferation Assay (B; 
Life Technologies, Carlsbad, CA, USA) according to manufacturer’s instructions at 0, 24, 48 
and 72 h after the addition of doxycycline (1 μg/mL). B, ASCT2 protein (60-75 kDa; Cell 
Signalling, Beverly, MA, USA) knockdown was confirmed in vitro. C, Cells (4 × 106) 
suspended in a solution of 50% Matrigel in RPMI (100 μL) were implanted orthotopically into 
the left and right abdominal mammary glands of 8-12 week old female athymic nu/nu mice 
(Animal Resource Centre, Perth, Australia), 5 mice per group from two separate 
experiments (n=10). Doxycycline (200 μg/mL) was administered ad libitum in drinking water 
from Day 0 and tumour growth was measured twice weekly until shControl tumours reached 
~1000 mm3, when all mice were culled. mCherry fluorescence of shControl and shASCT2 
xenografts was detected twice weekly using Xenogen IVIS Lumina II. Asterisks denote P-
values as follows: *P≤0.05; **P≤0.01; ***P≤0.001; ****P≤0.0001, n.s.=not significant; 2-way 
ANOVA. Data in B and C represent mean ± SEM, n≥3 experiments in B and n=10 from two 
independent experiments in C. Data in A are representative of 3 independent experiments.  
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Supplementary Table 3.1. RNA was extracted from 96 formalin-fixed paraffin-embedded 
triple-negative patient sample cores (AllPrep DNA/RNA FFPE Kit, Qiagen, Melbourne, 
Australia) obtained from Royal Prince Alfred Hospital and Concord Repatriation General 
Hospital, Australia, in accordance with ethics approval from Sydney Local Health District 
Ethics Board. mRNA levels were measured directly using a custom probeset on the 
NanoString nCounter DX platform according to manufacturer’s instructions. Six patient 
samples failed quality control checks and were excluded from subsequent analysis. Gene 
expression was normalised to mean expression of 6 housekeeper genes (CLTC, GAPDH, 
GUSB, HPRT1, PGK1, TUBB). Log2-transformed gene expression data from 90 patient 
samples for ASCT2/SLC1A5, ATF4, MYC, GLUL and GLS were correlated within TN 
subgroups as defined by manual clustering (Figure 3.4A) using a previously defined gene 
signature9, Pearson's correlation (r values shown). Bold indicates P<0.05. 
  
SLC1A5 SLC1A5 SLC1A5 SLC1A5 ATF4 ATF4 ATF4 MYC MYC
vs. ATF4 vs .MYC vs. GLUL vs. GLS vs. MYC vs. GLUL vs. GLS vs. GLUL vs. GLS
UNS/BL1 0.5003 0.2653 0.2371 0.4374 0.4275 0.6755 0.5583 0.4495 0.4654
BL2 0.1089 0.4558 0.1569 -0.4106 0.4126 0.5232 0.1782 0.0448 -0.3247
IM 0.2747 0.717 -0.2704 -0.2275 0.2774 0.6334 0.2862 0.2748 -0.2522
M 0.5375 0.5745 0.03588 0.3522 0.6584 0.3416 0.7188 0.5452 -0.07638
MSL 0.8779 0.9856 0.2054 0.6261 0.3528 0.8978 0.8334 0.1405 0.554
LAR 0.3149 -0.1305 0.3597 -0.2107 0.64 0.5413 0.3085 0.2055 0.3921
UNS/BL1+BL2 0.3492 0.3446 0.3103 0.1501 0.3686 0.6832 0.4465 0.3296 0.2167
UNS/BL1+BL2 
+M+MSL 0.4409 0.3907 0.1938 0.2455 0.5391 0.594 0.5828 0.3275 0.09991
BL2+M+MSL 0.316 0.5053 0.1418 -0.06398 0.632 0.6498 0.803 0.5167 0.3671
M+MSL 0.58 0.6263 0.08225 0.3887 0.4742 0.6847 0.5481 0.3864 0.2541
ALL 0.4048 0.409712 0.131634 0.092664 0.428058 0.434654 0.611078 0.120555 0.214133
Supplementary Table 1. RNA was extracted from 96 formalin-fixed paraffin-embedded triple-negative patient sample cores (AllPrep DNA/RNA FFPE Kit, Qiagen, Melbourne, Australia) obtained from Royal Prince Alfred Hospital and Concord Repatriation General Hospital, Australia, in aBold indicates p<0.05.
TN breast cancer 
subgroup(s)
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4.1 Characterisation of the intracellular metabolism of glutamine in 
breast cancer cells 
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4.2.1 Abstract 
Although a nonessential amino acid in normal cells, the demand for glutamine is dramatically 
increased throughout malignant transformation to support increased metabolic demands; namely, 
provision of catabolic substrates for ATP production and anabolic substrates for the citric acid cycle 
and subsequent macromolecule biosynthesis, as well as potentiating the uptake of other critical amino 
acids by acting as an obligate exchange substrate. Elevated expression of glutamine metabolism-
related genes, MYC-driven transcriptional events, and increased consumption and reliance on 
glutamine are all associated with aggressive breast cancers, including the high-risk triple-negative 
(TN) subtype. We recently showed that in breast cancer cells, glutamine uptake by the small neutral 
amino acid transporter, ASCT2, is required to sustain TN cell growth in vitro and in vivo. We 
therefore hypothesised that highly proliferative TN breast cancers that are sensitive to ASCT2 
inhibition may have unique metabolic signatures that could be additionally exploited for therapeutic 
purposes. Using a targeted metabolomics approach, we combined labelled substrate tracing, liquid 
chromatography coupled tandem-mass spectrometry (LC-MS/MS) and gas chromatography mass 
spectrometry (GC-MS) to analyse intracellular levels of key tricarboxylic acid (TCA) cycle 
intermediates, glycolytic metabolites, fatty acid precursors, and amino acids in human breast cancer 
cell lines. These analyses revealed distinct metabolic effects when glutamine uptake was blocked in 
vitro by L-g-glutamyl-p-nitroanilide (GPNA), a pharmacological inhibitor of ASCT2. These data 
confirm a broad reliance on glutamine availability in TN breast cancers, reinforced by TCGA gene 
expression data showing a specific upregulation of multiple glutamine metabolism enzymes that is 
completely absent in the Luminal A subtype. These data emphasise the link between increased 
glutamine metabolism and clinically aggressive breast cancers, thus highlighting the therapeutic 
potential of targeting glutamine metabolism pathways in these patients.  
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4.2.2 Introduction 
Like many solid tumours, breast cancers rely on glutamine to fuel cell growth and proliferation. The 
importance of glutamine is especially pronounced in high-risk proliferative subtypes, such as triple-
negative (TN) breast cancers. TN breast cancer patient samples and cell lines show increased 
expression of glutamine-metabolism related genes, as well as increased consumption of glutamine 
and increased reliance on exogenous glutamine (Kim et al., 2013b, Kung et al., 2011, Timmerman et 
al., 2013, van Geldermalsen et al., 2016, Jeon et al., 2015). Together these changes suggest a unique 
metabolic vulnerability in TN breast cancer cells that could be exploited therapeutically, “starving” 
cells of this essential nutrient to prevent cell growth. Accordingly, recent studies have demonstrated 
the efficacy of targeting glutaminase (GLS), the first and rate-limiting step of intracellular glutamine 
metabolism (Gross et al., 2014), with the glutaminase inhibitor CB-839 currently in clinical trials for 
a number of solid tumours, including TN breast cancers (NCT02071862). 
 
Upstream of glutaminase, a critical step in the requirement for glutamine is its transport into the cell. 
In many cancer cells, the small neutral amino acid transporter alanine, serine, cysteine-preferring 
transporter 2 (ASCT2) commonly facilitates the majority of this glutamine uptake. We and others 
have shown that inhibiting glutamine uptake by ASCT2 can suppress cell growth in prostate cancer 
(Wang et al., 2015), non-small cell lung cancer (Hassanein et al., 2013, Hassanein et al., 2015), 
hepatocellular carcinoma (Fuchs et al., 2004, Fuchs et al., 2007), melanoma (Wang et al., 2014a), 
acute myeloid leukaemia (Willems et al., 2013), and TN breast cancer (van Geldermalsen et al., 2016, 
Jeon et al., 2015). Notably, the effects of ASCT2 inhibition in breast cancer were shown to be 
subtype-dependent, with only TN basal-like breast cancer cells requiring ASCT2 to sustain their 
growth.  
 
Once inside the cell, glutamine directly supplies cellular metabolism by providing carbon skeleton 
intermediates for anaplerotic TCA, contributing to the biosynthesis of macromolecules, and acting as 
a catabolic substrate to generate ATP (DeBerardinis et al., 2007, Fan et al., 2013, Hosios et al., 2016). 
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Glutamine also supports tumour metabolism indirectly, as both glutamine and its deamination 
product, glutamate, can act as exchange substrates for other amino acids such as leucine or cystine in 
order to maintain intracellular amino acid homeostasis (Nicklin et al., 2009, Shin et al., 2017, 
Timmerman et al., 2013).  
 
Unlike glutaminase inhibitors, whose action on metabolism is well-characterised, little is known 
about the metabolic effects of ASCT2 inhibition in TN breast cancer. In this study, we therefore 
aimed to characterise the usage and fate of glutamine-derived carbon in both glutamine-indifferent 
Luminal A and glutamine-sensitive TN breast cancer cells to define critical metabolic nodes that 
differentiated glutamine reliance. These analyses confirmed a profound difference in how TN breast 
cancer cells normally use glutamine to fuel anabolic metabolism and ATP production; with increased 
enrichment of TCA intermediates, increased reliance on glutaminolysis for energy production, and 
low amounts of glutamine-independent anaplerosis observed in these cells. These data indicate a 
broad reliance on glutamine availability in TN breast cancers, reinforcing the therapeutic potential of 
targeting ASCT2-mediated glutamine uptake and downstream glutamine metabolism pathways in 
these patients.  
 
4.2.3 Materials & Methods 
Cell culture 
Human breast cancer cell lines MCF-7, HCC1806, and MDA-MB-231 were purchased from 
American Type Culture Collection. Cell lines were authenticated by STR fingerprinting every 2 years 
(CellBank Australia) and routinely tested for mycoplasma using a PCR detection kit. MCF-7 cells 
were grown in MEM medium (Life Technologies) containing 10% (v/v) fetal bovine serum (FBS), 2 
mM L-glutamine (Life Technologies), 1 mM Na pyruvate (Life Technologies) and penicillin-
streptomycin solution (Sigma-Aldrich, Australia). HCC1806 and MDA-MB-231 cells were grown in 
RPMI-1640 medium (Life Technologies) containing 10% (v/v) fetal bovine serum (FBS; HyClone), 
1 mM Na pyruvate (Life Technologies) and penicillin-streptomycin solution (Life Technologies). 
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Cells were maintained at 37°C in a fully humidified atmosphere containing 5% CO2. Inhibitors were 
resuspended in H2O and diluted 1:10 in media to final concentrations as follows: 2-amino-2-
norbornanecarboxylic acid (BCH, Sigma-Aldrich), 10 mM; Benzylserine (Ben, Bachem Swiss), 10 
mM; sulfasalazine (SASP, Sigma-Aldrich), 0.5 mM; L-g-glutamyl-p-nitroanilide (GPNA, Sigma-
Aldrich), 1 mM.  
 
13C-glutamine tracer experiments 
Cells were plated in triplicate at a density of 7 × 105 cells/well in 6-well plates in normal growth 
media and allowed to adhere for 6-8 h. Growth media was then removed and the cell monolayer was 
washed once with PBS. Media was then replaced with 1 mL of glutamine-free MEM (MCF-7) or 
RPMI 1640 (HCC1806, MDA-MB-231) containing 2 mM L-[13C5(U)]-Glutamine, and 100 µL 
GPNA (final concentration 1 mM) or 100 µL sterile endotoxin-free tissue culture grade water (Sigma) 
as a vehicle control. In the absence of 13C-enriched standards and paired unlabelled control samples, 
cells were incubated with 13C-glutamine for 12 h to approximate isotopic steady state.  
 
After 12 h incubation, metabolites were extracted using methanol:chloroform phase extraction 
method. Firstly, extracellular medium was removed and set aside for LC-MS/MS analysis. The cell 
monolayer was washed once with ice-cold 0.9% (w/v) NaCl solution and then rapidly quenched in 
50% (v/v) methanol:water mixture that had been prechilled to -30°C. A chlorophenylalanine/ 
norvaline standard mix (Sigma; 1 or 2 nmoles/well) was added to each well at this step to control for 
extraction efficiency. Cells were scraped into this mixture and then the entire volume was transferred 
to prechilled Falcon tubes and kept on ice. Each well was then rinsed once with equal volume ice-
cold UltraPureTM water (ThermoFisher) and this was combined with the first extract. One volume of 
prechilled chloroform was then added to each tube. The extraction mixes were vortexed vigorously 
for 10 sec and centrifuged at 3200 g for 5 min. The aqueous top phase of each sample was then 
transferred to a prechilled glass tube, gradually cooled to -30°C and then evaporated to dryness 
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without heat using a SpeedVac. Dried samples were promptly derivatised using tBDMS silylation 
and then analysed as described previously (Quek et al., 2016).  
Enrichment of 13C in metabolites from extracellular samples were analysed by LC-MS/MS as 
described previously (Yuan et al., 2012). 
Fractional contributions of 13C above a theoretical natural abundance of 1% enrichment were 
considered significant (Supplementary Tables 4.1 and 4.2). 
 
14C5-glutamine tracer experiments 
Cells were plated in triplicate at a density of 7 × 105 cells/well in 6-well plates in normal growth 
media and allowed to adhere at 37°C for 12-18 h. Growth media was removed, the cell monolayer 
was washed once with PBS and media was then replaced with glutamine-free RPMI 1640 (LifeTech) 
containing 2% (w/v) bovine serum albumin (BSA; Amresco), and 2 mM L-glutamine (Gibco). In 
vitro labelling proceeded in one of three ways: (a) a 15 min labelling experiment, (b) a 4 h labelling 
experiment, or (c) a 15 min labelled pulse with 4 h unlabelled chase. In all experiments, 0.5 µCi L-
[14C5 (U)]-Glutamine (PerkinElmer) was included in the labelled media. Where inhibitors were used, 
they were diluted 1:10 in the media described above, and sterile endotoxin-free tissue culture grade 
water (Sigma) was used as a vehicle control.  
At the end of each experiment, the carbon pool was resolved into six fractions using a TRIzol® 
extraction protocol modified from Hosios et al (2016). These fractions were: extracellular dissolved 
CO2, intracellular RNA, DNA and protein, and the intracellular polar and organic pools 
(Supplementary Figure 4.1A). For pulse-chase experiments, an additional seventh fraction was also 
collected which measured extracellular effluxed carbon (Supplementary Figure 4.1A). Details of each 
extraction are as follows: 
Extracellular dissolved CO2 was used as a measure of complete beta oxidation and was captured using 
the sodium hydroxide absorption method. This was achieved by the addition of an equal volume of 1 
		 129 
M perchloric acid to the extracellular media to liberate 14CO2 in gaseous form, which was then 
captured in 1 N sodium hydroxide.  
After removal of the extracellular medium, the cell monolayer was washed once with PBS and then 
homogenised in 1 mL TRIzol®. A guanidium thiocyanate-phenol-chloroform extraction was then 
performed according to manufacturers’ instructions. After centrifugation, RNA was precipitated from 
the top aqueous phase by addition of isopropanol (Sigma) and DNA was precipitated from the 
interphase/lower organic phase material by addition of 100% ethanol (Sigma), with glycogen 
included as a carrier to improve yield (Astral Scientific). After overnight precipitation, RNA pellets 
were briefly washed once with 70% ethanol, air dried and then resuspended in sterile nuclease-free 
water, while DNA pellets were washed twice with 70% ethanol for 10 min at room temperature with 
gentle inversion, air dried and then resuspended in 8 mM sodium hydroxide solution. The aqueous 
supernatant from the RNA extraction tubes was removed and transferred to new tubes as the “polar” 
fraction. Protein was then precipitated from the DNA supernatant by the addition of 3 volumes of 
acetone, followed by 20 min incubation at room temperature incubation and then centrifugation to 
sediment protein and insoluble material. The supernatant was removed and transferred to new tubes 
as the “organic” intracellular fraction. Precipitated protein pellets were washed three times in 95% 
ethanol/2.5% glycerol/0.3 M guanidine hydrochloride wash buffer, followed by a fourth and final 
wash using wash buffer without guanidine hydrochloride (97.5% ethanol/2.5% glycerol). The protein 
pellets were air dried briefly and then solubilised in cell lysis buffer to give the “protein” fraction.  
In pulse-chase experiments only, the chase medium was collected after 4 h and divided into two 
aliquots. The first aliquot was used for extracellular CO2 capture as described above. The second 
aliquot was directly transferred undiluted to a scintillation vial as the “media” fraction. 14C activity 
was measured in all phases by liquid scintillation counting in a Tri-Carb® Liquid Scintillation 
Analyser (PerkinElmer). 
The average counts per minute (CPM) from each tube was used to calculate the 14C activity of each 
sample in equivalent pmol of 14C-glutamine. These calculations were based on empirically 
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determined specific activity (decays per minute per picomole (dpm/pmol)) of a 14C-glutamine 
standard, which was measured for each experiment to ensure consistency and accuracy of counting.  
 
Seahorse FuelFlex analysis 
Oxygen consumption (as a proxy measure of mitochondrial beta-oxidation; OCR) and extracellular 
acidification rate (as an estimation of lactate production; ECAR) was measured in live cells using the 
Seahorse FuelFlex kit with a Seahorse XFp Analyser. Analyses were performed according to 
manufacturers’ instructions, with measurements taken when the metabolism of glutamine is inhibited 
with 3 µM BPTES (“dependency”), or when glutamine metabolism is permitted while glucose and 
fatty acid metabolism pathways are inhibited 4 µM UK5099 and 2 µM etomoxir (“capacity”). Briefly, 
cells were seeded into a Seahorse XFp Miniplate (2 ´ 104 cells/well) in full growth medium and 
allowed to adhere overnight. Growth media was then removed and replaced with pre-warmed running 
medium (consisting of non-buffered DMEM (Sigma-Aldrich, MO) supplemented with 1 mM sodium 
pyruvate and 10 mM glucose, pH 7.4. The Miniplate was then incubated for 60 min in a non-CO2 
incubator at 37°C before OCR and ECAR measurements were taken at 6.5 min intervals for 100 min, 
with the first inhibitor/s injected at 26 min, and then the remaining inhibitor/s injected at 65 min. Data 
analysis was performed according to manufacturers’ instructions. Where capacity is greater than 
dependency, the difference between these measurements determines the fuel usage “flexibility”.  
 
In silico gene expression analysis 
The provisional TCGA dataset of 1105 invasive breast cancer samples was accessed using cBio 
Cancer Genomics Portal (www.cbioportal.org). Tumour samples from the provisional TCGA dataset 
that were classified as basal-like or Luminal A (personal communication, C. Perou, 2017) were 
queried for mRNA expression of all glutamine-, glutamate-, or aKG-utilising enzymes, transcription 
factors that regulate amino acid metabolism, and genes involved in the anabolic or catabolic 
metabolism of the glutamine carbon skeleton (Supplementary Table 3). Gene expression data (mRNA 
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z-scores) were plotted as a heat map using GENE-E (Broad Institute) and then were subjected to 
unsupervised hierarchical clustering on rows and columns. 
 
4.2.4 Results 
TN breast cancer cells are reliant on glutamine for anaplerotic TCA 
Three breast cancer cell lines were chosen to represent both Luminal A breast cancer cells (MCF-7) 
and TN breast cancer cells (HCC1806, MDA-MB-231). We initially compared baseline metabolite 
levels in each cell line using targeted metabolomics. Heavy isotope-labelled glutamine (U-13C5-L-
glutamine) was traced into glutaminolytic products and TCA intermediates using gas chromatography 
coupled mass spectrometry (GCMS), and the fractional contribution of 13C in each metabolite was 
analysed.  
 
The six metabolites that showed significant enrichment of 13C (Supplementary Table 4.1; glutamate, 
aKG, malate, aspartate, fumarate and citrate) had higher fractional contributions in TN cells 
compared to luminal cells, showing uniformly increased incorporation of glutamine-derived carbons 
relative to Luminal A MCF-7 cells (Figure 4.1A; Supplementary Table 4.1). Unsupervised 
hierarchical clustering showed that glutamine clustered separately to these six metabolites and 
displayed an inverse pattern of enrichment, whereby lower enrichment of glutamine was generally 
observed with higher enrichment of downstream metabolites (Figure 4.1A). Notably, the enrichment 
of these six metabolites was significantly higher in the TN cell lines (Figure 4.1B), suggesting that 
these cells are more reliant on glutamine to replenish TCA intermediates. 
 
Glutamine-derived carbons can enter TCA cycle as m+5 aKG and be oxidised in a forward direction 
(Figure 4.1C; green solid line) or be converted to m+5 citrate by reductive carboxylation (Figure 
4.1C; red dotted line). Analysis of m+4 intermediates (forward TCA; Figure 4.1D) and m+3 
metabolites (reverse TCA; Figure 4.1E) showed that glutamine-derived carbon is contributing  
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Figure 4.1. Triple-negative breast cancer cells are more reliant on glutamine to fuel 
anaplerotic TCA cycle. A, relative fractional contribution of 13C to the seven intracellular 
metabolites that showed significant enrichment in Luminal A MCF-7 (MCF7) cells and triple-
negative (TN) HCC1806 and MDA-MB-231 (MDA231) cells after 12 h labelling with U-13C5-
L-glutamine, expressed as the fraction of carbon atoms in each metabolite derived from 
glutamine. Data were normalised within rows (row min to max) and subjected to 
unsupervised hierarchical clustering on both rows and columns. B, absolute fractional 
contribution of 13C to the significantly enriched metabolites shown in (A). C, carbon tracing 
map for the seven significantly enriched metabolites (carbon number indicated by empty 
circles). D, 13C enrichment of forward TCA intermediates. E, 13C enrichment of reverse TCA 
intermediates. Abbreviations: aKG, a-ketoglutarate; TCA, tricarboxylic. 
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primarily to anaplerotic forward TCA in all three cell lines. Enrichment of m+4 intermediates was 
also significantly higher in the TN cell lines (~40%) than in the luminal MCF-7 cells (~20%; Figure 
4.1D), indicating that luminal MCF-7 cells have lower levels of glutamine-dependent anaplerotic 
TCA. In contrast, enrichment of m+3 labelled species (representing reverse TCA) were significantly 
higher in MCF-7 cells (Figure 4.1E); however, the m+3 levels of labelling were low in three cell 
lines, indicating minimal contributions from reverse TCA.  
 
TN cells require more intracellular glutamine to fuel metabolism 
As TCA can also be used by cells to generate precursors for nucleotide, fatty acid, and protein 
biosynthesis, we next examined the broader intracellular fate of glutamine. Cells were incubated with 
U-14C5-glutamine, and then lysed and fractionated into six pools: dissolved CO2 collected from 
extracellular medium, intracellular acid-soluble metabolites (“polar”), chloroform-soluble 
metabolites (“organic”), and RNA, DNA, and protein (Supplementary Figure 4.1A).  
 
Firstly, we confirmed that after a brief 15 min incubation, MCF-7 and HCC1806 cells took up 
comparable amounts of labelled glutamine (Supplementary Figure 4.1B) and this total pool was 
traced largely into the polar (88-89%) and organic (8-9%) phases, with negligible labelling of RNA, 
DNA, protein and CO2 (each less than 1% of the total pool; Supplementary Figure 4.1C). To allow 
time for intracellular glutamine to progress into terminal metabolism, we then incubated cells with 
14C5-glutamine for 4 h. Overall the intracellular fate of glutamine did not appear markedly changed 
at this later timepoint, indicating that the majority of glutamine-derived carbon remains in the acid-
soluble polar pool (Figure 4.2A). However, one striking feature of these longer incubation 
experiments was that with 4 h of exposure to labelled glutamine, intracellular 14C continued to 
accumulate in HCC1806 cells (4-fold increase over 15 min levels) whereas intracellular 14C levels 
remained constant in MCF-7 cells. This occurred without any significant differences in the relative  
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Figure 4.2. Glutamine requirements for biosynthetic and bioenergetic metabolism are 
higher in triple-negative breast cancer cells. A, 14C enrichment in the dissolved CO2, 
RNA, DNA, polar, organic and protein phases extracted from MCF-7 and HCC1806 cells 
after 4 h labelling with U-14C5-glutamine. Data expressed as equivalent pmol of U-14C5-
glutamine. B, 14C enrichment of the extracellular media, dissolved CO2, RNA, DNA, polar, 
organic and protein phases extracted from MCF-7 and HCC1806 cells after 15 min pulse 
labelling with U-14C5-glutamine, followed by 4 h chase with unlabelled media. Data 
expressed as equivalent pmol of U-14C5-glutamine. C, data from (B) expressed as a 
percentage of total 14C signal detected in each sample. D, data from (B), with the media 
fraction excluded, expressed as a percentage of total intracellular 14C signal. E, fractional 
contribution of 13C to extracellular glutamate in MCF-7, HCC1806 and MDA-MB-231 (MDA-
231) cells after 12 h labelling with U-13C5-glutamine. F, Seahorse FuelFlex live cell analysis 
of oxygen consumption rate was performed in MCF-7 and HCC1806 cells in the presence 
of 4 µM UK5099 and 2 µM etomoxir (glutamine capacity) or 3 µM BPTES (glutamine 
dependency). G, oxidative phosphorylation (OXPHOS) contribution to mitochondrial 
respiration in MCF-7 and HCC1806 cells at baseline (grey), when treated 4 µM UK5099 and 
2 µM etomoxir (capacity; orange), or when treated with 3 µM BPTES (dependency; blue), 
expressed as a ratio of oxygen consumption rate (OCR) to extracellular acidification rate 
(ECAR). Asterisks denote p-values as follows: *≤ 0.05; **≤ 0.01; ***≤ 0.001; ****≤ 0.0001, 
n.s.=not significant; 2-way ANOVA.   
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distribution of 14C enrichment throughout the phases (Supplementary Figure 4.1D), suggesting 
similar pathways of utilisation in both cell lines but different levels of magnitude. Previous studies 
have suggested that glutamine is metabolised at a slower rate in MCF-7 cells due to lower expression 
of glutaminase (Kung et al., 2011, Zhou et al., 2017), thus providing negative feedback to slow the 
rate of glutamine transport into the cell. Alternatively, the action of other cell surface transporters, 
such as SLC7A5/LAT1 (Nicklin et al., 2009) or SLC7A11/xCT (Shin et al., 2017, Timmerman et al., 
2013), can facilitate efflux of 14C5-labelled glutamine (LAT1) or its 14C5-labelled metabolite, 
glutamate (xCT), causing decreased intracellular enrichment over time. To elucidate these pathways, 
we performed pulse-chase experiments where cells were pulsed with 14C5-labelled glutamine for 15 
min, washed, and then chased with unlabelled media for 4 h. After 4 h, the unlabelled chase media 
was removed from cells and split in half, with one half used for CO2 capture as normal, and one half 
used as an additional seventh fraction (“media”) for direct measurement of soluble 14C in the medium. 
These measurements revealed that the majority of labelled 14C taken up by either cell line is effluxed 
as soluble metabolites into the “media” fraction (Figure 4.2B), and that luminal MCF-7 cells showed 
significantly increased extracellular enrichment as a fraction of total signal (95% in MCF-7 cells vs 
89% in HCC1806 cells, p<0.0001, 2-way ANOVA with Tukey correction; Figure 4.2C). 
 
Notably, although the effluxed media fraction was by far the predominant fate of 14C across both cell 
lines, when intracellular labelling after the pulse-chase was considered alone, there were some key 
subtype-specific differences. Relatively more glutamine-derived carbon remained intracellular in the 
TN HCC1806 cells (2-fold increase: 2653 pmol in HCC1806 cells, 1359 pmol in MCF-7 cells; Figure 
4.2B), reflecting the greater reliance of TN cells on glutamine as a metabolic and biosynthetic 
substrate. In addition, the polar phase was significantly more enriched in the TN HCC1806 cells (3% 
of total signal in MCF-7 cells vs 7% in HCC1806 cells, Figure 4.2C, p<0.0001, 2-way ANOVA with 
Tukey correction; 55% of intracellular pool in MCF-7 cells vs 64% of intracellular pool in HCC1806 
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cells, p=0.0269, 2-way ANOVA with Tukey correction; Figure 4.2D), which accounted for the 
reciprocal difference in extracellular enrichment.  
 
To determine the identity of glutamine-derived carbon species in the extracellular media, we 
performed targeted liquid-chromatography coupled-tandem mass spectrometry (LC-MS/MS) 
metabolomics analysis on paired extracellular media samples (collected from the same experiments 
where intracellular metabolites were extracted, after 12 h labelling). This analysis confirmed that 
there was significant enrichment of 13C glutamate in the media of MCF-7, MDA-231 and HCC1806 
cells. This confirmed the importance of the rate-limiting activity of glutaminase in total glutamine 
metabolism. We confirmed this using an orthologous approach by treating cells with inhibitors of 
glutamine efflux (LAT1 inhibitors: BCH, benzylserine) or glutamate efflux (xCT inhibitor: 
sulfasalazine/SASP) during the 4 h chase period after a 15 min 14C pulse to see whether this would 
affect efflux. Inhibition of LAT1 with BCH or benzylserine (BenSer) did not significantly alter 
effluxed 14C accumulation over 4 h, however, xCT inhibition (SASP) significantly reduced 
extracellular 14C by 25% in MCF-7 cells and 27% in HCC1806 cells (Supplementary Figure 4.1E). 
This confirmed that a large component of the extracellular glutamine-derived carbon is glutamate 
effluxed through xCT.  
 
We also examined the utilisation of glutamine as a substrate for respiration by assessing fuel pathway 
preference and compensation in MCF-7 and HCC1806 cells with the Seahorse XF Mito Fuel Flex 
Test. These analyses showed that the dependency of HCC1806 cells on glutamine as a mitochondrial 
fuel was almost 4-fold greater than MCF-7 cells (62% vs 17%; Figure 4.2F), reinforcing our 
substrate-tracing data showing that more glutamine-derived carbon is incorporated in HCC1806 cells. 
HCC1806 cells also showed no flexibility in their glutamine usage, as their capacity to use glutamine 
was equal to their dependency (Figure 4.2F), indicating that these cells are oxidising glutamine at a 
maximal rate regardless of whether other substrates are available. In contrast, luminal MCF-7 cells 
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showed increased capacity to oxidise glutamine when alternative fuel pathways were inhibited, and 
therefore had greater flexibility in their usage of glutamine as a substrate. Comparison of oxygen 
consumption rate (OCR) with extracellular acidification rate (ECAR), showed that luminal MCF-7 
cells rely more on oxidative than glutaminolytic metabolism compared to TN HCC1806 cells (Figure 
4.2G, baseline). In MCF-7 cells, the OCR:ECAR ratio was significantly reduced when glutamine was 
the only available substrate (capacity), and to a lesser extent, when glutamine metabolism was 
inhibited (dependency), confirming that these cells perform less glutamine-dependent anaplerotic 
TCA and suggesting an increased shift towards a less oxidative metabolism in the context of 
glutamine restriction. HCC1806 cells also showed a significantly reduced OCR:ECAR ratio when 
measuring glutamine capacity or dependency; however, these changes were much smaller and were 
identical to each other, again reinforcing the rigidity of the metabolic program in TN cells. Together, 
these data demonstrated that TN breast cancer cells take up, incorporate and metabolise more 
glutamine than luminal MCF-7 cells, and that this intracellular glutamine was retained for both 
replenishment of anaplerotic TCA and catabolism of ATP, while a substantial portion was converted 
into glutamate for efflux through xCT.  
 
ASCT2 inhibition decreases glutamine incorporation into TCA 
We then investigated the effect of ASCT2 inhibition on these pathways of glutamine usage. We 
previously showed that TN breast cancers have increased ASCT2 expression, and TN cell lines 
require its function for growth and survival (van Geldermalsen et al., 2016, Jeon et al., 2015). As 
ASCT2 is a primary mediator of glutamine uptake in these cells, we hypothesised that targeting this 
transporter would cause global reduction in glutamine metabolism, resulting in decreased 
incorporation and utilisation of glutamine-derived carbon. Accordingly, when metabolites where 
extracted from luminal MCF-7 and TN HCC1806 cells treated with 1 mM GPNA throughout the 
13C5-labelling, we observed decreased labelling of the six significantly enriched metabolites (Figure 
4.3A-F; Supplementary Table 4.2), while enrichment of glutamine was unchanged (Figure 4.3G;   
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Figure 4.3. Inhibition of ASCT2 by GPNA decreases glutamine incorporation into TCA 
intermediates. Relative contribution of each mass species to total levels of glutamate (A), 
aKG (B), fumarate (C), malate (D), citrate (E), aspartate (F), and glutamine (G) in MCF-7 
and HCC1806 cells. Metabolites were extracted after 12 h labelling with U-13C5-glutamine, 
in the presence of 1 mM GPNA (right column) or vehicle control (left column). H, relative 
level of glutamine-dependent anaplerosis in MCF-7 and HCC1806 cells, expressed as a 
ratio of m+4 aKG to m+5 citrate after 12 h labelling with U-13C5-glutamine. Data show the 
13C enrichment in each of these mass species in the presence of 1 mM GPNA (red columns) 
or vehicle control (black columns), with the m+5 aKG:m+4 citrate ratio shown as a number 
above the paired columns.  
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Supplementary Table 4.2). Generally, this decreased enrichment was due to a significant reduction in 
the dominant m+4 fraction (Supplementary Figure 4.3), with minimal changes in the partially labelled 
species. Despite these changes in enrichment, the relative contribution of glutamine-independent 
anaplerosis remained consistent in both MCF-7 and HCC1806 cells, showing no change in the 
propagation of m+5 aKG to m+4 citrate with GPNA treatment (Figure 4.3H). These experiments 
were also repeated in an additional TN cell line (MDA-MB-231) to confirm the phenotype and 
showed the same pattern of globally decreased enrichment without any change in glutamine-
dependent anaplerosis (Supplementary Figures 4.3 and 4.4).  
 
ASCT2 inhibition decreases glutamine incorporation into all intracellular metabolic pathways 
We next confirmed that GPNA inhibition of ASCT2 over a short 15 min incubation significantly 
decreased labelling of the polar fraction only, representing decreased intracellular glutamine due to 
inhibited glutamine uptake (Supplementary Figure 4.2A-B). After 4 h of 14C-glutamine labelling, 
GPNA treatment caused significantly decreased overall incorporation of glutamine by 22% (MCF-7) 
or 29% (HCC1806), caused by significantly decreased enrichment in the polar phase only (Figure 
4.4A). In addition, GPNA treatment during the 4 h chase period following a 15 min 14C pulse caused 
significant contraction of the polar pool (from 55% to 43% of total intracellular 14C pool) in MCF-7 
cells only, with no change in HCC1806 cells (Figure 4.4B-C) or in extracellular enrichment of 
effluxed 14C (Figure 4.4D). Given that, in contrast to HCC1806 cells, MCF-7 cell viability is 
unaffected by GPNA treatment (van Geldermalsen et al., 2016), this preferential shrinkage of the 
polar pool may offer evidence of adaptive metabolic responses to ASCT2 inhibition. We also 
determined that limiting glutamine uptake reduces subsequent enrichment of effluxed 13C-glutamate 
(Figure 4.4E; significance not tested). The Seahorse FuelFlex data also indicated that at least part of 
the glutamine-labelled polar fraction is involved in ATP generation through either complete oxidation 
or lactate production, and not just replenishment of anaplerotic substrates.  
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Figure 4.4. Inhibition of ASCT2 by GPNA reduces glutamine enrichment of all 
intracellular and extracellular fractions. A, 14C enrichment in the dissolved CO2, RNA, 
DNA, polar, organic and protein phases extracted from MCF-7 and HCC1806 cells after 4 h 
labelling with U-14C5-glutamine, in the presence of 1 mM GPNA or vehicle control. Data are 
expressed as equivalent pmol of with U-14C5-glutamine. B, 14C enrichment of the dissolved 
CO2, RNA, DNA, polar, organic and protein phases extracted from MCF-7 and HCC1806 
cells after 15 min pulse labelling with U-14C5-glutamine, followed by 4 h chase with 
unlabelled media. Data are expressed as equivalent pmol of with U-14C5-glutamine. C, data 
from (B) expressed as a percentage of total intracellular 14C signal detected in each sample. 
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Glutamine metabolism gene expression can segregate TN from Luminal A breast cancers  
Given the clear differences in basal glutamine utilisation in TN cells compared to luminal MCF-7 
cells, and the global effects observed in GPNA treatment, we analysed expression of key metabolic 
enzymes that use glutamine, glutamate or aKG as a substrate, transcription factors that regulate amino  
acid metabolism, and genes involved in the anabolic or catabolic metabolism of the glutamine carbon 
skeleton (Supplementary Table 3 for full list of genes) to see whether these were differentially 
expressed across subtypes. We queried the provisional TCGA invasive breast carcinoma cohort 
(cBioPortal) for mRNA expression of these genes in the samples classified into either Luminal A or 
basal-like (TN) subtypes. When subjected to unsupervised hierarchical clustering based on z-scores 
of mRNA expression, the samples clustered into two main groups that largely separated the two 
subtypes (Figure 4.5). There was a cluster of highly expressed genes in the basal subgroup (top left) 
that were not expressed highly in the Luminal A samples. There were no clear clusters associated 
with the Luminal A group, however expression of the single gene, GLUL, was notably higher in this 
group compared to the basal group. This gene encodes glutamine synthetase and is negatively 
associated with glutamine dependence, with previous studies observing higher expression in 
glutamine-independent luminal cells (Kung et al., 2011). These data reinforce that pathways of 
glutamine metabolism and utilisation are strongly activated in TN cells specifically, highlighting the 
multiplicity of roles that glutamine plays in supporting the growth and metabolism of these cells.   
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Figure 4.5. A cluster of glutamine metabolism genes is highly expressed in breast 
cancer and can segregate triple-negative tumours from Luminal A tumours. 
Expression of key metabolic enzymes that use glutamine, glutamate or aKG as a substrate, 
transcription factors that regulate amino acid metabolism, and genes involved in the 
anabolic or catabolic metabolism of the glutamine carbon skeleton (Supplementary Table 3 
for full list) was examined in the provisional TCGA invasive breast cancer cohort. Samples 
were manually classified into basal-like/triple-negative (Comparison Group A; green) or 
Luminal A (Comparison Group B; brown) and gene expression data (mRNA, z-scores) were 
subjected to unsupervised hierarchical clustering on both rows and columns.  
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4.2.5 Discussion 
In this study, we have shown that the dominant fate of intracellular glutamine in breast cancer cells 
is into the acid-soluble polar phase (Figure 4.2A, D), containing polar metabolites and amino acids. 
Analysis of a targeted subset of metabolites and amino acids revealed significant incorporation of 
glutamine-derived carbon into oxidative forward TCA (fumarate, malate, citrate), glutaminolytic 
intermediates (glutamate, aKG), and non-essential amino acid biosynthesis (aspartate). The fate of 
glutamine was consistent across multiple breast cancer cell lines representing both Luminal A and 
TN subtypes, but cell lines varied in their dependency on glutamine as a substrate for anaplerotic 
TCA and ATP production. Furthermore, we have shown that breast cancer cell lines demonstrate 
subtype-specific features of glutamine metabolism, exhibiting increased uptake, incorporation and 
utilisation of glutamine in TN breast cancer cells compared to Luminal A cells.  
 
An unexpected result of our radiolabelled glutamine tracing experiments was that the majority of 
glutamine-derived carbon is effluxed and not retained inside the cell (Figure 4.2B, C). We also 
showed that a large portion of this signal is from intracellular glutamine converted to glutamate and 
then effluxed through xCT (Figure 4.2E, Supplementary Figure 4.1E), however the function of  
this pathway remains unclear. Possible non-metabolic functions are the exchange of glutamate for 
cystine to support redox homeostasis (Timmerman et al., 2013), or secretion of glutamate to stimulate 
autocrine and/or paracrine metabotropic glutamate receptor 1 pro-growth signalling pathways (Banda 
et al., 2014, Speyer et al., 2012). Previous studies have also suggested that xCT expression and 
activity determines sensitivity to glutamine (Timmerman et al., 2013) and glucose (Shin et al., 2017) 
deprivation, in both cases by limiting availability of intracellular glutamate. This indicates how 
intracellular availability of nutrients is coupled to the ability of the cell to adapt to nutrient stress, 
highlighting the therapeutic potential of targeting nutrient transporters. Regardless of its exact 
function, we showed that this pathway of xCT-mediated efflux is dependent on ASCT2-mediated 
glutamine influx and subsequent deamidation, as shown by the reduced glutamate 13C enrichment 
when cells were treated with GPNA (Figure 4.4E).  
		 144 
 
As others have shown (Terunuma et al., 2014, Zhou et al., 2017), we observed intracellular glutamine 
levels inversely correlated with glutamine flux into glutamine-derived metabolites (Figure 4.1A). In 
our study, these patterns were associated with breast cancer subtype: Luminal A MCF-7 cells showed 
reduced uptake of glutamine and less labelling of downstream metabolites, whereas TN cells took up 
more glutamine and incorporated significantly more glutamine-derived carbon into TCA and 
glutaminolytic metabolites (Figure 4.1A-B, Figure 4.2A). This was reflected in metabolic flexibility 
analyses, which showed that TN cells were combusting glutamine at a maximal rate, while Luminal 
A MCF-7 cells were able to increase glutaminolytic flux when metabolism of other substrates was 
inhibited (Figure 4.2F-G). Overall these data indicated much greater reliance on glutamine in TN 
cells, which was consistent with our expectations as these cells are known to be sensitive to glutamine 
deprivation. 
 
Glutamine can be used to fuel both forward TCA and reductive carboxylation, with altered tumoural 
metabolic needs often dictating different patterns of utilisation (Mullen et al., 2011, Metallo et al., 
2011). In our heavy isotope tracing experiments, the m+4 fraction of TCA intermediates was the 
dominant species in all cell lines, representing labelling of forward TCA. In contrast, the m+5 label 
of citrate (produced by reductive carboxylation of aKG) was observed to a much lesser degree (6:1 
m+4:m+5 citrate in the TN cells), indicative of low reverse TCA activity. This ratio was much higher 
in the Luminal A MCF-7 cells (2:1 m+4:m+5 citrate), however the levels of citrate labelling in 
MCF-7 cells were much lower overall. Notably, this ratio did not change in any of the cells lines 
when treated with GPNA, indicating no change in the relative contribution of reverse TCA when 
glutamine transport was inhibited. Likewise, lower levels of enrichment of the partially labelled TCA 
intermediate species (fumarate and malate; m+1, m+2, m+3) were also detected. However, when 
using U-13C5-glutamine the origin of these partially-labelled species is ambiguous, as they could 
represent either continued cycling of the glutamine-derived m+4 intermediates through a second 
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round of TCA, or the first-round entry of partially labelled citrate or α-ketoglutarate into anaplerotic 
TCA. These inferences require confirmation with use of singly-labelled 1- and 5-13C-glutamine to 
definitively delineate between forward anaplerotic TCA, reductive carboxylation, and entry of 
partially labelled intermediates. 
 
Glutamine is also a critical source of nitrogen in mammalian cells, facilitating transamination 
reactions by donating an amide to form glutamate, which is then able to donate or accept nitrogen 
groups to form its obligate amino acid or keto-acid (glutamine and aKG respectively). Overactivity 
of aminotransferases that catalyse these reactions has previously been reported in breast cancer cell 
lines (Friday et al., 2011), suggesting that these are important pathways in breast cancer. Our data 
show that Luminal A cells rely less on glutamine to generate glutamate than TN cells (Figure 4.2B), 
consistent with lower rates of glutamine deamidation to glutamate in these cells (Gross et al., 2014, 
Zhou et al., 2017), which was further reduced by GPNA treatment (Figure 4.3A). Recent data have 
suggested that these pathways of nitrogen usage are critical for the maintenance of de novo pyrimidine 
synthesis in TN cells (Brown et al., 2017), indicating a glutamine-dependent metabolic vulnerability 
in these cancers. As glutamine has been shown to contribute as much as 30% of total cellular nitrogen 
in proliferating cells (Hosios et al., 2016), heavy-isotope tracing studies using 15N-labelled glutamine 
may reveal additional critical pathways of amide/amine utilisation in glutamine-dependent breast 
cancer cells.  
 
Aspartate, the transamination product of the TCA intermediate, oxaloacetate, is a secondary nitrogen 
donor that functions, together with glutamate, to ensure intracellular nitrogen balance. Exogenous 
aspartate is even able to partially rescue cells from glutamine deprivation-mediated cell death 
(Korangath et al., 2015), highlighting the importance of the nitrogen pool in sustaining cell survival. 
Aspartate biosynthesis is therefore a key function of the TCA cycle (Sullivan et al., 2015). Consistent 
with this, we observed aspartate 13C enrichment across all cell lines (34-47%), with dominant m+4 
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enrichment. This suggests biosynthesis from m+4 oxaloacetate, which is formed during the first round 
of forward TCA from glutamine-derived m+5 aKG. The enrichment of aspartate was not higher than 
that of other significantly enriched TCA intermediates (fumarate, malate, citrate), suggesting that 
glutamine-derived carbon is not preferentially shunted into this biosynthetic pathway at the expense 
of downstream TCA in either Luminal A or TN cell lines (Figure 4.1B, Supplementary Table 4.1). In 
addition, GPNA treatment did not cause any specific changes in aspartate synthesis from 
oxaloacetate, as the reduced glutamine flux into aspartate was comparable to reductions observed in 
the other enriched metabolites (Figure 4.3, Supplementary Figure 4.2).  
 
As aspartate can be transamidated to generate asparagine for protein synthesis, and recent reports 
have suggested that asparagine is an important glutamine-derived metabolite in glutamine-dependent 
cells (Krall et al., 2016), we also examined 13C enrichment of asparagine. This showed borderline 
enrichment of 13C in the TN cell lines (3-5%) and low but significant enrichment in luminal MCF-7 
cells (11%), suggesting that is not a dominant pathway of glutamine utilisation (Supplementary Table 
4.1). Correspondingly, 14C enrichment of the protein fraction was low in both MCF-7 and HCC1806 
cells (Figure 4.2), in contrast to recent reports suggesting that the majority of glutamine is 
incorporated into protein in proliferating cells (Hosios et al., 2016). This discrepancy suggests that 
there may be cell- or tumour-specific pathways of glutamine incorporation into protein, but this 
conclusion needs to be confirmed using an extended labelling time with multiple timepoints to capture 
any changes in the kinetics of protein biosynthesis. 
 
Some metabolic pathways were surprisingly not enriched in our 13C tracing experiments. Notably, 
enrichment of the glutaminolytic endpoint products, pyruvate and lactate, was borderline in all cell 
lines (<5%; Supplementary Table 4.1), indicating a very small contribution from glutaminolytic 
conversion of malate to pyruvate, in contrast to previous studies of glioblastoma cells (DeBerardinis 
et al., 2007). Similarly, alanine, serine and glycine – all possible downstream products of pyruvate 
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amidation – were borderline enriched across all cell lines (alanine: 3-4%; serine and glycine 0-1%; 
Supplementary Table 4.1), showing little to no contribution from m+3 pyruvate. These data also 
indicated that glutamine carbons did not meaningfully contribute to one-carbon metabolism pathways 
via serine, or to pathways of nucleotide synthesis via glycine.  
 
The biosynthetic pathways that use glutamine carbon flux through one of three nodes: glutamate, 
aspartate, or pyruvate. Our data indicated that aspartate and glutamate are the important branch points 
in breast cancer cells, while, in contrast, pyruvate was not significantly labelled by glutamine-derived 
13C. As discussed above, aspartate and glutamate are important nitrogen species, however they are 
also key carbon intermediates in the production of nucleotides. Carbon incorporation from glutamine 
into nucleotides is dependent on flux through both glutamate and aspartate, with subsequent 
incorporation into pyrimidine precursors (Lane and Fan, 2015). Our carbon-tracing data showed that 
14C incorporation into nucleotides was reduced by 20% (DNA) or 30% (RNA) with GPNA treatment, 
despite nucleic acids comprising only 1-2% of the intracellular glutamine carbon pool (Figures 4.2A, 
4.4A). Future metabolomics studies should incorporate flux analyses in combination with tracing of 
nitrogen-labelled glutamine to determine whether this carbon utilisation is as important as nitrogen 
utilisation for maintaining pyrimidine synthesis (Lane and Fan, 2015, Brown et al., 2017). 
 
Numerous studies have examined the expression of glutamine-utilising enzymes in breast cancer, and 
have shown increased expression compared to normal breast (Jin et al., 2015, Zhang and Han, 2017), 
with some showing an association with TN subtype (Thornburg et al., 2008), ER negativity (Kim et 
al., 2013b), and glutamine dependence (Korangath et al., 2015). Of these, the best described is 
glutaminase, whose expression and activity in TN breast cancer is well-documented (Budczies et al., 
2013, Cassago et al., 2012, Kung et al., 2011, Timmerman et al., 2013). As our data suggest a global 
increase in glutamine metabolism in TN cells, we examined the major glutamine-utilising genes in a 
single gene expression cohort. Here we report the first global assessment of these glutamine-, 
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glutamate- or aKG -utilising enzymes, as well as the major genes involved in anabolic metabolism 
of the glutamine carbon skeleton downstream of aspartate or glutamate, the two key intermediates 
identified in our data (Supplementary Table 4.3). This analysis of the provisional TCGA invasive 
breast cancer cohort showed that expression of these genes is able to differentiate basal-like TN 
tumours from Luminal A tumours (Figure 4.5). This suggests that increased glutaminolytic 
metabolism and glutamine dependence in TN tumours is controlled to some extent at a gene 
expression level, and not just by increased enzyme activity and metabolic flux. 
 
In addition to its direct carbon and nitrogen contributions, glutamine also supports tumour metabolism 
indirectly by stimulating pro-growth mTORC1 signalling (Duran and Hall, 2012, Duran et al., 2012), 
controlling redox balance through generation of NADPH and glutathione, and being exchanged for 
other amino acids through cell surface nutrient transporters (Nicklin et al., 2009, Timmerman et al., 
2013). A recent paper also described an additional “non-metabolic” function of glutamine – namely 
the activation of pro-proliferative STAT3 signalling, which occurs independent of glutaminolysis 
(Cacace et al., 2017). Likewise, glutamate formed by deamidation of glutamine also performs non-
metabolic functions to facilitate and promote cell growth. Extracellular glutamate may contribute to 
the activation of pro-growth signalling pathways in an autocrine or paracrine fashion by binding 
metabotropic glutamate receptor 1 (Banda et al., 2014, Speyer et al., 2012). Although not explored 
here, it is possible that ASCT2 inhibition may decrease or prevent activation of these additional 
pathways, just as it globally decreased all of the intracellular metabolism pathways that were analysed 
in this study, and perhaps one or more of these are responsible for subtype-specific glutamine 
dependence.  
 
A potential application of our study is the development of ASCT2 inhibitors for therapeutic use in 
TN breast cancer. We have shown that targeting and inhibiting the critical uptake step is able to inhibit 
flux of glutamine into all downstream metabolic pathways, indicating the cascading effects that can 
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be achieved by targeting upstream. Other recent studies have shown that glutamine deprivation or 
inhibition of glutaminolysis can sensitise breast cancer cells to existing chemotherapeutics (Chen et 
al., 2016, Yang, 2016, Dilshara et al., 2017, Brown et al., 2017), providing further evidence for the 
feasibility of therapeutically targeting glutamine transporters in a combinatorial treatment setting. 
Other studies have demonstrated the efficacy of single-agent therapies targeting glutaminase, the first 
and rate-limiting step of intracellular glutamine metabolism. One of these novel inhibitors is currently 
in clinical trials for a number of solid tumours, including TN breast cancers (NCT02071862), further 
supporting the feasibility of therapeutically targeting ASCT2-mediated glutamine uptake.  
 
Interestingly, despite profound differences at baseline, overall there was no subtype-specific 
differences in the effect of GPNA on glutamine metabolism. ASCT2 inhibition by the 
pharmacological inhibitor, GPNA, resulted in comparable reductions in glutamine-derived carbon 
incorporation at steady state in both Luminal A and TN cell lines (Figure 4.3, Supplementary Figure 
4.2), and there was no change in glutamine-independent anaplerosis when ASCT2 was inhibited 
(Figure 4.3H, Supplementary Figure 4.3I). However, Luminal A MCF-7 cells were able to increase 
their use of glutamine as a substrate for respiration when deprived of glucose and fatty acids, 
suggesting submaximal flux through glutamine-metabolism pathways, whereas TN HCC1806 cells 
were unable to compensate in the same way (Figure 4.2F-G). This suggested that any adaptive 
metabolic flexibility in MCF-7 cells in response to GPNA treatment is not mediated through changes 
to the relative contribution of glutamine-derived carbon, but rather by changes in metabolic flux. This 
was complemented by our gene expression analysis (Figure 4.5), which revealed overexpression of a 
cluster of glutamine metabolism genes that was sufficient to segregate TN basal-like tumours from 
less aggressive Luminal A tumours. Together these data suggest activation of multiple metabolic 
pathways, at both a transcriptional and enzymatic level, function to support TN glutamine-dependent 
cell growth.   
		 150 
4.2.6 Supplementary Data 
Supplementary Table 4.1. Fractional contributions of 13C to metabolites extracted at steady 
state from breast cancer cell lines. Key: * significantly different to MCF-7; # significantly 
different to HCC1806; FC, fractional contribution; SD, standard deviation. 
 MCF-7 HCC1806 MDA-231 
Intracellular: FC (%) SD  
FC 
(%) SD  
FC 
(%) SD 
Glutamine 79.9 10.6 * 69.4 6.4 # 80.3 9.3 
Glutamate 43.4 8.4 * 66.7 6.0 *# 57.8 4.1 
aKG 44.7 8.4 * 67.3 5.3 *# 60.0 2.9 
Malate 36.4 6.4 * 59.5 5.0 *# 50.6 5.1 
Aspartate 34.2 7.3 * 47.9 6.6 # 34.7 3.8 
Fumarate 31.0 8.5 * 55.1 5.2 *# 46.6 3.9 
Citrate 25.8 4.4 * 43.0 3.6 *# 35.7 3.2 
Asparagine 10.7 1.5 * 3.4 1.4 *# 4.7 0.9 
Alanine 3.8 1.8 * 3.4 0.4 *# 3.0 0.3 
Pyruvate 4.6 2.3 * 3.3 0.6 *# 2.7 0.4 
Lactate 3.1 1.5 * 2.3 0.4 *# 2.1 0.3 
Serine 0.9 0.1 * 2.3 0.4 *# 0.9 0.1 
Glycine 1.0 0.1 * 1.0 0.1 *# 1.1 0.2 
Glycerol 1.4 0.2 * 1.1 0.1 *# 1.4 0.2 
Supplementary Table 4.2. Fractional contributions of 13C to metabolites extracted at steady 
state from breast cancer cell lines treated with 1 mM GPNA. Key: FC, fractional contribution; 
SD, standard deviation. 
 MCF-7 HCC1806 MDA-231 
Intracellular: FC (%) SD FC (%) SD FC (%) SD 
Glutamine 80.96 7.008 67.56 8.83 76.44 13.69 
Glutamate 34.6 7.005 59.95 5.162 52.12 2.924 
aKG 36.06 7.347 61.16 5.876 54.09 2.907 
Malate 29.3 5.507 54.03 5.012 45.11 5.145 
Aspartate 26.72 6.753 37.55 4.455 23.12 5.084 
Fumarate 23.83 8.558 49.66 4.847 41.38 2.839 
Citrate 20.67 3.31 39.77 3.694 32.79 2.701 
Asparagine 8.702 0.9993 2.991 1.242 3.83 0.8309 
Alanine 2.883 1.001 3.185 0.2655 2.88 0.2402 
Pyruvate 3.315 1.228 2.976 0.44 2.379 0.3 
Lactate 2.405 0.7643 2.299 0.2904 2.077 0.3226 
Serine 0.8919 0.1387 0.9887 0.0636 0.9655 0.07024 
Glycine 1.01 0.05938 1.097 0.08415 1.067 0.1479 
Glycerol 1.382 0.1975 1.35 0.1478 1.333 0.1427 
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Supplementary Table 4.3. Potential therapeutic targets in the glutamine uptake and 
metabolism pathways. 
Gene  Name Pathway Substrate 
GMPS GMP Synthetase Purine 
synthesis 
Glutamine 
GART Phosphoribosyl-Glycinamide Formyltransferase, 
Phosphoribosyl-Glycinamide Synthetase, 
Phosphoribosyl-Aminoimidazole Synthetase 
Purine 
synthesis 
None 
PSAT1 Phosphoserine Aminotransferase 1 One carbon 
metabolism 
(from 
pyruvate) 
aKG/ Glutamate 
ASNS Asparagine Synthetase Amino acid 
biosynthesis 
Glutamine 
CTPS1 CTP synthetase Pyrimidine 
synthesis 
Glutamine 
TYMS Thymidylate Synthetase Pyrimidine 
synthesis, 
folate 
metabolism 
None 
CAD Carbamoyl-Phosphate Synthetase 2, Aspartate 
Transcarbamylase, and Dihydroorotase 
Pyrimidine 
synthesis 
CPSII uses 
glutamine 
GARS Glycyl-tRNA Synthetase Protein 
synthesis 
None 
GPT2 Glutamic-Pyruvic Transaminase 2 aKG synthesis Glutamate 
ADSL Adenylosuccinate Lyase Purine 
synthesis 
None 
ATF4 Activating Transcription Factor 4 Amino acid 
response 
pathway 
 
GLS Glutaminase Glutamate 
synthesis 
Glutamine 
UMPS UMP Synthetase Pyrimidine 
synthesis 
None but uses 
carbamoyl 
phosphate (CPSII 
activity) and 
PRPP 
PAICS Phosphoribosylaminoimidazole Carboxylase and 
Phosphoribosylaminoimidazolesuccinocarboxami
de Synthase 
Purine 
synthesis 
 
PPAT Glutamine Phosphoribosylpyrophosphate 
Amidotransferase 
Purine 
synthesis 
Glutamine 
DHODH Dihydroorotate Dehydrogenase Pyrimidine 
synthesis 
None, 
downstream of 
carbamoyl 
phosphate and 
upstream of 
PRPP usage 
GOT1 Glutamate-Oxalate Transaminase 1 Aspartate 
synthesis 
Glutamate/ aKG 
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GCLM Glutamate-Cysteine Ligase Modifier Subunit Redox control 
(GSH 
synthesis) 
Glutamate 
DHFR Dihydrofolate reductase Pyrimidine 
synthesis, 
folate 
metabolism 
None  
CPS1 Carbamoyl Phosphate Synthetase I  Pyrimidine 
synthesis 
Glutamine 
SLC1A5/A
SCT2 
Alanine, Serine, Cysteine-preferring Transporter 
2 
Glutamine 
uptake 
 
GPT Glutamic-Pyruvic Transaminase aKG synthesis Glutamate 
BCAT2 Branched Chain Amino Acid Transaminase 2 Glutamate 
synthesis 
aKG 
ATIC 5-Aminoimidazole-4-Carboxamide 
Ribonucleotide Formyltransferase/IMP 
Cyclohydrolase 
Purine 
synthesis 
None 
CTPS2 CTP Synthase 2 Pyrimidine 
synthesis 
Glutamine 
GCLC Glutamate-Cysteine Ligase Catalytic Subunit Redox control 
(GSH 
synthesis) 
Glutamate  
GOT2 Glutamate-oxalate transaminase 2 Aspartate 
synthesis 
Glutamate/ aKG 
GLUD2 Glutamate Dehydrogenase 2 aKG synthesis Glutamate 
GLUD1 Glutamate Dehydrogenase 1 aKG synthesis Glutamate 
GLS2 Glutaminase 2 aKG synthesis Glutamine 
GLUL Glutamate-Ammonia Ligase /  
Glutamine Synthetase 
Glutamine 
synthesis 
Glutamate 
 
 
 
		 153 
 
Supplementary Figure 4.1. Supporting data related to Figure 4.2. A, schematic of the 
fractional separation strategy (modified from Hosios et al., 2016) used to isolate each of the 
phases analysed in 14C-glutamine tracing experiments. B, 14C enrichment of the extracellular 
media, dissolved CO2, RNA, DNA, polar, organic and protein phases extracted from MCF-
7 and HCC1806 cells after 15 min labelling with U-14C5-glutamine. Data expressed as 
equivalent pmol of U-14C5-glutamine. C, data from (B) expressed as a percentage of total 
14C signal detected in each sample. D, data from Figure 4.2A expressed as a percentage of 
total 14C signal detected in each sample. E, 14C enrichment of the extracellular media from 
MCF-7 and HCC1806 cells after 15 min pulse labelling with U-14C5-glutamine, followed by 4 
h chase with unlabelled media containing 10 mM BCH, 10 mM BenSer, 0.5 mM SASP, or 
vehicle control.  
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Supplementary Figure 4.2. Supporting data related to Figure 4.4. A, 14C enrichment in 
the dissolved CO2, RNA, DNA, polar, organic and protein phases extracted from MCF-7 and 
HCC1806 cells after 15 min labelling with U-14C5-glutamine, in the presence of 1 mM GPNA 
or vehicle control. Data are expressed as equivalent pmol of with U-14C5-glutamine. B, data 
from (B) expressed as a percentage of total 14C signal detected in each sample. C, data 
from Figure 4.4A expressed as a percentage of total 14C signal detected in each sample. 
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Supplementary Figure 4.3. Supporting data related to Figure 4.3. Relative contribution 
of each mass species to total levels of glutamine (A-C), glutamate (D-F), aKG (G-I), 
fumarate (J-L), malate (M-O), citrate (P-R), and aspartate (S-U) in MCF-7, HCC1806, and 
MDA-231 cells cells. Metabolites were extracted after 12 h labelling with U-13C5-glutamine, 
in the presence of 1 mM GPNA (red) or vehicle control (black). Asterisks indicate statistically 
significant difference to adjacent Control bar; * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, 
multiple t-tests with Holm-Sidak correction.  
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Supplementary Figure 4.4. Glutamine utilisation and incorporation in GPNA-treated 
triple-negative MDA-MB-231 cells. A, fractional contribution of 13C to intracellular 
metabolites in MDA-MB-231 (MDA-231) cells after 12 h labelling with U-13C5-glutamine in 
the presence of 1 mM GPNA (red) or vehicle control (black), expressed as the fraction of 
carbon atoms in each metabolite derived from glutamine. Relative contribution of each mass 
species to total levels of the seven significantly enriched metabolites, glutamate (B), aKG 
(C), fumarate (D), malate (E), citrate (F), aspartate (G), and glutamine (H) in MDA-231 cells. 
Metabolites were extracted after 12 h labelling with 13C-U-glutamine, in the presence of 1 
mM GPNA (right column) or vehicle control (left column). I, relative level of glutamine-
dependent anaplerosis in MDA-231 cells, expressed as a ratio of m+4 aKG to m+5 citrate 
after 12 h labelling with U-13C5- glutamine. Data show the 13C enrichment in each of these 
mass species in the presence of 1 mM GPNA (red columns) or vehicle control (black 
columns), with the m+5 aKG:m+4 citrate ratio shown as a number above the paired 
columns. 
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CHAPTER 5  
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5.1 Assessment of the efficacy of dual glutamine and leucine uptake 
inhibition in breast cancer cells  
 
5.1 Declarations 
This chapter has been prepared in a format for publication. As a result, introductory statements that 
appear elsewhere in this thesis (Sections 1.1-1.3) may also appear in this chapter. Materials and 
Methods are recorded here in brief; for full detailed methods please refer to Sections 2.1, 2.8-2.11 
and 2.19-2.21 of this thesis.  
5.1.1 Authorial contribution statement: 
The author (M.vG.) wrote the manuscript, performed all analysis, and designed and performed all 
experiments except those indicated below.  
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5.2.1 Abstract 
Cancer cells require increased levels of nutrients, including the amino acids leucine and glutamine, 
to sustain their rapid growth. These two amino acids have been shown to be important for growth and 
proliferation of some breast cancers, and therefore targeting the primary cell-surface transporters that 
mediate their uptake, L-type amino acid transporter 1 (LAT1) and alanine, serine, cysteine-preferring 
transporter 2 (ASCT2), is a potential therapeutic strategy. We have previously shown that the ASCT2 
inhibitor, benzylserine (BenSer), is also able to block LAT1 activity, thus inhibiting both leucine and 
glutamine uptake. We therefore aimed to investigate the effects of BenSer in breast cancer cell lines 
to determine whether combined LAT1 and ASCT2 inhibition could inhibit cell growth and 
proliferation. BenSer treatment significantly inhibited both leucine and glutamine uptake in MCF-7, 
HCC1806 and MDA-MB-231 breast cancer cells, causing decreased cell viability and cell cycle 
progression. We showed that these effects were not primarily leucine-mediated, and that dual 
inhibition of both leucine and glutamine uptake was required for maximal cytostatic effects. Gas 
chromatography-mass spectrometry (GCMS) analysis of intracellular amino acid concentration 
revealed that BenSer-mediated inhibition of leucine and glutamine uptake was sufficient to disrupt 
multiple pathways of amino acid metabolism, causing reduced oxygen consumption, decreased 
mTORC1 signalling, and activation of amino acid response (AAR) mediator, activating transcription 
factor 4 (ATF4). Together these data showed that dual leucine-glutamine transporter blockade 
inhibited breast cancer cell growth and viability by disrupting intracellular amino acid homeostasis, 
leading to activation of multiple stress response signalling pathways. 
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5.2.2 introduction 
Cancer cells require a constant exogenous supply of nutrients to fuel their rapid growth. In recent 
years, much attention has been given to the importance of amino acids as a substrate for supporting 
and sustaining tumorigenic proliferation. These amino acids are used for the three critical elements 
of rapid cell proliferation: biosynthesis of macromolecules, generation of cellular energy, and 
stimulation of the mTORC1 pathway. In cancer, two particularly crucial amino acids are leucine and 
glutamine. These two amino acids contribute to the three pathways outlined above but have an 
additional role in maintaining amino acid balance across the plasma membrane by serving as 
facultative cotransport or antiport substrates for other amino acids. As a result, cell growth in many 
cancers is dependent on the availability of leucine and glutamine.  
 
To satisfy these demands, human cancer cells selectively upregulate amino acid transporters to 
facilitate rapid uptake of amino acid substrates. Leucine uptake is predominantly mediated by the L-
type amino acid transporter (LAT) family, a Na+-independent group of four transporters (LAT1, 
SLC7A5; LAT2, SLC7A8; LAT3, SLC43A1; LAT4, SLC43A2) with affinity for branched chain and 
neutral amino acids (Babu et al., 2003, Bodoy et al., 2005, Pineda et al., 1999, Segawa et al., 1999). 
Members of the LAT family are significantly upregulated in a number of human malignancies 
including prostate (Wang et al., 2011, Wang et al., 2013), melanoma (Wang et al., 2014a) and breast 
(Furuya et al., 2012), as we reviewed recently (Wang and Holst, 2015). Glutamine transport in cancer 
is commonly mediated by alanine, serine, cysteine-preferring transporter 2 (ASCT2; SLC1A5), 
which has been shown for multiple cancers including melanoma (Wang et al., 2014a), non-small cell 
lung cancer (Hassanein et al., 2013, Hassanein et al., 2015), prostate cancer (Wang et al., 2015), acute 
myeloid leukaemia (Willems et al., 2013), multiple myeloma (Bolzoni et al., 2016), and breast cancer 
(van Geldermalsen et al., 2016, Jeon et al., 2015). Other glutamine transporters such as SNAT1 
(SLC38A1) and SNAT2 (SLC38A2) have also been shown to play a role in glutamine uptake in 
triple-negative breast cancer (Jeon et al., 2015) osteosarcoma and cervical cancer cells (Broer et al 
2016). 
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As we and others have shown that blocking glutamine uptake prevents cell growth in triple-negative 
basal-like breast cancer cells (van Geldermalsen et al., 2016, Jeon et al., 2015), and it was recently 
shown that breast cancer cells are sensitive to leucine deprivation (Xiao et al, 2016), we hypothesised 
that dual targeting of glutamine and leucine uptake would be effective in breast cancer, as it is in 
melanoma (Wang et al, 2014). BenSer was first characterised as a specific ASCT2 inhibitor in 2004 
(Grewer and Grabsch, 2004) and has since been used as a competitive inhibitor of small, neutral 
amino acid transport in cancer cell lines (Wang et al., 2014a, Wang et al., 2015). We have previously 
shown that the ASCT2 inhibitor, Benzylserine (BenSer), can also inhibit leucine uptake by LAT1 
(Wang et al., 2014a), thus making it an ideal putative inhibitor for this dual leucine-glutamine 
deprivation therapy. 
 
5.2.3 Materials and Methods 
Cell culture 
Human breast cancer cell lines MCF-7, HCC1806, and MDA-MB-231 were purchased from 
American Type Culture Collection. Cell lines were authenticated by STR fingerprinting every 2 years 
(CellBank Australia, Westmead, Sydney, NSW, Australia) and routinely tested for mycoplasma using 
a PCR detection kit. MCF-7 cells were grown in MEM medium (Life Technologies) containing 10% 
(v/v) fetal bovine serum (FBS), 2 mM L-glutamine (Life Technologies), 1 mM Na pyruvate (Life 
Technologies) and penicillin-streptomycin solution (Sigma-Aldrich, Australia). HCC1806 and 
MDA-MB-231 cells were grown in RPMI-1640 medium (Life Technologies) containing 10% (v/v) 
fetal bovine serum (FBS; HyClone), 1mM Na pyruvate (Life Technologies) and penicillin-
streptomycin solution (Life Technologies). Cells were maintained at 37°C in a fully humidified 
atmosphere containing 5% CO2. Inhibitors were resuspended in H2O and diluted 1:10 in media to 
final concentrations: BenSer (BenSer, Bachem Swiss), 2-amino-2-norbornanecarboxylic acid (BCH, 
Sigma-Aldrich), 10 mM. 
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Antibodies 
Antibodies used in this study were against α-tubulin (Santa Cruz), pT389-p70S6K, p70S6K, ATF4 
(Cell Signalling), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Abcam). Horseradish 
peroxidase–conjugated donkey anti-mouse IgG donkey and anti-rabbit IgG were used as Western blot 
secondary antibodies (Millipore).  
 
Uptake assay 
The [3H]-L-glutamine and [3H]-L-leucine uptake assays were performed as detailed previously 
(Wang et al., 2011). Briefly, cells (1 × 105/well) were incubated with 0.3 µCi [3H]-L-glutamine or 
[3H]-L-leucine (200 nM; Perkin Elmer) in glutamine-free MEM or leucine-free RPMI media 
(Invitrogen) for 15 min at 37°C in the presence or absence of 10 mM BenSer or BCH. Cells were 
collected and transferred to filter paper using a 96-well plate harvester (Wallac PerkinElmer), dried, 
exposed to scintillation fluid and counts measured using a liquid scintillation counter (PerkinElmer).  
 
Cell viability assays 
Cells (3 × 103 per well) were seeded in 96-well plates and allowed to adhere overnight. Cells were 
then incubated in the presence or absence of 10 mM BenSer or BCH for up to 72 h. Media was 
refreshed every 24 h. Proliferation was measured at days 0, 1, 2 and 3 by the addition of MTT solution 
(10 µL; Millipore) to each well and returning plates to incubation for at least 5 hr. Following this, 
100 µL of isopropanol/HCl solution was added to each well and then mixed thoroughly using a 
multichannel pipette. Absorbance in each well was then immediately read at 570 nm and 640 nm. 
 
BrdU incorporation assay 
Cells (3 × 105 per well) were seeded in 6-well plates and allowed to adhere overnight. Cells were then 
incubated in the presence or absence of 10 mM BenSer or BCH for 24 h. BrdU (150 µg/mL) was then 
added to culture media and incubated for another 2 h, followed by detachment using Tryple 
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(Invitrogen). Cells were fixed and stained using the BD APC-BrdU flow kits (BD). The BrdU 
antibody was diluted 1:50. Nuclei were counter-stained by 7-aminoactinomycin D (7-AAD). Analysis 
was performed using a BD Fortessa flow cytometer. Data were analysed using FlowJo software (Tree 
Star Inc.). 
 
Annexin-V assay 
Cells (3 × 105 per well) were seeded in 6-well plates, allowed to adhere overnight, before incubation 
in the presence or absence of 10 mM BenSer for 24 h. Positive control cells were irradiated in a UV 
Stratalinker 2400 (Stratagene) with a 400,000 µJ dosage and incubated in fresh media for 16 h. Cells 
were detached using Tryple and resuspended in 100 µl of binding buffer (HEPES–buffered PBS 
supplemented with 2.5 mM calcium chloride) containing anti-annexin V-APC (BD; diluted 1:100) 
and incubated for 30 min in the dark on ice. PI solution (10 µg/mL) was added, and the cells were 
analysed using a BD Fortessa flow cytometer and FlowJo software. 
 
SDS-PAGE and Western blotting 
Cells (5 × 105 per well) were seeded in 6-well plates, allowed to adhere overnight, before incubation 
in the presence or absence of 10 mM BenSer for 6 h. Cells were lysed by the addition of lysis buffer 
(200 µl) with protease inhibitor Cocktail III (Bioprocessing Biochemical, California) and phosphatase 
inhibitor (Cell Signalling). Equal protein (micro–BCA method; Pierce, IL) was loaded on 4–12% 
gradient gels (Invitrogen, Australia), electrophoresed and transferred to PVDF membrane. The 
membrane was blocked with 2.5% (w/v) BSA in PBS-Tween20 (PBST) and then incubated with the 
primary and secondary antibodies. The secondary HRP-labelled antibodies were detected using 
enhanced chemiluminescence reagents (Pierce) on a BioRad ChemiDoc (BioRad).  
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GCMS analysis of intracellular amino acids 
Cells were plated in triplicate at a density of 7 × 105 cells/well in 6-well plates and allowed to adhere 
for 6-8 h. Media was then replaced with 1mL fresh media containing 100 µL BenSer (final 
concentration 10 mM) or 100 µL sterile endotoxin-free tissue culture grade water (Sigma) as a vehicle 
control. After 12 h incubation, intracellular amino acids were extracted by methanol:chloroform 
extraction. Briefly, medium was removed and the cell monolayer was washed once with ice-cold 
0.9% (w/v) NaCl solution and then rapidly quenched in 50% (v/v) methanol:water mixture that had 
been prechilled to -30°C. A chlorophenylalanine/norvaline standard mix (Sigma; 1 or 2 nmoles/well) 
was added to each well at this step to control for extraction efficiency. Cells were scraped into this 
mixture and then the entire volume was transferred to prechilled Falcon tubes and kept on ice. Each 
well was then rinsed once with equal volume ice-cold UltraPureTM water (ThermoFisher) and this 
was combined with the first extract. One volume of prechilled chloroform was then added to each 
tube. The extraction mixes were vortexed vigorously for 10 sec and centrifuged at 3200 g for 5 min. 
The aqueous top phase of each sample was then transferred to a prechilled glass tube, gradually cooled 
to -30°C and then evaporated to dryness without heat using a SpeedVac. Dried samples were promptly 
derivatised using tBDMS silylation and then analysed as described previously (Quek et al., 2016).  
 
In silico gene expression analysis 
The METABRIC cohort of ~2500 clinical breast cancer samples (Curtis et al., 2012, Pereira et al., 
2016) and all breast cancer cell lines included in The Cancer Cell Line Encyclopedia (Barretina et 
al., 2012) were assessed using cBio Cancer Genomics Portal (www.cbioportal.org). Gene expression 
(RNA log2 expression data) was queried for 12 putative BenSer target transporters: SLC7A5, 
SLC7A8, SLC3A2, SLC43A1, SLC43A2, SLC6A5 (not available in the METABRIC cohort), 
SLC6A9, SLC1A1, SLC1A2, SLC1A3, SLC1A6, and SLC1A7. METABRIC data were additionally 
sorted on clinical attributes (“Pam50 + Claudin-low subtype”) to assign samples into subtypes. These 
data were plotted as box-and-whisker plots (whiskers indicating min to max). 
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5.2.4 Results 
BenSer inhibits leucine and glutamine uptake in breast cancer cells  
To confirm that BenSer inhibits both glutamine and leucine uptake in breast cancer cells, we used a 
[3H]-labelled amino acid uptake assay as described previously (Wang et al., 2011, Wang et al., 2015). 
Briefly, cells were incubated with [3H]-L-glutamine or [3H]-L-leucine for 15 min in the presence or 
absence of 10 mM BenSer to determine the direct effects on amino acid uptake. We used three 
different breast cancer cell lines: estrogen-receptor (ER)-positive, Luminal A MCF-7 cells, triple-
negative basal-like HCC1806 cells, and triple-negative claudin-low MDA-MB-231 (MDA-MB-231) 
cells, to represent a variety of breast cancer subtypes. Treatment with BenSer reduced glutamine 
uptake to ~65% of control across all three cell lines (Figure 5.1A), while leucine uptake was inhibited 
more strongly to ~45% (MCF-7 and MDA-MB-231) and 22% (HCC1806) of control (Figure 5.1B). 
Previous data have shown that total glutamine uptake in these three cell lines is HCC1806>MDA-
MB-231>MCF-7 (CPM> CPM > CPM; van Geldermalsen et al., 2016). Despite these variations in 
glutamine uptake, the % inhibition after BenSer was similar for all three cell lines. Analysis of total 
leucine uptake again showed the highest level in HCC1806, with much lower levels in MCF-7 and 
MDA-MB-231 cells (Figure 5.1C). Interestingly, despite this high leucine uptake in HCC1806 cells, 
BenSer had the largest effect on leucine uptake in this cell line. As this uptake assay is performed 
over 15 minutes, these data suggested that BenSer was able to directly inhibit both glutamine and 
leucine uptake in breast cancer cells.  
 
BenSer inhibits breast cancer cell growth 
To determine the effect of BenSer on breast cancer cell growth, cells were cultured in the presence 
of 10 mM BenSer for 3 days and cell viability was measured every 24 h using an MTT assay. BenSer 
treatment significantly reduced cell viability in all three cell lines, regardless of their subtype or 
proliferation rate (Figure 5.1D-F). Inhibitory effects were observed within the first 48 h in all cell   
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Figure 5.1. Benzylserine inhibits breast cancer cell growth by blocking leucine and 
glutamine uptake. Glutamine (A) and leucine (B) uptake over 15 min were measured in 
MCF-7, HCC1806 and MDA-MB-231 (MDA-231) cells in the presence or absence of 10 mM 
BenSer. C, data from (B) showing raw counts per minute (CPM). D, relative cell viability 
measured by MTT assay in MCF-7 (D), HCC1806 (E), and MDA-231 (F) cells cultured for 3 
days in the presence or absence of 10 mM BenSer. Data represent mean ± SEM of at least 
three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001; unpaired 
student’s t-test (A-B), 2-way ANOVA (D-F). 
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lines. We next set out to determine whether these reductions in viability were due to cell cycle 
blockade or apoptosis. 
 
We first used BrdU incorporation and propidium iodide staining to analyse cell cycle phase. Each 
cell line showed distinct differences in baseline cell cycle profiles, with MCF-7 cells being mainly in 
G0/G1, HCC1806 cells in S phase, and MDA-MB-231 cells in G2/M phase. Despite these difference 
in baseline cell cycle profile, BenSer treatment reduced cell cycle progression, resulting in a 10-20% 
increase in cells accumulated at G0/G1 phase (Figure 5.2A-C), although this reduction was significant 
in MCF-7 cells only (significance not tested in MDA-MB-231 cells). In MCF-7 and HCC1806 cells, 
the increased numbers of cells in G0/G1 was accompanied by decreases in S phase, and in MDA-MB-
231 cells, a decrease in G2/M phase. Further repeats of these experiments are ongoing to confirm 
whether the observed trends are significant. We next examined apoptosis using flow cytometry to 
detect levels of “flipped” Annexin-V in the plasma membrane, combined with propidium iodide (PI) 
to measure cell permeability. Treatment with BenSer for 24 h increased the number of apoptotic 
(Ann+/PI- and Ann+/PI+) cells in MCF-7, HCC1806, and MDA-MB-231 cells (Figure 5.2D-F), 
although not significantly in any case (significance not tested in MDA-MB-231 cells), suggesting 
that the effects of BenSer treatment were predominantly cytostatic. These data suggested a broad 
applicability of BenSer treatment across different breast cancer subtypes and proliferation rates, 
which was of particular interest to us because sensitivity to ASCT2 inhibition alone appears to be 
subtype-restricted to highly proliferative triple-negative cancers, and not Luminal A breast cancer 
cell lines (van Geldermalsen et al., 2016).  
 
To investigate this further, we used the LAT family inhibitor, BCH, to determine whether the growth 
inhibitory effects of BenSer were leucine-mediated. BCH treatment mirrored BenSer treatment in all  
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Figure 5.2. Benzylserine treatment reduces cell cycle progression with minimal 
effects on apoptosis. Cell cycle progression measured by BrdU incorporation in MCF-7 
(A), HCC1806 (B) and MDA-MB-231 (MDA-231; C) cells cultured in the presence or 
absence of 10 mM BenSer for 24 h. Annexin-V staining in MCF-7 (D), HCC1806 (E) and 
MDA-MB-231 (MDA-231; F) cells cultured in the presence or absence of 10 mM BenSer for 
24 h. Data represent mean ± SEM of at least three independent experiments, except for C 
(n=2) and F (n=1). *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001; 2-way ANOVA (A-B, D-
E). Significance not tested in C or F. 
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3 cell lines, potently blocking [3H]-L-leucine uptake to similar extents (Figure 5.3A) without any 
effect on [3H]-L-glutamine uptake (Figure 5.3B). However, BCH treatment did not mirror the effects 
of BenSer on cell viability (Figure 5.3C-E). While there was a modest but significant (~10%) 
reduction in cell viability in MCF-7 and MDA-MB-231 cells (Figure 5.3C, E), this did not reflect the 
reduction seen after BenSer treatment. Additionally, there was no significant effect on HCC1806 cell 
viability (Figure 5.3D). Complete leucine deprivation was recently shown to reduce breast cancer cell 
growth in vitro and in vivo, and leucine titrations suggested a minimal amount of leucine (10% of 
normal amounts) is absolutely required for continued cell growth and survival (Xiao et al., 2016). 
These data suggest that the dual targeting of leucine and glutamine uptake by BenSer may have an 
additive or synergistic effect, and that reduced uptake of both amino acids is required for optimal 
inhibition of cell growth. Interestingly, however, combined treatment of MCF-7 and HCC1806 cells 
with both a leucine uptake inhibitor (BCH) and a glutamine uptake inhibitor (L-g-glutamyl-p-
nitroanilide; GPNA), did not recapitulate the effects of BenSer treatment (Supplementary Figure 
5.1A-B), suggesting that BenSer may block uptake of leucine and glutamine by acting on other 
additional amino acid transporters. 
 
BenSer treatment affects multiple pathways of intracellular amino acid metabolism 
Due to the importance of leucine and glutamine in supporting cell growth pathways, we next 
examined the effect of BenSer treatment on intracellular amino acid concentrations. These analyses 
were done using gas chromatography coupled mass spectrometry (GC-MS) on methanol:chloroform 
extracted metabolites from MCF-7, HCC1806 and MDA-MB-231 cells incubated with or without 10 
mM BenSer for 12 h. BenSer treatment significantly reduced the intracellular concentrations of the 
small neutral amino acids, alanine, glycine, and asparagine, by ~50% in all three cell lines (Figure 
5.4A-C). Intracellular aspartate, the deamination product of asparagine, was similarly reduced across 
all three cell lines but to a lesser extent (0.3-fold reduction; Figure 5.4D). An additional seven neutral 
amino acids (valine, leucine, isoleucine, methionine, threonine, phenylalanine, tyrosine) showed  
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Figure 5.3. Inhibition of leucine uptake alone does not recapitulate the effects of 
BenSer. Leucine (A) and glutamine (B) uptake over 15 min were measured in MCF-7, 
HCC1806 and MDA-MB-231 (MDA-231) cells in the presence or absence of 10 mM BCH. 
Relative cell viability measured by MTT assay in MCF-7 (D), HCC1806 (E), and MDA-231 
(F) cells cultured for 3 days in the presence or absence of 10 mM BCH. Data represent 
mean ± SEM of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p<0.0001; unpaired student’s t-test (A-B), 2-way ANOVA (D-F). 
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Figure 5.4. BenSer reduces intracellular amino acid concentrations. Intracellular levels 
of alanine (A), glycine (B), asparagine (C), aspartate (D), valine (E), leucine (F), isoleucine 
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(G), methionine (H), threonine (I), phenylalanine (J), tyrosine (K), serine (L), glutamine (M) 
and cysteine (N) measured in MCF-7, HCC1806 and MDA-MB-231 (MDA231) cells after 24 
h incubation in the presence or absence of 10 mM BenSer. Data are normalised to cellular 
protein content and expressed as a fold-change compared to Control. Data represent mean 
± SEM of two independent experiments performed in triplicate. *p < 0.05, **p < 0.01, 
***p < 0.001, ****p<0.0001; unpaired student’s t-test. 
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reduced intracellular concentrations in all three cell lines (Figure 5.4E-K). For all of these seven 
amino acids, the fold-change decrease was greater in MCF-7 cells than HCC1806 or MDA-MB-231 
cells, indicating a stronger effect in MCF-7 cells. In contrast, levels of serine, glutamine, and cysteine 
were each reduced in only one cell line (Figure 5.4L-N). Levels of the remaining 4 amino acids 
(glutamate, lysine, arginine, tryptophan) were not significantly altered in any cell line (Supplementary 
Figure 5.2). Proline, histidine and ornithine levels were not measured in these experiments. Together  
these data show that BenSer treatment affects the intracellular concentration of at least 14 amino 
acids, and that these are not limited to LAT1 or ASCT2 substrates, indicating that BenSer treatment 
can disrupt multiple amino acid metabolism pathways and suggesting this is a possible mechanism 
by which it exerts its growth inhibitory effects.  
 
Targets of BenSer are expressed in breast cancer cell lines  
We and others have reported that breast cancers (Furuya et al., 2012, Kim et al., 2013b, Timmerman 
et al., 2013, Jeon et al., 2015) and breast cancer cell lines (Liang et al., 2011, Shennan et al., 2004, 
van Geldermalsen et al., 2016) express high levels of the transporters targeted by BenSer, LAT1 and 
ASCT2, but little is known about the expression of other potential BenSer targets, such as other LAT 
transporters (SLC7A8, SLC43A1, SLC43A2), glycine transporters (GlyTs; SLC6A9, SLC6A5), 
glutamine transporters (SNATs; SLC38A1, SLC38A2) and essential amino acid transporters 
(EAATs; SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7). Using cBioPortal, we assessed the 
expression of these transporters in the METABRIC cohort of ~2500 clinical breast cancer samples 
(Curtis et al., 2012, Pereira et al., 2016) and all breast cancer cell lines included in The Cancer Cell 
Line Encyclopedia (Barretina et al., 2012). These analyses confirmed aberrantly high expression of 
LAT1 (SLC7A5) and its heterodimeric heavy chain, SLC3A2, in clinical samples and cell lines, with 
significantly higher expression in more proliferative breast cancer subtypes (Figure 5.5; basal, 
claudin-low, HER2). These analyses also showed high expression of all other neutral amino acid 
transporters, but with little difference in expression across genetic subtypes (PAM50 classification  
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Figure 5.5. Putative BenSer targets are expressed in breast cancer. A, gene expression 
(mRNA log2 values) of LAT transporters (SLC7A5, SLC7A8, SLC43A1, SLC43A2), LAT 
common heavy chain (SLC3A2), glycine transporters (GlyTs; SLC6A5, SLC6A9), glutamine 
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transporters (SNATs: SLC38A1, SLC38A2; ASCT2/SLC1A5) and essential amino acid 
transporters (EAATs; SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7) was analysed in all 
breast cancer cell lines (n=55) included in The Cancer Cell Line Encyclopedia (TCCLE). 
Grouped data are plotted as box-and-whisker plots (max to min), with log2 mRNA expression 
in MCF-7 (red), HCC1806 (blue) and MDA-MB-231 (MDA-231) cells overlaid as individual 
data points. B, mRNA expression (log2 values) of SLC7A5 (B), SLC7A8 (C), SLC3A2 (D), 
SLC43A1 (E), SLC43A2 (F), SLC6A9 (G), SLC1A5 (H), SLC38A1 (I), SLC38A2 (J), SLC1A1 
(K), SLC1A2 (L), SLC1A3 (M), SLC1A6 (N), and SLC1A7 (O) in the METABRIC dataset 
(n=2509). Data were grouped into the “PAM50 + Claudin-low” subtypes based on clinical 
attribute data retrieved from www.cbioportal.org/ and are plotted as box-and-whisker plots 
(Tukey).  
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plus claudin-low), suggesting that upregulation of these transporters occurs non-specifically in breast 
cancer and that therapies designed to target these pathways could have broad efficacy across clinical 
subgroups.  
 
BenSer treatment inhibits mTORC1 signalling and activates amino acid response pathways 
One critical sensor of amino acid availability is the mTORC1 pro-growth signalling axis, which is 
potently activated by intracellular leucine and glutamine (Duran et al., 2012, Nicklin et al., 2009), 
and functions to promote protein translation and thereby cellular growth and proliferation. To 
determine whether the suppression of cell growth observed was being mediated through mTORC1 
signalling, we performed Western blotting for downstream targets of mTORC1. Analysis of the 
activation of mTORC1 signalling in MCF-7, HCC1806, and MDA-MB-231 cells showed that after 
6 h incubation with BenSer, levels of p-p70S6K were decreased in MCF-7 cells, but not in either of 
the TN cell lines (Figure 5.6A). We next set out to determine whether the altered intracellular amino 
acid concentrations caused by BenSer treatment activates amino acid response (AAR) pathways, 
another critical sensor of amino acid levels. GCN2 is an important mediator of the AAR pathway, 
where it senses uncharged tRNA abundance – increased when intracellular amino acid availability is 
low – and activates signal transduction pathways through phosphorylation of eIF2a. A major 
outcome of this signalling pathway is increased expression of ATF4 (Kilberg et al., 2009), mediated 
by upregulated translation in response to nutrient starvation (Harding et al., 2003). We performed 
Western blotting for ATF4 protein in breast cancer cells treated with BenSer for 6 h to determine 
whether BenSer-induced disruption of amino acid homeostasis was sufficient to induce the AAR 
pathway. These blots showed the opposite pattern to mTORC1, with increased expression of ATF4 
in HCC1806 and MDA-MB-231 only (Figure 5.6B), indicating activation of the AAR in these cells. 
These differences may be due to the subtype-specific differences in intracellular amino acid levels 
seen in response to BenSer treatment (Figure 5.4). MCF-7 cells showed larger reductions in 
comparison to the TN cells, suggesting that the magnitude of disruption to amino acid homeostasis  
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Figure 5.6. Benzylserine treatment induces changes in mTORC1 and amino acid 
response signalling pathways. A, total and phosphorylated (p-) p70S6K signalling protein 
(70, 85 kDa) was detected by Western blotting in MCF-7, HCC1806 and MBDA-MB-231 
cells cultured in the presence or absence of 10 mM BenSer for 6 h. * indicates non-specific 
band detected at 65 kDa. B, levels of ATF4 (49 kDa) protein detected by Western blotting 
in MCF-7, HCC1806 and MBDA-MB-231 cells cultured in the presence or absence of 10 
mM BenSer for 6 h. Cells cultured in glutamine-free (Gln-) media were included in all blots 
as a positive control and GAPDH (37 kDa) was used as a loading control. Data in (A) and 
(B) are representative blots from at least three independent experiments.  
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may dictate which adaptive response is initiated. Alternatively, there may be subtype-specific 
preferences for particular stress response pathways, with Luminal A MCF-7 cells preferentially 
inhibiting mTORC1 signalling, while TN cells instead activate the AAR. 
 
5.2.5 Discussion 
Intracellular amino acid concentrations are regulated by interconnected systems of exchange, influx 
and efflux, all mediated by specific cell surface transporters. Additional regulation of transporter 
function by transcriptional, translational, and allosteric mechanisms, is overlaid onto these processes, 
creating a complex regulatory network. We and others have shown that altering the levels of only a 
single amino acid (Krall et al., 2016, Xiao et al., 2016) or a single transporter (van Geldermalsen et 
al., 2016, Wang et al., 2011) is sufficient to impair or prevent cancer cell growth. There also appears 
to be cell type-specific tropism for particular amino acids and/or their transporters, as the key 
therapeutic targets identified thus far differ markedly across malignancies; or indeed, of note in breast 
cancer, within subtypes of the same cancer (van Geldermalsen et al., 2016). However, due to the 
dynamic nature of amino acid transport, and the primacy of leucine and glutamine in maintaining 
these processes, we proposed that modulating the levels of just these two amino acids is sufficient to 
disrupt whole cell amino acid balance across multiple breast cancer subtypes, as it has been shown in 
melanoma (Wang et al., 2014a). This study used the amino acid analogue, BenSer, as our lead 
compound for testing the efficacy of dual leucine-glutamine uptake inhibition. To date, the exact 
mechanism by which it exerts its anti-growth action remains largely unknown, for example, we have 
shown using Xenopus oocyte uptake assays that BenSer can also directly inhibit LAT1 (Wang et al., 
2014a). In this current study, we have shown that BenSer inhibits breast cancer cell growth by 
preventing leucine and glutamine uptake, thus disrupting intracellular amino acid homeostasis, 
triggering AAR pathways, and inhibiting mTORC1 signalling. 
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Notably, BenSer treatment did not affect intracellular glutamine or glutamate (the deamination 
production of glutamine) levels after 12 h treatment, despite significantly inhibiting glutamine uptake 
in [3H]-glutamine uptake assays. This suggests that breast cancer cells may display some metabolic 
flexibility when amino acid homeostasis is disrupted, causing cells to prioritise the regeneration of 
particular amino acid pools within the cell as an adaptive mechanism. Both glutamine and glutamate 
play a critical role within the cell by acting as donors and acceptors of nitrogen for biosynthetic 
reactions, and thus replenishment of this pool is critical for sustaining multiple cellular metabolic 
processes. Breast cancer cells express high levels of glutamine metabolism-related enzymes, 
including glutamine synthetase (Kung et al., 2011, van Geldermalsen et al., 2016), which permits the 
synthesis of glutamine from glutamate and ammonia. Leucine levels remained reduced at 24 h, 
suggesting that either the adaptive mechanisms to restore leucine availability were less successful, or 
that leucine-dependent metabolic processes are simply less critical to cell survival than those that 
require glutamine or glutamate. 
 
Interestingly, although the growth of all breast cancer cell lines was inhibited by BenSer treatment, 
there were some subtype-specific effects. Overall, MCF-7 cells were the most sensitive to BenSer 
treatment, showing the strongest inhibition of cell growth (Figure 5.1D-F, 5.2A-C), reduction of 
intracellular amino acid concentrations (Figures 5.4), and inhibition of mTORC1 signalling (Figure 
5.6). The claudin-low triple-negative cell line, MDA-MB-231, showed the mildest effects when 
treated with BenSer. As MDA-MB-231 cells also express a gene signature associated with epithelial-
to-mesenchymal transition (EMT) processes associated with metastasis (Prat et al., 2010), this may 
suggest altered amino acid requirements during metastatic progression of breast cancer cells, as 
shown by others recently (Halldorsson et al., 2017). Notably we did not see any significant decrease 
in transporter gene expression in MDA-MB-231 cells (Figure 5.5A) or claudin-low tumours from the 
METABRIC cohort (Figure 5.5B-O), indicating that expression levels do not necessarily correlate 
with the importance of a transporter, as we have shown previously for ASCT2 (van Geldermalsen et 
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al., 2016). This highlights the need for future studies to identify an appropriate biomarker that can 
prospectively stratify individual breast tumours on their responsiveness to dual leucine-glutamine 
deprivation strategies.  
 
As a structural analogue of ASCT2 substrates, BenSer has binding affinity in the high micromolar 
range (Grewer and Grabsch, 2004) but usually requires millimolar doses to inhibit transport in human 
cell lines, likely due to competition with high concentrations of amino acids in the culture media 
(Wang et al., 2014a). Although we showed that BenSer was efficacious in reducing breast cancer cell 
growth in vitro, at these concentrations, the drug is well outside the appropriate range for clinical 
translation. Therefore, new compounds would need to be developed with higher affinity for LAT1 
and ASCT2 to enable testing at clinically relevant doses. Additionally, future in vitro studies using 
BenSer should interpret results with caution, as we have preliminary data from oocyte uptake assays 
indicating off-target binding to other receptors (SNAT1, SNAT2, LAT2) in the millimolar effective 
dose range (data not shown). 
 
However, this study has provided proof of principle data to support the biological feasibility of dual 
leucine-glutamine restriction for inhibiting breast cancer cell growth. BenSer treatment restricted cell 
growth in three different breast cancer cell lines, each representative of a different clinical subtype, 
growth rate, and metastatic potential. Further dose-response studies are needed to clarify the 
minimum restriction required to slow cell growth. Previous data have shown that the intensity and 
duration of stress conditions dictate the response driven by AAR pathway activation; low levels of 
cell stress may contribute to adaptive resistance mechanisms, whereas high levels promote apoptosis 
(B'Chir et al., 2013, Ye et al., 2010). Like inhibitors of mTORC1 signalling, therapies targeting this 
axis have the potential to either promote or prevent tumour cell survival, and therefore future studies 
should focus on delineating these pharmacodynamic effects. This is especially pertinent in light of 
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the subtype-specific stress responses that we observed in response to BenSer (Figure 5.6), indicating 
that the same treatment may stimulate different adaptive responses across breast cancer subtypes. 
 
Recent data have shown how ATF4, MYC and mTORC1 stress-response pathways may converge in 
cancers that are reliant on glutamine (Babcock et al., 2013, Csibi et al., 2013, Csibi et al., 2014, Qing 
et al., 2012, Ren et al., 2015), such as TN breast cancer, where oncogenic MYC is a suspected driver 
of glutamine-reliance (Terunuma et al., 2014). This may suggest a unique therapeutic sensitivity to 
AAR pathway disruption in this currently underserved patient population. However, even breast 
cancers that are not MYC-driven appear to rely on intact AAR pathways to drive adaptive cancer cell 
survival; for example, leucine deprivation in glutamine-independent luminal breast cancer cells 
inhibits growth via GCN2-mediated signalling (Xiao et al., 2016). This suggests that a therapy 
targeting AAR pathways may have synergy with amino acid uptake inhibitors, thus extending their 
efficacy to a broader patient population.  
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5.2.6 Supplementary data 
 
 
Supplementary Figure 5.1. Combined LAT1 and ASCT2 inhibition does not 
recapitulate the effects of BenSer. Relative cell viability measured by MTT assay in MCF-
7 (A) and HCC1806 (B) cells cultured for 3 days in the presence or absence of 10 mM BCH 
and 1 mM GPNA. Data represent mean ± SEM of at least three independent experiments. 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001; 2-way ANOVA. 
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Supplementary Figure 5.2. Intracellular levels of amino acids that are not affected by 
benzylserine treatment. Intracellular levels of glutamate (A), lysine (B), arginine (C), and 
tryptophan (D) measured in MCF-7, HCC1806 and MDA-MB-231 (MDA231) cells after 24 h 
incubation in the presence or absence of 10 mM BenSer. Data are normalised to cellular 
protein content and expressed as a fold-change compared to Control. Data represent mean 
± SEM of two independent experiments performed in triplicate. For (D), p-value shown was 
calculated with unpaired student’s t-test. 
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6.1 General Discussion and Future Directions 
 
 
This thesis focuses on the uptake and metabolism of the amino acid, glutamine, in breast cancer. This 
involved assessing the expression and function of the glutamine transporter, ASCT2, as well as the 
downstream fate of glutamine, to determine the feasibility of therapeutically targeting this pathway 
for the inhibition of breast cancer cell growth. These investigations confirmed that ASCT2 was highly 
expressed in breast cancer cell lines and patient samples, and that this expression coincided with 
glutamine-dependence in TN basal-like breast cancer cells (Chapter 3). These TN breast cancer cells 
showed profound differences in their utilisation, incorporation and metabolism of glutamine when 
compared to Luminal A breast cancer cells, which was reflected in increased gene expression of 
enzymes in glutamine-dependent metabolic pathways in TN breast cancer patient samples (Chapter 
4). Blocking glutamine uptake with the ASCT2 inhibitor, GPNA, inhibited glutamine incorporation 
into all downstream pathways (Chapter 4), but caused subtype-specific effects on cell growth, with 
only TN breast cancer cells showing decreased cell viability, cell cycle progression, and mTORC1 
signalling (Chapter 3). In contrast, combined inhibition of ASCT2 and the leucine transporter, LAT1, 
enhanced the potency of glutamine uptake-inhibition and extended its efficacy to Luminal A breast 
cancer cells, disrupting amino acid homeostasis and triggering AAR pathways (Chapter 5). Together, 
these data provide compelling evidence for targeting glutamine metabolism in TN breast cancer by 
inhibiting ASCT2-mediated uptake. 
 
 
One critical aspect of glutamine metabolism (Chapter 4) that has not been addressed in this study is 
its contribution to nitrogen balance within the cell. As carbon tracing studies did not identify any 
differentially regulated nodes in the glutamine metabolism pathway, it is currently unclear whether 
Luminal A cells are insensitive to ASCT2 blockade because they are more adaptive in their usage of 
glutamine or because they simply have lower absolute requirements for glutamine. Our ongoing work 
seeks to determine whether GPNA induces any changes in nitrogen incorporation and utilisation, and 
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if so, whether these changes are subtype-specific. These experiments will be performed using 15N-
labelled glutamine combined with targeted LC-MS/MS analysis, complementing the 13C 
metabolomics work (Chapter 4) to form a comprehensive study of glutamine metabolism. 
 
An additional aspect which was not explored in our glutamine metabolism study (Chapter 4) is a 
comparison of multiple labelling timepoints, to enable measurements of metabolic flux. Our single 
timepoint (12 h) showed significant differences in steady-state glutamine metabolism between 
Luminal A and TN cells, however despite this, ASCT2 inhibition by GPNA did not cause measurably 
different responses across subtypes. It is possible that subtype-specific effects of glutamine uptake 
inhibition are mediated through differential regulation of flux through particular enzymatic pathways, 
which is unable to be captured by steady-state measurements. Future work should incorporate 
measurements from multiple labelling timepoints to determine if regulation of enzymatic flux is a 
mechanism dictating glutamine dependence. Related work in this field has investigated the use of 
imaging and contrast agents for measurements of metabolic flux, for example, the use of 18F-labelled 
glutamine measured by positron emission tomography (PET) to assess the uptake and kinetics of 
glutamine metabolism in vivo (Lieberman et al., 2011, Qu et al., 2011). Use of these agents has 
already been applied preclinically in breast cancer to measure the effects of Phase I GLS inhibitors 
(Zhou et al., 2017), highlighting the growing interest in developing clinically applicable measures of 
glutamine metabolism and metabolic flux. 
 
As we showed differences in flexibility of glutamine utilisation for mitochondrial respiration (Chapter 
4), we also anticipate that ASCT2 inhibition may differentially suppress oxygen consumption rates 
and/or mitochondrial function. Future work will assess this using the Seahorse Mito Stress Test to 
measure the effects of GPNA on basal OCR, as well any disruption to mitochondrial function as 
assessed by response to rotenone/antimycin A, oligomycin and FCCP challenges. 
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Our study of the dual leucine-glutamine inhibitor, BenSer (Chapter 5), requires further validation. 
Ongoing work for this study includes testing the binding specificity of BenSer to putative target 
transporters, including LAT2, LAT3, LAT4, SNAT1, and SNAT2. Preliminary data for these 
transporters indicate the BenSer may also inhibit LAT2, SNAT1 and SNAT2, suggesting 
promiscuous binding to transporters that are able to transport glutamine, but not transporters that are 
only able to transport leucine (LAT3 and LAT4). These data are a significant contribution to the 
literature, as only our group has shown that BenSer binds transporters other than its purported target, 
ASCT2 (Wang et al., 2014a). However, this binding pattern is consistent with the structure of BenSer, 
an amino acid analogue that was modelled on structural similarities between the ligand-binding site 
of ASCT2 and related glutamine transporters (Grewer and Grabsch, 2004). Further structure-function 
studies should be performed to elucidate the binding sites of BenSer so as to be confident of its 
mechanism of action.  
 
Also of note from Chapter 4, the cytostatic effects of BenSer on MCF-7, HCC1806 and MDA-231 
cells were greater than those exerted by GPNA (Figure 3.1D-E, Supplementary Figure 3.1B). This 
was expected, as although they both inhibit glutamine uptake to a similar extent (Figure 3.1C, Figure 
5.1A), BenSer also strongly inhibits leucine uptake (Figure 5.1B), which has been shown to be an 
important amino acid for breast cancer cell growth (Xiao et al., 2016).  To support this, we also have 
preliminary data suggesting that BenSer likely has a more promiscuous activity, binding and blocking 
uptake to several additional amino acid transporters (data not shown; discussed in Chapter 5). 
Together these suggest that targeting multiple transporters maybe be more effective than single 
transporter blockade. However, it is currently unclear whether target transporters with similar 
substrate affinities, or instead target transporters with more divergent substrates, would best augment 
the inhibition of cell growth observed with single transporter blockade alone. 
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Additional work that we intend to perform for this dual inhibition study (Chapter 5) is use of the 
Seahorse Mito Stress Test to measure OCR and ECAR to determine if BenSer treatment has any 
effect on mitochondrial function. We have previously shown that BenSer inhibits OCR in prostate 
cancer cells (Wang et al., 2015), indicating that intracellular amino acid homeostasis may be 
important for maintaining normal cellular respiration.  
 
This study used a basic science approach to investigate the role of the amino acid transporter, ASCT2, 
in breast cancer, and assess its potential as a therapeutic target by linking these data with gene 
expression analyses in human breast cancer samples. By integrating these resources, we have 
identified a subpopulation of breast cancer patients who would benefit most from treatments that 
target ASCT2 and its downstream pathways. Alongside the work included in this thesis, others in our 
group have simultaneously worked to develop lead compounds that could achieve this in a clinical 
setting. Building on the findings of this study, next steps are to continue the development and testing 
of our novel ASCT2 inhibitors, and to test these compounds in combination with CB-839 (Gross et 
al., 2014), a GLS inhibitor in Phase I clinical trials in TN breast cancer. This will be done alongside 
evaluation of other clinical chemotherapeutics to investigate any potential drug synergy in this patient 
population, allowing us emphasise a translational investigative approach for targeting the ASCT2 
glutamine uptake and metabolism pathway.  
 
The translational potential of our project has also led to commercialisation opportunities for both the 
University of Sydney and Centenary Institute (Inter-Institutional Agreement in place for intellectual 
property). This has included a funded investment (amount confidential) by the Medical Research 
Commercialisation Fund, which includes a partnership with CSIRO for medicinal chemistry (2.5 FTE 
chemists) and development of the ASCT2 inhibitors. This funding provides 2.6 FTE researchers at 
Centenary Institute/University of Sydney, formed a new company (MetabloQ Pharmaceuticals), and 
will provide all aspects of preclinical and clinical development of these ASCT2 inhibitors, in 
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partnership with researchers at the University of Sydney, Royal Prince Alfred Hospital, Lifehouse, 
Garvan Institute and St Vincent’s Hospital. This ongoing work will involve testing further iterations 
of our lead compounds for efficacy and specificity in vitro, before progressing to pharmacodynamic 
testing in an established patient-derived xenograft (PDX) workflow, with the aim of rapid translation 
to the clinic (Phase I/II clinical trials) in the next 3-5 years. This optimistic timeline is based on our 
previous success in deriving and screening novel small molecule inhibitors of LAT3 to inhibit 
prostate cancer cell growth (Wang et al., 2014b, Wang et al., 2014c). 
 
Other recent studies in this area provide additional support for clinical translation of novel ASCT2-
targeting therapies. The ASCT2-/- mouse is viable with a mild immune phenotype that does not affect 
immune function (Nakaya et al., 2014, Masle-Farquhar et al., 2017), suggesting minimal off-target 
effects from drugs that block this transporter. ASCT2 has also been investigated as a biomarker, with 
accumulation of 18F-glutamine measured by positron emission tomography (PET) significantly 
associated with ASCT2 expression in lung and colorectal cancer (Hassanein et al., 2016, Schulte et 
al., 2016). In addition, we anticipate that the efficacy of ASCT2 inhibitors may extend to melanomas 
that harbour the V600 mutation in BRAF, which occurs in approximately 50% of metastatic 
melanoma. Others have shown that glutamine dependence is increased throughout disease 
progression in these BRAF-mutant melanomas, and that targeting these pathways may prevent 
resistance to BRAF inhibitor (BRAFi) therapies (Hernandez-Davies et al., 2015, Baenke et al., 2016), 
which remains a significant therapeutic challenge for these patients (Long et al., 2015). Our 
preliminary data shows that expression of both ASCT2 and its regulator, ATF4, are increased in 8/10 
and 9/10 BRAFi-resistant subclones in comparison to their parent cell lines (data not shown), 
suggesting that the increased reliance of resistant cell lines on glutamine may be facilitated by 
increased ASCT2 expression. This work is now the subject of a Cancer Council NSW project grant 
aiming to investigate nutrient stress-mediated adaptive responses as novel targets in BRAF mutant 
melanoma, using our novel ASCT2 inhibitors as lead compounds for combinatorial therapy with 
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BRAF and MEK inhibitors to improve initial response and prevent or delay resistance in BRAF 
mutant melanoma. These data stimulate additional questions as to the optimal timing of ASCT2-
targeting therapies – would they be best used in early disease to slow or block metastatic outgrowth; 
or in later-stage disease, where glutamine-dependence and ASCT2 overexpression are well-
established. Our data indicate that targeting ASCT2 in breast cancer cells causes a predominantly 
cytostatic effect in vitro, and as a result caused a reduction in tumour growth rate rather than tumour 
shrinkage in vivo (Chapter 3). This suggests that combinatorial therapy regimens may be required to 
achieve an optimal response from established tumours in vivo. Future work should establish which, 
if any, current chemotherapy drugs show a synergistic effect with ASCT2 inhibition in order to 
reinforce the translatability of these findings. 
 
As with any therapeutic intervention, the potential to initiate adaptive pathways and resistance 
mechanisms in response to ASCT2 inhibition should also be considered. Gene expression analysis of 
xenograft tissue (Figure 3.3E) in this study indicated significant transcriptional changes in response 
to ASCT2 knockdown throughout tumour engraftment and growth, suggesting that loss of ASCT2 is 
sufficient to initiate adaptive processes. To this end, future work should explore whether GPNA-
sensitive breast cancer cells, such as the TN cell lines we examined in Chapter 3, are able to adapt 
over time to develop resistance to GPNA treatment, and if so, what mechanisms enable this. Recent 
publications suggest that cancer cells may be able to adapt to long-term amino acid transporter 
inhibition by upregulating other transporters with similar substrate affinity; for example, SNAT1 and 
SNAT2 to replace ASCT2-mediated glutamine uptake (Broer et al., 2016). Alternatively, cells may 
alter their reliance on certain metabolites, or display flexibility in their substrate usage, as indicated 
by our data in Chapter 4 (Figure 4.2F-G). A likely regulator of this process is ATF4, which can 
directly regulate expression of amino acid transporters such as LAT1, ASCT2, and xCT (Wang et al., 
2011, Dixon et al., 2014). Accordingly, our previous work in prostate cancer showed that inhibition 
of LAT family transporters activates ATF4 transcription (Wang et al., 2013), and in this study, 
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treatment with BenSer also stimulated increased ATF4 expression (Chapter 5; Figure 5.6). The 
direction of this regulatory relationship explains why the expression of ASCT2 and ATF4 are 
correlated in TNBC samples (Figure 3.4C), and also why ATF4 is increased in ASCT2 knockdown 
(Figure 3.3E). However, in the context of our stably transduced knockdown system, this adaptive 
response (i.e. increased levels of ATF4) was ineffective in increasing expression of the two amino 
acid transporter genes reported from our TLDA panel, ASCT2 and SLC3A2 (Figure 3.3E), perhaps 
highlighting that the intensity or duration of therapy may dictate the depth of the adaptive response. 
Future work should assess these mechanisms to clearly delineate any potential resistance 
mechanisms, as well as the kinetics of these adaptations, to better optimise the delivery of transporter-
inhibiting therapies. 
 
An important caveat to this body of work, which draws the majority of its conclusions from 
observations of cancer cell lines, is that transformed cells are an imperfect model of human disease. 
Even within molecular subtypes, breast cancer is extremely heterogeneous, and no individual cell line 
can capture all of this variation. Biological assumptions are made more robust when based on a 
comprehensive panel of cell lines, as this is more truly representative of the clinical reality, and thus 
is more readily translatable. Our results should therefore be interpreted in light of this limitation, 
particularly when commenting on subtype-specific features, as these observations are drawn from 
only a small suite of breast cancer cell lines. Our conclusions would therefore be strengthened by the 
inclusion of additional cell lines to represent a more diverse range of tumours from each subtype.  
 
Likewise, our gene expression analyses of primary tumour tissue should be expanded for publication 
in order to provide better coverage of the intrinsic heterogeneity in breast cancer patient samples. 
Where possible, multiple patient cohorts should be incorporated into future analyses to control for 
inter-centre variability in patient recruitment, sample collection, processing and subtyping.  
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One interesting aspect not explored in this work is the relevance of our findings to other proliferative 
breast cancer subtypes, namely Luminal B and HER2-positive tumours. Previous work has shown 
that expression of multiple glutamine metabolism related proteins (GLS, GDH, ASCT2) is increased 
in HER2-positive tumours (Kim et al., 2013b), suggesting that these tumours may also be sensitive 
to ASCT2 inhibition. Similarly, Luminal B breast cancers were recently shown to highly express a 
MYC-regulated glutaminolytic gene signature that may indicate increased reliance on glutamine 
availability (Craze et al., 2018). While our Nanostring analysis in Chapter 3 focussed only on TN 
samples, expanding these analyses to additional subtypes may reveal broader classes of breast cancer 
tumours that are also amenable to ASCT2-targeting therapies.  
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9.1  Appendix 
 
9.1 Primers 
9.1.1 Mycoplasma PCR testing primers 
Primer name Sequence 
5’Myco GAGTTTGATCCTGGCTCAG 
3’Myco TCTCGGCCCGGCTAAACATCAT 
GAPDH-F GAAACTGTGGCGTGATGGC 
GAPDH-R CACCACTGACACGTTGGCAG 
 
9.1.2 TLDA primers 
ThermoFisher Primer 
ID Gene symbol 
Exon-exon 
boundary Amplicon size (bp) 
Hs00153153_m1 HIF1A 4-5 76 
Hs00153408_m1 MYC 2-3 107 
Hs00153451_m1 E2F1 3-4 84 
Hs00169585_m1 PPP1R15A 2-3 66 
Hs00177936_m1 RPS6KA3 17-18 130 
Hs00179759_m1 HIPK2 12-13 76 
Hs00180269_m1 BAX 4-5 62 
Hs00185826_m1 SLC7A5 1-2 110 
Hs00192530_m1 QARS 5-6 74 
Hs00202033_m1 SIRT4 2-3 106 
Hs00215872_m1 WIPI1 2-3 101 
Hs00228632_m1 EDEM3 1-2 70 
Hs00230684_m1 EIF2A 9-10 106 
Hs00231069_m1 ATF3 2-3 108 
Hs00231667_m1 E2F2 1-2 72 
Hs00234508_m1 MTOR 20-21 103 
Hs00248075_m1 BBC3 3-4 101 
Hs00248163_m1 GLS 11-12 75 
Hs00269284_m1 MAP4K3 12-13 117 
Hs00355782_m1 CDKN1A 2-3 66 
Hs00358796_g1 DDIT3 3-4 93 
Hs00365928_g1 GLUL 2-3 81 
Hs00374243_m1 SLC3A2 10-11 77 
Hs00426680_mH CDC20 10-11 109 
Hs00736699_m1 NOXA1 3-4 66 
Hs00794796_m1 SLC7A8 7-8 87 
Hs00909569_g1 ATF4 1-2 68 
Hs00921938_m1 SLC7A11 7-8 57 
Hs00938777_m1 CDK1 3-4 109 
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Hs00964100_g1 UBE2C 4-5 64 
Hs00983079_m1 SLC1A4 2-3 74 
Hs00984006_m1 EIF2AK3 3-4 83 
Hs00992327_m1 SLC43A1 14-15 70 
Hs00998733_m1 GLS2 7-8 94 
Hs01005622_m1 FASN 3-4 62 
Hs01010957_m1 EIF2AK4 3-4 64 
Hs01034249_m1 TP53 10-11 108 
Hs01048033_m1 ERLEC1 3-4 99 
Hs01056542_m1 SLC1A5 5-6 68 
Hs01060665_g1 ACTB 2-3 63 
Hs01082394_m1 TRIB3 3-4 83 
Hs01089954_m1 SLC38A2 14-15 128 
Hs01548894_m1 CDK2 2-3 58 
Hs01562175_m1 SLC38A1 8-9 101 
Hs01562315_m1 PRKAA1 8-9 118 
Hs02621445_s1 NUP62 2 77 
Hs02758991_g1 GAPDH 6-7 93 
Hs99999901_s1 18S 1 187 
 
9.1.3 RT-qPCR primers 
Primer name 
Gene 
target 
name 
Exon-exon 
boundary Primer sequence 
Amplicon size 
(bp) 
SLC7A5-
Ex8_qPCRfor SLC7A5 7-8 
AGAGCAGCGTCA
TCACACAC 78 SLC7A5-
Ex7_qPCRrev 
CCATCCTCTCCAT
GATCCAC 
SLC7A8-
Ex5_qPCRfor SLC7A8 5-6 
ATGGCTCTGGGA
AGGTTCTT 97 SLC7A8-
Ex6_qPCRrev 
CTTTCCTTCAGGG
CTCCTTT 
SLC43A1-
Ex6_qPCRfor SLC43A1 6-7 
GGTGAACATGAT
GACCACGA 92 SLC43A1-
Ex7_qPCRrev 
TGATTGGCTCTTA
CGCCTCT 
SLC43A2-
Ex6_qPCRfor SLC43A2 6-7 
ACGACGATGAAG
GAGACACC 91 SLC43A2-
Ex7_qPCRrev 
GCCTTGATGATTG
GGTCCTA 
PPAT-
Ex2_qPCRfor PPAT 2-3 
TGGTGTGTCCAAT
TCCAAGA 91 PPAT-
Ex3_qPCRrev 
TCACACAAGGGA
ATGGGTCT 
GMPS-
Ex5_qPCRfor GMPS 5-6 
TGGCACGTTCTGG
AAACATA 79 
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GMPS-
Ex6_qPCRrev 
ACTTCAGGGTGG
AACTGTGC 
PFAS-
Ex6_qPCRfor PFAS 6-7 
CACTGTGGAGGC
CTTTGACT 67 PFAS-
Ex7_qPCRrev 
GCCCTTGAAGAA
CCAGTGTC 
CAD-
Ex25_qPCRfor CAD 25-26 
AGTCTCGGCACA
GCTGACTT 69 CAD-
Ex26_qPCRrev 
CTCAAAGTGCCA
GTCCACAG 
CTPS1-
Ex3_qPCRfor CTPS1 3-4 
ACTTGGGGAAAA
CTGTCCAA 63 CTPS1-
Ex4_qPCRrev 
CTCATCACCCACT
CCTGGAT 
CTPS2-
Ex2_qPCRfor CTPS2 2-3 
TTCTCCACCATCA
TTTAAGACG 66 CTPS2-
Ex3_qPCRrev 
ATCGATGCTGGC
ACTTTTTC 
GLS-
Ex2_qPCRfor GLS 2-3 
CAATTGCTGAAG
GACAAGAGAA 78 GLS-
Ex3_qPCRrev 
CAGACGTTCGCA
ATCCTGTA 
GLS2-
Ex15_qPCRfor GLS2 15-16 
CAGCTGAAGGAC
ACATCGAA 70 GLS2-
Ex16_qPCRrev 
TCCTTGGCAAAA
GGATTCAC 
GLUL-
Ex2_qPCRfor GLUL 2-3 
TGTCACTGTTGGA
ACCCTCA 80 GLUL-
Ex3_qPCRrev 
GCCCAAGTGTGT
GGAAGAGT 
MYC-
Ex1_qPCRfor MYC 1-2 
TTCGGGTAGTGG
AAAACCAG 100 MYC-
Ex2_qPCRrev 
CACCGAGTCGTA
GTCGAGGT 
SLC38A1-
Ex11_qPCRfor SLC38A1 11-12 
AATGCAATGGTG
GGTAAAGC 69 SLC38A1-
Ex12_qPCRrev 
TGACACGTGTAC
GCCAAAAT 
SLC38A2-
Ex13_qPCRfor SLC38A2 13-14 
GCTGCAGATGCA
CCAATAAA 62 SLC38A2-
Ex14_qPCRrev 
TTACTTGTCATCT
TTGTCCCAAC 
hB2M_for 
B2M 2-3-4 
TGCCGTGTGAAC
CATGTGAC 91 
hB2M-rev CGGCATCTTCAAACCTCCAT 
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9.1.4 Sequencing primers:  
Primer name Sequence Comments 
FH1trevseq  GCTGATACTGGGGTTCTAAGG  
H1promforseq  AGGAAGATGGCTGTGAGGG  
M13forseq  TGTAAAACGACGGCCAGTC  
M13revseq  CAGGAAACAGCTATGAC  
 
 
9.1.5 Cloning oligonucleotides 
Primer name Sequence Comments 
ASCT2.sh-s tcccCTGGATTATGAGGAATGGATActcga
gTATCCATTCCTCATAATCCAGTTTTTT
c 
Sense strand of shA63 with 
BsmBI/XhoI overhangs for 
cloning into pFH1tetflex 
intermediate vector 
ASCT2.sh-as tcgaGAAAAAACTGGATTATGAGGAAT
GGATActcgagTATCCATTCCTCATAATC
CAG 
Antisense strand of shA63 
with BsmBI/XhoI overhangs 
for cloning into pFH1tetflex 
intermediate vector 
 
9.2 shRNA hairpin sequences 
shRNA name Sequence Comments 
pLKO.1-puro vector 
shControl  TTTGGATTGAAGGGAGCTCTA Non-targeting plant 
microRNA (athmiR159a). 
Cloned into pLKO.1-puro 
vector in-house. 
shA28  CGGGCTGCTTATCCGCTTCTTCAACTC
GAGTTGAAGAAGCGGATAAGCAGCTT
TTTG 
Sigma MISSIONTM shRNA 
catalogue number 
TRCN0000043119 
shA63 CCGGCTGGATTATGAGGAATGGATAC
TCGAGTATCCATTCCTCATAATCCAGT
TTTTG 
Sigma MISSIONTM shRNA 
catalogue number 
TRCN0000288863 
pFH1t(INSR)UTG vector 
shControl TTTGGATTGAAGGGAGCTCTA Non-targeting plant 
microRNA (athmiR159a). 
Cloned into 
pFH1t(INSR)UTG in-house. 
shASCT2 CCGGCTGGATTATGAGGAATGGATAC
TCGAGTATCC 
ATTCCTCATAATCCAGTTTTTG 
Hairpin sequence from shA63. 
Cloned into 
pFH1t(INSR)UTG in-house. 
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9.3 Antibodies 
 
Target Supplier Catalogue number 
Dilution 
Western 
blot IF/IHC 
Flow 
cytometry 
Primary Antibodies 
ASCT2 
Cell Signalling 8057S 1:1000 1:100  
Sigma HPA035240  1:1000  
Glyceraldehyde-
3-phosphate 
dehydrogenase 
(GAPDH) 
Abcam ab8245 1:2000   
α-tubulin Santa Cruz sc-23948 1:5000   
pT389-p70S6K Cell Signalling 9206S 1:1000   
p70S6K Cell Signalling 9205S 1:1000   
pS473-Akt Cell Signalling 4051S 1:1000   
Akt Cell Signalling 9272S 1:1000   
LC3B1/II Cell Signalling 2775S 1:1000   
cleaved PARP Cell Signalling 9541S 1:1000   
Cleaved caspase 
3  9664S 1:1000 1:100  
Caspase 3 Cell Signalling 9665S 1:1000   
UBE2C Sapphire Biosciences A-650 1:1000   
CDC20 Abcam ab26483 1:1000   
ATF4 Cell Signalling 11815S 1:1000   
Annexin-V 
conjugated APC BD Biosciences 550474   1:100 
BrdU 
conjugated APC BD Biosciences    1:100 
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Secondary Antibodies 
Horseradish 
peroxidase–
conjugated 
donkey anti-
mouse IgG 
Merck Millipore AP192P 1:5000   
Horseradish 
peroxidase–
conjugated 
donkey anti-
rabbit IgG 
Merck Millipore AP182P 1:5000   
Alexa-
Fluor488-
conjugated goat 
anti-rabbit IgG 
LifeTech A11034 1:2000   
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9.4 High-magnification microscopy images 
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